marwan sabbagh md page 1 10/12/2017 - nacog.org sabbagh.pdf · marwan sabbagh md page 1 10/12/2017...
TRANSCRIPT
Marwan Sabbagh MD Page 1 10122017
CURRICULUM VITAE
MARWAN NOEL SABBAGH MD FAAN CCRI BIRTH DATE December 18 1965 OFFICE ADDRESS Barrow Neurological Institute 240 W Thomas Rd Ste 301 Phoenix AZ 85013 OFFICE PHONEFAX (602) 406-4784 E-MAIL MarwanSabbaghdignityhealthorg CURRENT POSITION Karsten Solheim Chair for Dementia Director Alzheimerrsquos and Memory Disorders Division Professor of Neurology Barrow Neurological Institute Phoenix AZ Research Professor Department of Neurology University of Arizona College of Medicine-Phoenix Phoenix AZ Affiliate Faculty Professor of Neurology Creighton University School of Medicine Phoenix AZ Associate Director Clinical Core Arizona Alzheimerrsquos Disease Center Board of Directors (2013-present) United Council of Neurological Subspecialties Minneapolis MN PREVIOUS POSITIONS Director (2011-2015) Director The Cleo Roberts Center for Clinical Research (2000-2015)
Senior Scientist Haldeman Lab (2010-2015) Chief Medical-Scientific Officer and Research Medical Director (2008-2011)
Banner-Sun Health Research Institute Sun City AZ Steering Committee Member (2000-2015) Alzheimer Disease Cooperative Study Alzheimerrsquos Disease Neuroimaging Initiative Adjunct Assistant Clinical Professor (2000-2004) Assistant Professor (1997-2000) Clinical Instructor (1995-1997) Department of Neurosciences School of Medicine University of California San Diego San Diego CA Associate Director (1997-2000) Neuroscience Center at Alvarado Hospital San Diego CA Attending Physician (1995-2000)
AREA AGENCY ON AGING NACOG
Building Strong Communities
Conference Session Planning Worksheet October 5-6 2017
Speaker(s) Marwan N Sabbagh MD
Session Title Not all dementia is Alzheimerrsquos disease An update on diagnosis
Session Description lecture
Session Objectives (Minimum of 3)
1 To review all forms of dementia 2 To discuss new approaches to diagnosis 3 To inform the audience about Mild Cognitive Impairment as a prodome to dementia
For AAA NACOG Internal Use Only
Session Worksheet Approved________________________________________Date________________
2 UCSD Medical Center San Diego CA Staff Physician (1995-2000) Alzheimers Disease Research Center (ADRC) University of California San Diego San Diego CA Assistant Clinical Professor of Pharmacy Practice (1998-2000) Western College of Pharmacy Pomona CA Volunteer Physician (1995-2000) St Vincent De Paul Medical Clinic San Diego CA Volunteer Physician (2000-2005) St Vincent De Paul Clinic Phoenix AZ
Staff Neurologist (2003-2007) Phoenix Indian Medical Center Phoenix AZ Visiting Scientist (2000-2006) Department of Neurology Mayo Clinic Scottsdale Scottsdale AZ Adjunct Professor (2004-2009) College of Nursing Arizona State University Tempe AZ Adjunct Professor (2003-2008) Physician Assistant Osteopathic and Podiatry Programs Midwestern University Glendale AZ Clinical Instructor (2000-2008) Geriatric Fellowship Program Sun Health St Josephrsquos Hospitals Phoenix AZ
Board of Directors (2005-2011) Chairman of Medical-Scientific Advisory Committee Desert Southwest Chapter Alzheimerrsquos Association Phoenix AZ Co-Director (2007-2010) Clinical Therapeutics Core Arizona Alzheimerrsquos Registry Arizona Alzheimerrsquos Consortium Chairman-Scientific Advisory Board (2008-2012) Amerisciences Incorporated Houston TX TRAINING Fellowship (Geriatric Neurology amp Dementia) 1995-1997 under the mentorship of Drs Leon Thal and Robert Katzman Department of Neurosciences
3 University of California San Diego School of Medicine San Diego California Residency (Neurology) 1992-1995 Baylor College of Medicine Houston Texas Internship (Internal Medicine) 1991-1992 Good Samaritan Regional Medical Center Phoenix Arizona EDUCATION MD - University of Arizona College of Medicine 1991 BA - University of California - Berkeley 1987 HONORSAWARDS Student Summer Fellow Arizona Cancer Society 1988
Student Representative to the Western Federation of Clinical Research University of Arizona 1990
Allistair Karmody Award Finalist 1991 Travel Fellowship Award Recipient American Neurological Association 1996 Peter F Drucker Award Co-recipient 1998 Dystonia Doctor of Excellence San Diego County 2000 Life Member of the National Registry of Whorsquos Who 172142 2001 Arizona Business Journal Healthcare Hero Finalist 2004 Fellow of the American Academy of Neurology 2004 WestMarc Innovator Award 2015 BOARDS Diplomate of the National Board of Medical Examiners 1992 Certificate 407526 Diplomate of the American Board of Psychiatry and Neurology 1996 Certificate 43257 Recertified in 2007 Certified Clinical Research Investigator 03-F052 Diplomate of the UCNS Board of Geriatric Neurology LICENSES Arizona Medical License 1994 (AZ22378) California Medical License 1995 (CAG08170) Medicare UPING13648 AHCCCS540113 HOSPITAL AFFILIATIONS Saint Josephrsquos Hospital and Medical Center Phoenix AZ MEMBERSHIPS American Medical Association 1988-1993 American Federation of Clinical Research 1988-1991 American College of Physicians 1991-1997 American Academy of Neurology 1992-Present San Diego Neurological Society 1995-2000 Society for Neuroscience 1997- 2005 Arizona Geriatric Society 2001-Present Society for Behavioral and Cognitive Neurology 2001-2008 EDITOR FOR Neurology and Therapy (editor-in-chief) Journal of Alzheimerrsquos Disease (associate editor) BMC Neurology (section editor-dementia) Expert Opinion on Investigational Drugs (editorial board)
Alzheimerrsquos and Dementia Translational Research and Clinical Interventions (editorial board)
AD HOC REVIEWER FOR The Journal of Neuropsychiatry and Clinical Neuroscience Physiology and Behavior Grants Committee - Alzheimerrsquos Association Brain Research
4 Neurobiology of Aging Neurology Archives of Neurology Clinical Neurosciences and Disease Study Section CND-1 NIH Neuropharmacology Small Business ZRG1 BDCN-A (11) B CSR NIH Emerging Technology and Training in Neuroscience ETTN CSR NIH Aging Program Project Review ZRG1 BDCN-L 42P Alzheimers Disease Pilot Clinical Trials ZRG1 BBBP-V (55) R European Archives of Psychiatry and Clinical Neurosciences Journal of Clinical Psychiatry Neuroscience Letters Neuroepidemiology Biological Psychiatry International Journal of Geriatric Psychiatry Annals of Neurology PUBLICATIONS (Google scholar h-index 61) Books 1 Sabbagh MN The Alzheimerrsquos Answer Reduce Your Risk and Keep Your Brain Healthy 2008 2010
(paperback) John Wiley and Sons Hoboken New Jersey 2 Sabbagh MN Alzheimer Guia practica Respuestas a las cuestiones fundamentales desde su
diagnostico hsta como se aplica el tratamiento (Spanish Edition) 2010 RobinBooks Barcelona Spain 3 Martin G Sabbagh MN (eds) Palliative Care For Advanced Alzheimerrsquos and Dementia Guidelines and
Standards for Evidence Based Care 2010 Springer Publishing Company New York NY
4 Sabbagh M MacMillan B The Alzheimerrsquos Prevention Cookbook Recipes to Boost Brain Health 2012 TenSpeed Press Emeryville California
5 Nair A Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford United Kingdom Invited Chapters 1 Smith RG Sabbagh M White P Brod S Oral tolerance therapy of autoimmune disease In Appel SH
(ed) Current Neurology 1996 Mosby New York 16165-189 2 Shaibani AT Sabbagh MN Khan B Pathological Human Crying In Ad JJM Vingerhoets Randolph R
Cornelius (eds) Adult Crying A Biopsychosocial Approach 2002 Brunner-Routledge East Sussex UK
3 Sparks DL Connor DJ Browne PJ Wasser DR Lopez JE Sabbagh MN The Alzheimerrsquos disease atorvastatin treatment trial scientific basis and position on the use of the HMG-CoA reductase inhibitors (statins) that do or do not cross the blood-brain barrier In Fillit H OrsquoConnell AW Drug Discovery and Drug Development for Alzheimerrsquos Disease 2002 Springer Publishing Company New York 244-252
4 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C Lochhead J
Browne P Cholesterol copper and statin therapy in AD In Gauthier S Schelten P Cummings J Alzheimerrsquos Disease and Related Disorders Annual 5 2005 Taylor and Francis London 89-110
5 Reisberg B Weigel J Franssen E Kadiyala S Auer S Souren L Sabbagh M Golomb J Clinical features
of severe dementia-staging In Burns A Winblad B (eds) Severe Dementia 2006 John Wiley and Sons Hoboken New Jersey 95-127
6 McCarthy M Gallagher M Sabbagh M Appropriate use of medications in advanced dementia In Long C
(ed) Palliative Care for Advanced Dementia Guidelines and Standards 2006 Alzheimerrsquos Association Desert Southwest Chapter Phoenix AZ 40-51
7 Rogers J Beach T Li R Liang Z Lue L-F Roher A Sabbagh M Shen Y Strohmeyer R Walker D
Inflammatory mechanisms in Alzheimers disease and other neurodegenerative disorders In Chemistry and Molecular Aspects of Drug Design and Action (Kourounakis and Rekka eds) CRC Press (Boca Raton FL) pp 3-12 2007
5 8 Barry Reisberg Jerzy Wegiel Emile Franssen Sridhar Kadiyala Stefanie Auer Liduiumln Souren Marwan
Sabbagh and James Golomb Clinical Features of Severe Dementia Staging in Severe Dementia (Burns and Winblad eds) 2010 John Wiley and Sons Hoboken NJ Chapter 8
9 Reisberg B Jamil IA Khan S Monteiro I Torossian C Ferris S Sabbagh M Gauthier S Auer
S Shulman MB Kluger A Franssen E and Wegiel J Staging dementia In Principles and Practice of Geriatric Psychiatry 3rd edition M T Abou-Saleh C Katona and A Kumar (Eds) Chichester England Wiley-Blackwell 2010 p 162-169
10 Belden CM Burciu C Sabbagh M (2014) Global Deterioration Scale (Individuals) In Michalos AC (Ed)
Encyclopedia of Quality of Life and Well-Being Research Springer Dordrecht Netherlands Springer pp 2562-2564
11 Sabbagh MN Nair AK Approach to the Geriatric Neurology Patient The Neurologic Examination In Nair A
Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p71-84
12 Nair AK Sabbagh MN Amyloid imaging In Nair A Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p 162-169
13 Singh J Sabbagh MN Nair AK Evidence based pharmacological treatment of dementia In Nair A
Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p 557-573
14 Decourt B1 Macias M
1 Berk C
1 Sabbagh M
1 Adem A
2 BACE1 inhibitors attractive therapeutics for
Alzheimerrsquos disease In Ur-Rahman A Choudhary MI Frontiers in Drug Design and Discovery 2014 Bentham Science p518-546
Invited Reviews and Editorials 1 Taher A Sabbagh M Doody R Laughter and crying in neurologic disorders Neuropsychiatry
Neuropsychology amp Behavioral Neurology 7(4) 243-250 1994 2 Sabbagh MN Galasko D Thal LJ Beta amyloid and treatment opportunities for Alzheimers disease
Alzheimers Disease Reviews 1998 31-19 3 Shaibani AT Sabbagh MN Pseudo-Neurologic Syndromes Recognition and Diagnosis American Family
Physician 1998 57(10) 2485-2494 4 Sabbagh MN Application of the Changing Therapies for Alzheimerrsquos Disease in Clinical Practice
American Speech and Language Association 1998 3(1) 7-12
5 Sabbagh MN Galasko D Koo E Thal LJ -amyloid and treatment opportunities for Alzheimers disease Journal of Alzheimers Disease 2000 2(3-4) 231-259
6 Sparks DL Connor DJ Browne PJ Lopez JE Sabbagh MN HMG-CoA reductase inhibitors (statins) in
the treatment of Alzheimerrsquos disease and why it would be ill-advised to use one that crosses the blood-brain barrier Journal of Nutrition Health and Aging 2002 6(5) 324-330
7 Sparks DL Connor DJ Browne P and Sabbagh MN Should the guidelines for monitoring serum
cholesterol levels in the elderly be re-evaluated Journal of Molecular Neuroscience 2002 19 209-212 8 Sabbagh MN Lukas RJ Sparks DL Reid RT The nicotinic acetylcholine receptor smoking and
Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2002 4 (4) 317-325 9 Sparks DL Sabbagh MN Breitner JCS Hunsaker J Is cholesterol a culprit in AD International
Psychogeriatrics 2003 15 (suppl1) 153-159 10 Sabbagh MN Farlow MR Relkin NR Beach TG Do cholinergic therapies have disease modifying effects
in Alzheimerrsquos disease Alzheimerrsquos and Dementia 20062(2) 118-125 11 Sparks DL Sabbagh M Connor D Soares H Lopez J Stankovic G Johnson-Traver S Ziolkowski C
Browne P Statin therapy in AD Acta Neurologica Scandinavica 2006 185S78-86
6 12 Thind K Sabbagh MN Pathological Correlates of Cognitive Decline in Alzheimerrsquos Disease PanMinerva
Medica 2007 49(4)191-195 13 Beach TG Sue LI Walker DG Roher AE Lue LF Vedders L Connor DJ Sabbagh M Rogers J The
Sun Health Research Institute Brain Donation Program Description and Experience 1987-2007 Cell Tissue Bank 2008 Mar 18 [Epub ahead of print]
14 Sabbagh MN Richardson S Relkin N Disease modifying approaches to Alzheimers disease Challenges
and opportunities Lessons from donepezil therapyrdquo Alzheimerrsquos and Dementia 2008 4(1) S109-S118 15 Sabbagh MN Commentary on the baseline data of the atorvastatindonepezil study for Alzheimerrsquos
disease Alzheimerrsquos and Dementia 2008 4 (3)174-175 16 Khatchaturian ZS Petersen RC Gauthier S Buckholtz N Corey-Bloom J Evans B Fillit H Foster N
Greenberg B Grundman M Sano M Simpkins J Schneider LS Weiner MW Galasko D Hyman B Kuller L Schenk D Snyder S Thomas RG Tuszinski MH Vellas B Wurtman RJ Snyder PJ Frank RA Albert M Doody R Ferris S Kaye J Koo E Morrison-Bogorad M Reisberg B Salmon DP Gilman S Mohs R Aisen PS Breitner JCS Cummings JL Kawas C Phelps C Poirier J Sabbagh M Touchon J Khatchaturian AS Bain L A roadmap for the prevention of dementia the inaugural Leon Thal Symposium Alzheimerrsquos and Dementia 2008 4 (3)156-163
17 Rogers J Sabbagh MN Relationships of strokes and non-steroidal anti-inflammatory drug use to
apolipoprotein E4-conferred of Alzheimerrsquos disease and dementia Neurology 2008 702-4 18 Quinn J Sabbagh MN Editorial Biochemical Markers in Persons with Pre-Clinical Familial Alzheimers
Disease Neurology 2008 7178-79 19 Jacobson S Sabbagh MN Donepezil potential neuroprotective and disease modifying effects Expert
Opinion on Drug Metabolism and Toxicology 2008 4(10)1363-1369 20 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathologica 2008 Nov 4 [epub ahead of print] 21 Lue LF Jacobson S Walker D Sabbagh MN The receptor for advanced glycation end-products its role
in Alzheimerrsquos and other diseases Future Neurology 2009 4(2) 167-177 22 Sabbagh MN Tariot PN Commentary on A roadmap for the prevention of dementia II Leon Thal
Symposium 2008 A national registry to identify a cohort for Alzheimerrsquos disease prevention studies Alzheimerrsquos and Dementia 20095 128-129
23 Khachaturian ZS Snyder PJ Doody RS Aisen P Comer M Dwyer J Frank RA Holzapfel A
Khachaturian AS Korczyn AD Phelps C Roses A Simpkins JW Schneider LS Albert MS Egge R Deves A Ferris S Greenberg BD Johnson C Kukull WA Poirier J Schenk D Thies W Gauthier S Gilman S Bernick C Cummings JL Fillit H Grundman M Kaye J Mucke L Reisberg B Sano M Pickeral O Petersen RC Mohs RC Buckholtz N Carrillo M Corey-Bloom JP Foster NL Jacobsen S Lee V Potter WZ Sabbagh MN Salmon D Trojanowski JQ Wexler N Bain LJ A roadmap for the prevention of dementia II Leon Thal Symposium 2008 Alzheimerrsquos and Dementia 2009 585-92
24 Sabbagh MN Drug Development for Alzheimerrsquos Disease Where Are We Now and Where Are We
Headed American Journal of Geriatric Pharmacotherapy 2009 7(3) 167-185 25 Sabbagh MN Thind K Sparks DL On cholesterol levels and statins in Alzheimerrsquos disease and cognitive
decline progress and setbacks Alzheimerrsquos Disease and Associated Disorders 2009 (Oct-Dec) 23(4)303-305
26 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathol 2009 Feb117(2)217-218
7 27 Sabbagh MN Shill HA Dimebon (latrepirdine) a potential treatment with a novel mechanism of action for
the treatment of Alzheimers disease and Huntington disease Current Opinion in Investigational Drugs 2010 Curr Opin Investig Drugs 2010 Jan11(1)80-91
28 Arab L Sabbagh MN Lifestyle changes do they lower Alzheimerrsquos risk Journal of Alzheimerrsquos Disease
201020(3)785-94 Review PubMedPMID 20182018
29 Sabbagh MN Commentary On The Perspective Design Of Comprehensive Alzheimers Disease Centers To Address Unmet National Needs by JQ Trojanowski et al Alzheimerrsquos and Dementia 2010 Mar6(2)156-7 No abstract available
30 Khachaturian AS Sabbagh M Commentary on Developing a national strategy to prevent dementia
Leon Thal Symposium 2009 Creating a national database for successful aging Alzheimers Dement 2010 Mar6(2)132-4 No abstract available
31 Zaven Khachaturian [Convener ndash Facilitator] - Presenters Deborah Barnes Richard Einstein Sterling
Johnson Virginia Lee Allen Roses Mark A Sager William R Shankle Peter J Snyder Ronald C Petersen Gerard Schellenberg and John Trojanowski - Discussants Paul Aisen Marilyn S Albert Charles Bernick John C S Breitner Neil Buckholtz Maria Carrillo Steven Ferris Barry D Greenberg Michael Grundman Ara S Khachaturian Lewis H Kuller Oscar L Lopez Paul Maruff Richard C Mohs Marcelle Morrison-Bogorad Creighton Phelps Michael Phillips Stephen Rao Eric Reiman Marwan Sabbagh Mary Sano Randy Schiffer Lon S Schneider Eric Siemers Pierre Tariot Jacques Touchon Bruno Vellas Reporter Lisa J Bain Developing a National Strategy to Prevent Dementia Alzheimerrsquos and Dementia 2010 Mar6(2)89-97
32 Sabbagh MN Berk C Latrepirdine for Alzheimerrsquos disease trials and tribulations Future Neurology 2010
September 2010 Vol 5 No 5 Pages 645-651
33 Sabbagh MN Cummings J Progressive Cholinergic Decline in Alzheimerrsquos Disease Consideration for Treatment With Donepezil 23 mg in Patients With Moderate to Severe Symptomatology BMC Neurology 2011 1121
34 DeCourt B Sabbagh MN BACE1 as a potential biomarker for Alzheimerrsquos disease Journal of
Alzheimerrsquos Disease 201124 Suppl 253-9]
35 Jacobson SA Sabbagh MN Investigational drugs for the treatment of Alzheimerrsquos disease failed trials Alzheimerrsquos Research and Therapy 2011 Apr 153(2)14 [Epub ahead of print]
36 Patel S Shah R Coleman P Sabbagh MN Potential Peripheral Biomarkers for the Diagnosis of
Alzheimerrsquos Disease International Journal of Alzheimerrsquos Disease 2011572495 Epub 2011 Oct 23
37 Mehta M Adem A Sabbagh MN The nicotinic receptor smoking and Alzheimerrsquos revisited Frontiers in Bioscience E4 169-180 January 1 2012
38 Sabbagh MN Berk C Appraisal of higher doses of donepezil in the treatment of mild moderate and
severe Alzheimers disease International Journal of Alzheimerrsquos Disease 20122012707468 Epub 2011 Dec 1
39 Arab L Sadeghi R Walker DG Lue LF Sabbagh MN Consequences of aberrant insulin regulation in the
brain Can treating diabetes be effective for Alzheimerrsquos Disease Current Neuropharmacology 2011 9(4) 693-705
40 Mehta M Adem A Sabbagh MN New acetylcholinesterase inhibitors for Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 728983 8 pages doi1011552012728983
41 Sabbagh MN Sparks DL Statins to treat Alzheimerrsquos an incomplete story Expert Review in
Neurotherapeutics January 2012 Vol 12 No 1 Pages 27-30
8 42 Sabbagh MN Porsteinsson AP Nair A Adem A Novel Therapeutics in Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 207969 2 pages
43 Sabbagh MN Geula C Messis C Friedland R Conference Report on the 5th International Conference on
Alzheimerrsquos Disease in the Middle East May 7-9 2009 Limmassol Cyprus Journal of Alzheimerrsquos Disease 2012 May 21Epub ahead of print] No abstract available PMID22614876
44 Lue LF Andrade C Sabbagh MN Walker DG Is there inflammatory synergy in type II diabetes mellitus
and Alzheimerrsquos disease International Journal of Alzheimerrsquos Disease 2012918680 Epub 2012 Jun 21
45 Sabbagh MN Ahmadi MM Belden C The Use of Informant-Based Questionnaires in Differentiating Mild Cognitive Impairment from Normal Aging Expert Review of Neurotherapeutics 2012 Jun12(6)637-9
46 Jeffrey L Cummings1 David Geldmacher
2 Martin Farlow
3 Marwan Sabbagh
4 Daniel Christensen
5 amp
Peter Betz6 for the Donepezil 23 mg Expert Working Group High-Dose Donepezil (23 mgday) for the
Treatment of Moderate and Severe Alzheimerrsquos Disease Drug Profile and Clinical Guidelines CNS Neurosci Ther 2013 Mar 6 doi 101111cns12076 [Epub ahead of print]
47 DeCourt B Mobley W Reiman E Shah RJ Sabbagh MN Recent perspectives on Alzheimerrsquos disease pathological changes in Down syndromerdquo J Alzheimers Dis Parkinsonism 2013 S7 httpdxdoiorg 1041722161-0460S7-002
48 Adem A El-Agnaf O Sabbagh MN Neurodegeneration The first IBRO-Middle East Neuroscience
Conference Current Alzheimerrsquos Research 2013 10 (6)557-8
49 Berk C Sabbagh MN Drugs in Late Stage Development for Alzheimerrsquos Disease Drugs Aging 2013 Aug 14 [Epub ahead of print]
50 Berk C Paul G Sabbagh MN Investigational Drugs in Alzheimerrsquos Disease Current Progress Expert
Opinion on Investigational Drugs 2014 Expert Opin Investig Drugs 2014 Jun23(6)837-46 doi 101517135437842014905542 Epub 2014 Apr 5
51 Richards D Sabbagh MN Florbetaben for PET Imaging of Neuritic Beta-Amyloid Plaques in the Brain
Neurology and Therapy 2014 DOI 101007s40120-014-0022-9
52 Hartley D Blumenthal T Carrillo M DiPaolo G Esralew L Gardiner K Granholm AC Iqbal K Krams M Lemere C Lott I Mobley W Ness S Nixon R Potter H Reeves R Sabbagh M Silverman W Tycko B Whitten M Wisniewski T Down syndrome and Alzheimers disease Common pathways common goals Alzheimers Dement 2014 Dec 12 pii S1552-5260(14)02860-X doi 101016jjalz201410007
53 Saunders KT Langbaum JB Holt CJ Chen W High N Langlois C Sabbagh M Tariot PN Arizona
Alzheimers Registry Strategy and Outcomes of a Statewide Research Recruitment Registry J Prev Alzheimers Dis 2014 Sep1(2)74-79
54 Walker DG Lue LF Paul G Patel A Sabbagh MN Advanced Glycation Endproduct Modulators A New
Therapeutic Target in Alzheimerrsquos Disease Expert Opinion in Investigational Drugs Posted online on January 14 2015 (doi1015171354378420151001490)
55 Malek-Ahmadi M Sabbagh MN Development and validation of the Alzheimerrsquos Questionnaire (AQ)
Journal of Nature and Science 20151(5)e104
56 Anand K Sabbagh MN Early investigational drugs targeting tau protein for the treatment of Alzheimers Disease Expert Opinion in Investigational Drugs 2015 24 (10)1-6
57 Sabbagh MN Edgin JO Clinical Assessment of Cognitive Decline in Adults with Down Syndrome
Current Alzheimerrsquos Research 2015 Sep 20 [epub ahead of print]
58 Arab L Sabbagh MNAre Certain Lifestyle Habits Associated with Lower Alzheimers Disease Risk J Alzheimers Dis 2015 Oct 148(3)877 doi 103233JAD-159004 No abstract available
9 59 Bahureska L Schwenk M Sabbagh M Mohler J Saleh A Najafi B The Impact of Mild Cognitive
Impairment on Balance and Gait a Systematic Review and Meta-Analysis Gerontology 2016 (DOI101159000445831)
60 Anand K Sabbagh MN Amyloid imaging poised for integration into medical practice Neurotherapeutics 2016 Aug 29 [Epub ahead of print] Review
61 Marwan Sabbagh1 SeolHeui Han
2 SangYun Kim
3 Hae-Ri Na
4 Jae-Hong Lee
5 Nagaendran Kandiah
6
Kammant Phanthumchinda7 Chuthamanee Suthisisang
8 Vorapun Senanarong
9 Ming-Chyi Pai
10 Diatri
Narilastri11
Ajit M Sowani12
Encarnita Ampil13
Amitabh Dash14
for the Asia Pacific EXpert Panel (APEX) for Donepezil 23 mg Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimerrsquos disease in the Asia-Pacific region Dement Geriatr Cogn Disord Extra 20166382-395 (DOI101159000448214)
62 Decourt B Lahiri DK Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimers Disease Curr Alzheimer Res 2016 Sep 30
63 Sabbagh MN Editorial Introduction Neurol Ther 2016 Nov 9 [Epub ahead of print]
64 Shefner JM Sabbagh MN An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases Editorial Introduction Neurotherapeutics 2016 Dec 8 [Epub ahead of print] No abstract available
65 Sabbagh MN DeCourt B Editorial Current and Emerging Therapeutics in AD Current Alzheimerrsquos Research 201714 (3) 354-355
66 DeCourt B Lahiri D Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimerrsquos Disease Current Alzheimerrsquos Research 201714 (3) 412-425
67 Mehta DG Paul G Shi J Sabbagh MN Why are drugs failing in Alzheimerrsquos disease 2010-2015 Expert Opin Investig Drugs 2017 May 2 doi 1010801354378420171323868 [Epub ahead of print]
68 Sabbagh MN Lue LF Fayard D Shi J Increasing precision of clinical diagnosis of AD using a combined algorithm incorporating clinical and novel biomarker data Neurology and Therapy 2017 (submitted)
69 Sabbagh MN Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimerrsquos Disease and Related Disorders Neurology and Therapy 2017 (submitted)
70 Sabbagh MN Editorial Clinical Effects of Oral Tramiprosate in APOE44 Homozygous Patients with Mild Alzheimerrsquos Disease Suggest Disease Modification JPAD 2017 (submitted)
71 Geidy Serrano Marwan S Sabbagh Michael Sierks Tyler A Kokjohn Thomas G Beach Chera L Maarouf Steven G Clarke4 Alex Roher APPAβ Structural Diversity and Alzheimerrsquos Disease Pathogenesis Neurochemistry International 2017 (submitted)
Peer-Reviewed Manuscripts
1 Adem A Sabbagh M Nordberg A Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex Journal of Neural Transmission 1988 7211-18
2 Sabbagh M Garza J Patten B Thoracoscopic thymectomy in myasthenia gravis Muscle amp Nerve
1995 181475-1477
3 Sabbagh M Lynn P Jhingran S et al Correlation of SPECT Regional cerebral blood flow defects to psychometric testing in patients with Alzheimers disease Journal of Neuropsychiatry and Clinical Neurosciences 1997 9 68-74
4 Corey-Bloom J Sabbagh MN Bondi MW Hansen L Alford MF Thal LJ Hippocampal sclerosis
contributes to dementia in the elderly Neurology 1997 48(1) 154-160
5 Olichney J Sabbagh M Hofstetter RC Galasko D Grundman M Katzman R Thal L The impact of
apolipoprotein 4 on the cause of death in Alzheimerrsquos disease Neurology 1997 49(1) 76-81
10 6 Olichney J Ellis R Katzman R Sabbagh M Hansen L Types of cerebrovascular lesions associated
with severe cerebral amyloid angiopathy in Alzheimers disease Annals of the New York Academy of Sciences 1997 826 493-497
7 Sabbagh MN Reid R Corey-Bloom J Rao T Lloyd K Hansen L Alford M Masliah E Adem A Thal
LJ Correlation of nicotinic binding to neurochemical markers in Alzheimerrsquos disease Journal of Neural Transmission 1998105(7) 709-717
8 Sabbagh MN Corey-Bloom J Tiraboschi P Thomas R Masliah E Thal LJ Neurochemical markers
do not correlate with cognitive decline in the Lewy Body Variant of Alzheimerrsquos disease Archives of Neurology 1999 56(12) 1568-1572
9 Tiraboschi P Hansen LA Sabbagh MN Schoos B Alford M Masliah E Thal LJ Corey-Bloom J
Cholinergic dysfunction in diseases with Lewy bodies Neurology 2000 54407-411
10 Corey-Bloom J Tiraboschi P Hansen LA Schoos B Alford M Sabbagh MN Masliah E Thal LJ E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimerrsquos disease Neurology 2000 54403-406
11 Reid RT Sabbagh MN Corey-Bloom J Tiraboschi P Thal LJ Nicotinic receptor in dementia with
Lewy Bodies comparisons with Alzheimerrsquos disease Neurobiology of Aging 2000 21 (5) 741-746
12 ReidRT Sabbagh MN Thal LJ Does apolipoprotein e (apo e) genotype influence nicotinic receptor binding in Alzheimers disease J Neural Transmission 2001 108(8-9) 1043-1050
13 Sabbagh MN Reid RT Hansen LA Alford M Thal LJ Correlation of nicotinic receptor binding with
clinical and neuropathological changes in Alzheimerrsquos disease and dementia with Lewy bodies J Neural Transmission 2001 108 (10) 1149-1157
14 Caselli R Beach T Sue L Connor DJ Sabbagh MN Progressive Aphasia with Lewy Bodies
Dementia and Geriatric Cognitive Disorders 2002 14 (2) 55-58
15 Sabbagh M Silverberg N Majeed B Samant S Sparks DL Seward J Connor DJ Length of stay in skilled nursing facilities is longer for patients with dementia J Alz Dis 2003 5(1) 57-63
16 Smith RG Roher A Appel SH Doody RS Killian DM Corey-Bloom J Sabbagh MN Autonomic
sudomotor dysfunction discriminates Alzheimerrsquos disease and non-demented control individuals Current Medicinal Chemistry Immunology Endocrine and Metabolic Agents 2003 3233-243
17 Reid RT Sabbagh MN Effects of Donepezil Treatment on Rat Nicotinic Acetylcholine Receptor
Levels In Vivo and In Vitro Journal of Alzheimerrsquos Disease 2003 5(6) 429-436
18 Caviness JN Adler CH Sabbagh M Connor DJ Hernandez JL Lagerlund T Abnormal Cortico-muscular Coherence is associated with the small amplitude cortical myoclonus in Parkinsonrsquos Disease Movement Disorders 2003 18 (10) 1157-62
19 Beach TG Sue L Scott S Layne K Newell A Walker D Baker M Sahara N Yen S-H Hutton M
Caselli R Adler C Connor D Sabbagh M Hippocampal Sclerosis Dementia with Tauopathy Brain Pathology 2003 13 263-278
20 Sparks DL Lopez J Sabbagh M Connor D Seward J Browne P A position paper based on
observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the AD Cholesterol-Lowering Treatment Trial J Molecular Neuroscience 2003 20 407-410
21 Caselli RJ Beach TG Sue LI Connor DJ Sabbagh MN Progressive aphasia with Lewy bodies
Dementia Review Series 2003 4 10-11
22 Sabbagh MN Thompson N Tweedy D Stipho-Majeed S Kawas C Connor DJ Successful and Unsuccessful Recruitment and Retention Strategies for Alzheimerrsquos Disease Clinical Trials Pharmaceutical Regulation and Development 2003 1(4) 269-276
11 23 Johnson SC Baxter LC Susskind-Wilder L Connor DJ Sabbagh MN Caselli RJ Hippocampal
Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment Neuropsychologia 2004 42(7) 980-989
24 Li R Lindholm K Yang LB Yue X Citron M Yan R Beach T Sue L Sabbagh M Cai H Wong P
Price D Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimers disease patients Proc Natl Acad Sci U S A 2004 Mar 9 101(10)3632-3637
25 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A Masliah E Alford M Thal
LJ Corey-Bloom J Alzheimerrsquos disease without neocortical neurofibrillary tangles ldquoa second lookrdquo Neurology 2004 621141-1147
26 Davie JE Azuma T Goldinger SD Connor DJ Sabbagh MN Silverberg N Sensitivity to Expectancy
Violations in Healthy Aging and Mild Cognitive Impairment Neuropsychology 2004 18(2) 269-275
27 Sabbagh MN Silverberg NB Descheny RL Baxter LC Connor DJ Crocker-Sabbagh IP Dementia with Lewy bodies in a Native American Alzheimerrsquos Disease and Associated Disorders 2004 18 (4)259-261
28 Sabbagh MN Zahiri HR Ceimo J Cooper K Gaul W Connor DJ Sparks DL Is there a characteristic
lipid profile in Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2004 6 (6) 585-589
29 Sabbagh MN Tyas SL Emery SC Hansen LA Alford MF Reid RT Tiraboschi P Thal LJ Smoking Affects the Phenotype of Alzheimerrsquos Disease Neurology 2005 Apr 1264(7)1301-3
30 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Petanceska S Browne P Wassar D Johnson-Traver S Lochhead J Ziolwolski C Benefit of Atorvastatin in the treatment of mild to moderate Alzheimerrsquos disease results from the Alzheimerrsquos disease cholesterol lowering treatment (ADCLT) trial Archives of Neurology 2005 62753-757
31 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Browne P Johnson-Traver S Lochhead J
Ziolwolski C Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD Current Alzheimerrsquos Research 2005 Jul2(3)343-53
32 Sabbagh MN Silverberg N Bircea S Majeed B Samant S Caviness JN Reisberg B Adler CH Is
the functional decline in PD similar to the functional decline of AD Parkinsonism and Related Disorders 2005 11 311-315
33 Sabbagh MN Hake AM Ahmed S Farlow MR The use of memantine in Dementia with Lewy Bodies
Journal of Alzheimerrsquos Disease 2005 7(4) 285-289
34 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C rols MCI AD and the AD Cholesterol
Lowering Treatment Trial Current Alzheimerrsquos Research 2005 2527-539
35 Rogers J Li R Mastroeni D Grover A Leonard B Ahern G Cao P Kolody H Vedders L Kolb WP Sabbagh M Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes Neurobiology of Aging 2006 271733-1739
36 Caviness JN Shill HA Sabbagh MN Evidente VGH Hernandez J Adler CH Cortico-Muscular
coherence is increased in the small postural tremor of Parkinsonrsquos disease Movement Disorders 2006 21 (4)492-499
37 Sabbagh MN Sandhu S Lahti T Kolody H Silverberg NB Sparks DL What is the effect of the
apolipoprotein E genotype on the lipid profile in Alzheimerrsquos disease Current Alzheimerrsquos Research 2006 3(2) 157-160
38 Sparks DL Connor DJ Sabbagh MN Petersen RB Lopez J Browne P Circulating cholesterol
levels apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
AREA AGENCY ON AGING NACOG
Building Strong Communities
Conference Session Planning Worksheet October 5-6 2017
Speaker(s) Marwan N Sabbagh MD
Session Title Not all dementia is Alzheimerrsquos disease An update on diagnosis
Session Description lecture
Session Objectives (Minimum of 3)
1 To review all forms of dementia 2 To discuss new approaches to diagnosis 3 To inform the audience about Mild Cognitive Impairment as a prodome to dementia
For AAA NACOG Internal Use Only
Session Worksheet Approved________________________________________Date________________
2 UCSD Medical Center San Diego CA Staff Physician (1995-2000) Alzheimers Disease Research Center (ADRC) University of California San Diego San Diego CA Assistant Clinical Professor of Pharmacy Practice (1998-2000) Western College of Pharmacy Pomona CA Volunteer Physician (1995-2000) St Vincent De Paul Medical Clinic San Diego CA Volunteer Physician (2000-2005) St Vincent De Paul Clinic Phoenix AZ
Staff Neurologist (2003-2007) Phoenix Indian Medical Center Phoenix AZ Visiting Scientist (2000-2006) Department of Neurology Mayo Clinic Scottsdale Scottsdale AZ Adjunct Professor (2004-2009) College of Nursing Arizona State University Tempe AZ Adjunct Professor (2003-2008) Physician Assistant Osteopathic and Podiatry Programs Midwestern University Glendale AZ Clinical Instructor (2000-2008) Geriatric Fellowship Program Sun Health St Josephrsquos Hospitals Phoenix AZ
Board of Directors (2005-2011) Chairman of Medical-Scientific Advisory Committee Desert Southwest Chapter Alzheimerrsquos Association Phoenix AZ Co-Director (2007-2010) Clinical Therapeutics Core Arizona Alzheimerrsquos Registry Arizona Alzheimerrsquos Consortium Chairman-Scientific Advisory Board (2008-2012) Amerisciences Incorporated Houston TX TRAINING Fellowship (Geriatric Neurology amp Dementia) 1995-1997 under the mentorship of Drs Leon Thal and Robert Katzman Department of Neurosciences
3 University of California San Diego School of Medicine San Diego California Residency (Neurology) 1992-1995 Baylor College of Medicine Houston Texas Internship (Internal Medicine) 1991-1992 Good Samaritan Regional Medical Center Phoenix Arizona EDUCATION MD - University of Arizona College of Medicine 1991 BA - University of California - Berkeley 1987 HONORSAWARDS Student Summer Fellow Arizona Cancer Society 1988
Student Representative to the Western Federation of Clinical Research University of Arizona 1990
Allistair Karmody Award Finalist 1991 Travel Fellowship Award Recipient American Neurological Association 1996 Peter F Drucker Award Co-recipient 1998 Dystonia Doctor of Excellence San Diego County 2000 Life Member of the National Registry of Whorsquos Who 172142 2001 Arizona Business Journal Healthcare Hero Finalist 2004 Fellow of the American Academy of Neurology 2004 WestMarc Innovator Award 2015 BOARDS Diplomate of the National Board of Medical Examiners 1992 Certificate 407526 Diplomate of the American Board of Psychiatry and Neurology 1996 Certificate 43257 Recertified in 2007 Certified Clinical Research Investigator 03-F052 Diplomate of the UCNS Board of Geriatric Neurology LICENSES Arizona Medical License 1994 (AZ22378) California Medical License 1995 (CAG08170) Medicare UPING13648 AHCCCS540113 HOSPITAL AFFILIATIONS Saint Josephrsquos Hospital and Medical Center Phoenix AZ MEMBERSHIPS American Medical Association 1988-1993 American Federation of Clinical Research 1988-1991 American College of Physicians 1991-1997 American Academy of Neurology 1992-Present San Diego Neurological Society 1995-2000 Society for Neuroscience 1997- 2005 Arizona Geriatric Society 2001-Present Society for Behavioral and Cognitive Neurology 2001-2008 EDITOR FOR Neurology and Therapy (editor-in-chief) Journal of Alzheimerrsquos Disease (associate editor) BMC Neurology (section editor-dementia) Expert Opinion on Investigational Drugs (editorial board)
Alzheimerrsquos and Dementia Translational Research and Clinical Interventions (editorial board)
AD HOC REVIEWER FOR The Journal of Neuropsychiatry and Clinical Neuroscience Physiology and Behavior Grants Committee - Alzheimerrsquos Association Brain Research
4 Neurobiology of Aging Neurology Archives of Neurology Clinical Neurosciences and Disease Study Section CND-1 NIH Neuropharmacology Small Business ZRG1 BDCN-A (11) B CSR NIH Emerging Technology and Training in Neuroscience ETTN CSR NIH Aging Program Project Review ZRG1 BDCN-L 42P Alzheimers Disease Pilot Clinical Trials ZRG1 BBBP-V (55) R European Archives of Psychiatry and Clinical Neurosciences Journal of Clinical Psychiatry Neuroscience Letters Neuroepidemiology Biological Psychiatry International Journal of Geriatric Psychiatry Annals of Neurology PUBLICATIONS (Google scholar h-index 61) Books 1 Sabbagh MN The Alzheimerrsquos Answer Reduce Your Risk and Keep Your Brain Healthy 2008 2010
(paperback) John Wiley and Sons Hoboken New Jersey 2 Sabbagh MN Alzheimer Guia practica Respuestas a las cuestiones fundamentales desde su
diagnostico hsta como se aplica el tratamiento (Spanish Edition) 2010 RobinBooks Barcelona Spain 3 Martin G Sabbagh MN (eds) Palliative Care For Advanced Alzheimerrsquos and Dementia Guidelines and
Standards for Evidence Based Care 2010 Springer Publishing Company New York NY
4 Sabbagh M MacMillan B The Alzheimerrsquos Prevention Cookbook Recipes to Boost Brain Health 2012 TenSpeed Press Emeryville California
5 Nair A Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford United Kingdom Invited Chapters 1 Smith RG Sabbagh M White P Brod S Oral tolerance therapy of autoimmune disease In Appel SH
(ed) Current Neurology 1996 Mosby New York 16165-189 2 Shaibani AT Sabbagh MN Khan B Pathological Human Crying In Ad JJM Vingerhoets Randolph R
Cornelius (eds) Adult Crying A Biopsychosocial Approach 2002 Brunner-Routledge East Sussex UK
3 Sparks DL Connor DJ Browne PJ Wasser DR Lopez JE Sabbagh MN The Alzheimerrsquos disease atorvastatin treatment trial scientific basis and position on the use of the HMG-CoA reductase inhibitors (statins) that do or do not cross the blood-brain barrier In Fillit H OrsquoConnell AW Drug Discovery and Drug Development for Alzheimerrsquos Disease 2002 Springer Publishing Company New York 244-252
4 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C Lochhead J
Browne P Cholesterol copper and statin therapy in AD In Gauthier S Schelten P Cummings J Alzheimerrsquos Disease and Related Disorders Annual 5 2005 Taylor and Francis London 89-110
5 Reisberg B Weigel J Franssen E Kadiyala S Auer S Souren L Sabbagh M Golomb J Clinical features
of severe dementia-staging In Burns A Winblad B (eds) Severe Dementia 2006 John Wiley and Sons Hoboken New Jersey 95-127
6 McCarthy M Gallagher M Sabbagh M Appropriate use of medications in advanced dementia In Long C
(ed) Palliative Care for Advanced Dementia Guidelines and Standards 2006 Alzheimerrsquos Association Desert Southwest Chapter Phoenix AZ 40-51
7 Rogers J Beach T Li R Liang Z Lue L-F Roher A Sabbagh M Shen Y Strohmeyer R Walker D
Inflammatory mechanisms in Alzheimers disease and other neurodegenerative disorders In Chemistry and Molecular Aspects of Drug Design and Action (Kourounakis and Rekka eds) CRC Press (Boca Raton FL) pp 3-12 2007
5 8 Barry Reisberg Jerzy Wegiel Emile Franssen Sridhar Kadiyala Stefanie Auer Liduiumln Souren Marwan
Sabbagh and James Golomb Clinical Features of Severe Dementia Staging in Severe Dementia (Burns and Winblad eds) 2010 John Wiley and Sons Hoboken NJ Chapter 8
9 Reisberg B Jamil IA Khan S Monteiro I Torossian C Ferris S Sabbagh M Gauthier S Auer
S Shulman MB Kluger A Franssen E and Wegiel J Staging dementia In Principles and Practice of Geriatric Psychiatry 3rd edition M T Abou-Saleh C Katona and A Kumar (Eds) Chichester England Wiley-Blackwell 2010 p 162-169
10 Belden CM Burciu C Sabbagh M (2014) Global Deterioration Scale (Individuals) In Michalos AC (Ed)
Encyclopedia of Quality of Life and Well-Being Research Springer Dordrecht Netherlands Springer pp 2562-2564
11 Sabbagh MN Nair AK Approach to the Geriatric Neurology Patient The Neurologic Examination In Nair A
Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p71-84
12 Nair AK Sabbagh MN Amyloid imaging In Nair A Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p 162-169
13 Singh J Sabbagh MN Nair AK Evidence based pharmacological treatment of dementia In Nair A
Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p 557-573
14 Decourt B1 Macias M
1 Berk C
1 Sabbagh M
1 Adem A
2 BACE1 inhibitors attractive therapeutics for
Alzheimerrsquos disease In Ur-Rahman A Choudhary MI Frontiers in Drug Design and Discovery 2014 Bentham Science p518-546
Invited Reviews and Editorials 1 Taher A Sabbagh M Doody R Laughter and crying in neurologic disorders Neuropsychiatry
Neuropsychology amp Behavioral Neurology 7(4) 243-250 1994 2 Sabbagh MN Galasko D Thal LJ Beta amyloid and treatment opportunities for Alzheimers disease
Alzheimers Disease Reviews 1998 31-19 3 Shaibani AT Sabbagh MN Pseudo-Neurologic Syndromes Recognition and Diagnosis American Family
Physician 1998 57(10) 2485-2494 4 Sabbagh MN Application of the Changing Therapies for Alzheimerrsquos Disease in Clinical Practice
American Speech and Language Association 1998 3(1) 7-12
5 Sabbagh MN Galasko D Koo E Thal LJ -amyloid and treatment opportunities for Alzheimers disease Journal of Alzheimers Disease 2000 2(3-4) 231-259
6 Sparks DL Connor DJ Browne PJ Lopez JE Sabbagh MN HMG-CoA reductase inhibitors (statins) in
the treatment of Alzheimerrsquos disease and why it would be ill-advised to use one that crosses the blood-brain barrier Journal of Nutrition Health and Aging 2002 6(5) 324-330
7 Sparks DL Connor DJ Browne P and Sabbagh MN Should the guidelines for monitoring serum
cholesterol levels in the elderly be re-evaluated Journal of Molecular Neuroscience 2002 19 209-212 8 Sabbagh MN Lukas RJ Sparks DL Reid RT The nicotinic acetylcholine receptor smoking and
Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2002 4 (4) 317-325 9 Sparks DL Sabbagh MN Breitner JCS Hunsaker J Is cholesterol a culprit in AD International
Psychogeriatrics 2003 15 (suppl1) 153-159 10 Sabbagh MN Farlow MR Relkin NR Beach TG Do cholinergic therapies have disease modifying effects
in Alzheimerrsquos disease Alzheimerrsquos and Dementia 20062(2) 118-125 11 Sparks DL Sabbagh M Connor D Soares H Lopez J Stankovic G Johnson-Traver S Ziolkowski C
Browne P Statin therapy in AD Acta Neurologica Scandinavica 2006 185S78-86
6 12 Thind K Sabbagh MN Pathological Correlates of Cognitive Decline in Alzheimerrsquos Disease PanMinerva
Medica 2007 49(4)191-195 13 Beach TG Sue LI Walker DG Roher AE Lue LF Vedders L Connor DJ Sabbagh M Rogers J The
Sun Health Research Institute Brain Donation Program Description and Experience 1987-2007 Cell Tissue Bank 2008 Mar 18 [Epub ahead of print]
14 Sabbagh MN Richardson S Relkin N Disease modifying approaches to Alzheimers disease Challenges
and opportunities Lessons from donepezil therapyrdquo Alzheimerrsquos and Dementia 2008 4(1) S109-S118 15 Sabbagh MN Commentary on the baseline data of the atorvastatindonepezil study for Alzheimerrsquos
disease Alzheimerrsquos and Dementia 2008 4 (3)174-175 16 Khatchaturian ZS Petersen RC Gauthier S Buckholtz N Corey-Bloom J Evans B Fillit H Foster N
Greenberg B Grundman M Sano M Simpkins J Schneider LS Weiner MW Galasko D Hyman B Kuller L Schenk D Snyder S Thomas RG Tuszinski MH Vellas B Wurtman RJ Snyder PJ Frank RA Albert M Doody R Ferris S Kaye J Koo E Morrison-Bogorad M Reisberg B Salmon DP Gilman S Mohs R Aisen PS Breitner JCS Cummings JL Kawas C Phelps C Poirier J Sabbagh M Touchon J Khatchaturian AS Bain L A roadmap for the prevention of dementia the inaugural Leon Thal Symposium Alzheimerrsquos and Dementia 2008 4 (3)156-163
17 Rogers J Sabbagh MN Relationships of strokes and non-steroidal anti-inflammatory drug use to
apolipoprotein E4-conferred of Alzheimerrsquos disease and dementia Neurology 2008 702-4 18 Quinn J Sabbagh MN Editorial Biochemical Markers in Persons with Pre-Clinical Familial Alzheimers
Disease Neurology 2008 7178-79 19 Jacobson S Sabbagh MN Donepezil potential neuroprotective and disease modifying effects Expert
Opinion on Drug Metabolism and Toxicology 2008 4(10)1363-1369 20 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathologica 2008 Nov 4 [epub ahead of print] 21 Lue LF Jacobson S Walker D Sabbagh MN The receptor for advanced glycation end-products its role
in Alzheimerrsquos and other diseases Future Neurology 2009 4(2) 167-177 22 Sabbagh MN Tariot PN Commentary on A roadmap for the prevention of dementia II Leon Thal
Symposium 2008 A national registry to identify a cohort for Alzheimerrsquos disease prevention studies Alzheimerrsquos and Dementia 20095 128-129
23 Khachaturian ZS Snyder PJ Doody RS Aisen P Comer M Dwyer J Frank RA Holzapfel A
Khachaturian AS Korczyn AD Phelps C Roses A Simpkins JW Schneider LS Albert MS Egge R Deves A Ferris S Greenberg BD Johnson C Kukull WA Poirier J Schenk D Thies W Gauthier S Gilman S Bernick C Cummings JL Fillit H Grundman M Kaye J Mucke L Reisberg B Sano M Pickeral O Petersen RC Mohs RC Buckholtz N Carrillo M Corey-Bloom JP Foster NL Jacobsen S Lee V Potter WZ Sabbagh MN Salmon D Trojanowski JQ Wexler N Bain LJ A roadmap for the prevention of dementia II Leon Thal Symposium 2008 Alzheimerrsquos and Dementia 2009 585-92
24 Sabbagh MN Drug Development for Alzheimerrsquos Disease Where Are We Now and Where Are We
Headed American Journal of Geriatric Pharmacotherapy 2009 7(3) 167-185 25 Sabbagh MN Thind K Sparks DL On cholesterol levels and statins in Alzheimerrsquos disease and cognitive
decline progress and setbacks Alzheimerrsquos Disease and Associated Disorders 2009 (Oct-Dec) 23(4)303-305
26 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathol 2009 Feb117(2)217-218
7 27 Sabbagh MN Shill HA Dimebon (latrepirdine) a potential treatment with a novel mechanism of action for
the treatment of Alzheimers disease and Huntington disease Current Opinion in Investigational Drugs 2010 Curr Opin Investig Drugs 2010 Jan11(1)80-91
28 Arab L Sabbagh MN Lifestyle changes do they lower Alzheimerrsquos risk Journal of Alzheimerrsquos Disease
201020(3)785-94 Review PubMedPMID 20182018
29 Sabbagh MN Commentary On The Perspective Design Of Comprehensive Alzheimers Disease Centers To Address Unmet National Needs by JQ Trojanowski et al Alzheimerrsquos and Dementia 2010 Mar6(2)156-7 No abstract available
30 Khachaturian AS Sabbagh M Commentary on Developing a national strategy to prevent dementia
Leon Thal Symposium 2009 Creating a national database for successful aging Alzheimers Dement 2010 Mar6(2)132-4 No abstract available
31 Zaven Khachaturian [Convener ndash Facilitator] - Presenters Deborah Barnes Richard Einstein Sterling
Johnson Virginia Lee Allen Roses Mark A Sager William R Shankle Peter J Snyder Ronald C Petersen Gerard Schellenberg and John Trojanowski - Discussants Paul Aisen Marilyn S Albert Charles Bernick John C S Breitner Neil Buckholtz Maria Carrillo Steven Ferris Barry D Greenberg Michael Grundman Ara S Khachaturian Lewis H Kuller Oscar L Lopez Paul Maruff Richard C Mohs Marcelle Morrison-Bogorad Creighton Phelps Michael Phillips Stephen Rao Eric Reiman Marwan Sabbagh Mary Sano Randy Schiffer Lon S Schneider Eric Siemers Pierre Tariot Jacques Touchon Bruno Vellas Reporter Lisa J Bain Developing a National Strategy to Prevent Dementia Alzheimerrsquos and Dementia 2010 Mar6(2)89-97
32 Sabbagh MN Berk C Latrepirdine for Alzheimerrsquos disease trials and tribulations Future Neurology 2010
September 2010 Vol 5 No 5 Pages 645-651
33 Sabbagh MN Cummings J Progressive Cholinergic Decline in Alzheimerrsquos Disease Consideration for Treatment With Donepezil 23 mg in Patients With Moderate to Severe Symptomatology BMC Neurology 2011 1121
34 DeCourt B Sabbagh MN BACE1 as a potential biomarker for Alzheimerrsquos disease Journal of
Alzheimerrsquos Disease 201124 Suppl 253-9]
35 Jacobson SA Sabbagh MN Investigational drugs for the treatment of Alzheimerrsquos disease failed trials Alzheimerrsquos Research and Therapy 2011 Apr 153(2)14 [Epub ahead of print]
36 Patel S Shah R Coleman P Sabbagh MN Potential Peripheral Biomarkers for the Diagnosis of
Alzheimerrsquos Disease International Journal of Alzheimerrsquos Disease 2011572495 Epub 2011 Oct 23
37 Mehta M Adem A Sabbagh MN The nicotinic receptor smoking and Alzheimerrsquos revisited Frontiers in Bioscience E4 169-180 January 1 2012
38 Sabbagh MN Berk C Appraisal of higher doses of donepezil in the treatment of mild moderate and
severe Alzheimers disease International Journal of Alzheimerrsquos Disease 20122012707468 Epub 2011 Dec 1
39 Arab L Sadeghi R Walker DG Lue LF Sabbagh MN Consequences of aberrant insulin regulation in the
brain Can treating diabetes be effective for Alzheimerrsquos Disease Current Neuropharmacology 2011 9(4) 693-705
40 Mehta M Adem A Sabbagh MN New acetylcholinesterase inhibitors for Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 728983 8 pages doi1011552012728983
41 Sabbagh MN Sparks DL Statins to treat Alzheimerrsquos an incomplete story Expert Review in
Neurotherapeutics January 2012 Vol 12 No 1 Pages 27-30
8 42 Sabbagh MN Porsteinsson AP Nair A Adem A Novel Therapeutics in Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 207969 2 pages
43 Sabbagh MN Geula C Messis C Friedland R Conference Report on the 5th International Conference on
Alzheimerrsquos Disease in the Middle East May 7-9 2009 Limmassol Cyprus Journal of Alzheimerrsquos Disease 2012 May 21Epub ahead of print] No abstract available PMID22614876
44 Lue LF Andrade C Sabbagh MN Walker DG Is there inflammatory synergy in type II diabetes mellitus
and Alzheimerrsquos disease International Journal of Alzheimerrsquos Disease 2012918680 Epub 2012 Jun 21
45 Sabbagh MN Ahmadi MM Belden C The Use of Informant-Based Questionnaires in Differentiating Mild Cognitive Impairment from Normal Aging Expert Review of Neurotherapeutics 2012 Jun12(6)637-9
46 Jeffrey L Cummings1 David Geldmacher
2 Martin Farlow
3 Marwan Sabbagh
4 Daniel Christensen
5 amp
Peter Betz6 for the Donepezil 23 mg Expert Working Group High-Dose Donepezil (23 mgday) for the
Treatment of Moderate and Severe Alzheimerrsquos Disease Drug Profile and Clinical Guidelines CNS Neurosci Ther 2013 Mar 6 doi 101111cns12076 [Epub ahead of print]
47 DeCourt B Mobley W Reiman E Shah RJ Sabbagh MN Recent perspectives on Alzheimerrsquos disease pathological changes in Down syndromerdquo J Alzheimers Dis Parkinsonism 2013 S7 httpdxdoiorg 1041722161-0460S7-002
48 Adem A El-Agnaf O Sabbagh MN Neurodegeneration The first IBRO-Middle East Neuroscience
Conference Current Alzheimerrsquos Research 2013 10 (6)557-8
49 Berk C Sabbagh MN Drugs in Late Stage Development for Alzheimerrsquos Disease Drugs Aging 2013 Aug 14 [Epub ahead of print]
50 Berk C Paul G Sabbagh MN Investigational Drugs in Alzheimerrsquos Disease Current Progress Expert
Opinion on Investigational Drugs 2014 Expert Opin Investig Drugs 2014 Jun23(6)837-46 doi 101517135437842014905542 Epub 2014 Apr 5
51 Richards D Sabbagh MN Florbetaben for PET Imaging of Neuritic Beta-Amyloid Plaques in the Brain
Neurology and Therapy 2014 DOI 101007s40120-014-0022-9
52 Hartley D Blumenthal T Carrillo M DiPaolo G Esralew L Gardiner K Granholm AC Iqbal K Krams M Lemere C Lott I Mobley W Ness S Nixon R Potter H Reeves R Sabbagh M Silverman W Tycko B Whitten M Wisniewski T Down syndrome and Alzheimers disease Common pathways common goals Alzheimers Dement 2014 Dec 12 pii S1552-5260(14)02860-X doi 101016jjalz201410007
53 Saunders KT Langbaum JB Holt CJ Chen W High N Langlois C Sabbagh M Tariot PN Arizona
Alzheimers Registry Strategy and Outcomes of a Statewide Research Recruitment Registry J Prev Alzheimers Dis 2014 Sep1(2)74-79
54 Walker DG Lue LF Paul G Patel A Sabbagh MN Advanced Glycation Endproduct Modulators A New
Therapeutic Target in Alzheimerrsquos Disease Expert Opinion in Investigational Drugs Posted online on January 14 2015 (doi1015171354378420151001490)
55 Malek-Ahmadi M Sabbagh MN Development and validation of the Alzheimerrsquos Questionnaire (AQ)
Journal of Nature and Science 20151(5)e104
56 Anand K Sabbagh MN Early investigational drugs targeting tau protein for the treatment of Alzheimers Disease Expert Opinion in Investigational Drugs 2015 24 (10)1-6
57 Sabbagh MN Edgin JO Clinical Assessment of Cognitive Decline in Adults with Down Syndrome
Current Alzheimerrsquos Research 2015 Sep 20 [epub ahead of print]
58 Arab L Sabbagh MNAre Certain Lifestyle Habits Associated with Lower Alzheimers Disease Risk J Alzheimers Dis 2015 Oct 148(3)877 doi 103233JAD-159004 No abstract available
9 59 Bahureska L Schwenk M Sabbagh M Mohler J Saleh A Najafi B The Impact of Mild Cognitive
Impairment on Balance and Gait a Systematic Review and Meta-Analysis Gerontology 2016 (DOI101159000445831)
60 Anand K Sabbagh MN Amyloid imaging poised for integration into medical practice Neurotherapeutics 2016 Aug 29 [Epub ahead of print] Review
61 Marwan Sabbagh1 SeolHeui Han
2 SangYun Kim
3 Hae-Ri Na
4 Jae-Hong Lee
5 Nagaendran Kandiah
6
Kammant Phanthumchinda7 Chuthamanee Suthisisang
8 Vorapun Senanarong
9 Ming-Chyi Pai
10 Diatri
Narilastri11
Ajit M Sowani12
Encarnita Ampil13
Amitabh Dash14
for the Asia Pacific EXpert Panel (APEX) for Donepezil 23 mg Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimerrsquos disease in the Asia-Pacific region Dement Geriatr Cogn Disord Extra 20166382-395 (DOI101159000448214)
62 Decourt B Lahiri DK Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimers Disease Curr Alzheimer Res 2016 Sep 30
63 Sabbagh MN Editorial Introduction Neurol Ther 2016 Nov 9 [Epub ahead of print]
64 Shefner JM Sabbagh MN An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases Editorial Introduction Neurotherapeutics 2016 Dec 8 [Epub ahead of print] No abstract available
65 Sabbagh MN DeCourt B Editorial Current and Emerging Therapeutics in AD Current Alzheimerrsquos Research 201714 (3) 354-355
66 DeCourt B Lahiri D Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimerrsquos Disease Current Alzheimerrsquos Research 201714 (3) 412-425
67 Mehta DG Paul G Shi J Sabbagh MN Why are drugs failing in Alzheimerrsquos disease 2010-2015 Expert Opin Investig Drugs 2017 May 2 doi 1010801354378420171323868 [Epub ahead of print]
68 Sabbagh MN Lue LF Fayard D Shi J Increasing precision of clinical diagnosis of AD using a combined algorithm incorporating clinical and novel biomarker data Neurology and Therapy 2017 (submitted)
69 Sabbagh MN Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimerrsquos Disease and Related Disorders Neurology and Therapy 2017 (submitted)
70 Sabbagh MN Editorial Clinical Effects of Oral Tramiprosate in APOE44 Homozygous Patients with Mild Alzheimerrsquos Disease Suggest Disease Modification JPAD 2017 (submitted)
71 Geidy Serrano Marwan S Sabbagh Michael Sierks Tyler A Kokjohn Thomas G Beach Chera L Maarouf Steven G Clarke4 Alex Roher APPAβ Structural Diversity and Alzheimerrsquos Disease Pathogenesis Neurochemistry International 2017 (submitted)
Peer-Reviewed Manuscripts
1 Adem A Sabbagh M Nordberg A Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex Journal of Neural Transmission 1988 7211-18
2 Sabbagh M Garza J Patten B Thoracoscopic thymectomy in myasthenia gravis Muscle amp Nerve
1995 181475-1477
3 Sabbagh M Lynn P Jhingran S et al Correlation of SPECT Regional cerebral blood flow defects to psychometric testing in patients with Alzheimers disease Journal of Neuropsychiatry and Clinical Neurosciences 1997 9 68-74
4 Corey-Bloom J Sabbagh MN Bondi MW Hansen L Alford MF Thal LJ Hippocampal sclerosis
contributes to dementia in the elderly Neurology 1997 48(1) 154-160
5 Olichney J Sabbagh M Hofstetter RC Galasko D Grundman M Katzman R Thal L The impact of
apolipoprotein 4 on the cause of death in Alzheimerrsquos disease Neurology 1997 49(1) 76-81
10 6 Olichney J Ellis R Katzman R Sabbagh M Hansen L Types of cerebrovascular lesions associated
with severe cerebral amyloid angiopathy in Alzheimers disease Annals of the New York Academy of Sciences 1997 826 493-497
7 Sabbagh MN Reid R Corey-Bloom J Rao T Lloyd K Hansen L Alford M Masliah E Adem A Thal
LJ Correlation of nicotinic binding to neurochemical markers in Alzheimerrsquos disease Journal of Neural Transmission 1998105(7) 709-717
8 Sabbagh MN Corey-Bloom J Tiraboschi P Thomas R Masliah E Thal LJ Neurochemical markers
do not correlate with cognitive decline in the Lewy Body Variant of Alzheimerrsquos disease Archives of Neurology 1999 56(12) 1568-1572
9 Tiraboschi P Hansen LA Sabbagh MN Schoos B Alford M Masliah E Thal LJ Corey-Bloom J
Cholinergic dysfunction in diseases with Lewy bodies Neurology 2000 54407-411
10 Corey-Bloom J Tiraboschi P Hansen LA Schoos B Alford M Sabbagh MN Masliah E Thal LJ E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimerrsquos disease Neurology 2000 54403-406
11 Reid RT Sabbagh MN Corey-Bloom J Tiraboschi P Thal LJ Nicotinic receptor in dementia with
Lewy Bodies comparisons with Alzheimerrsquos disease Neurobiology of Aging 2000 21 (5) 741-746
12 ReidRT Sabbagh MN Thal LJ Does apolipoprotein e (apo e) genotype influence nicotinic receptor binding in Alzheimers disease J Neural Transmission 2001 108(8-9) 1043-1050
13 Sabbagh MN Reid RT Hansen LA Alford M Thal LJ Correlation of nicotinic receptor binding with
clinical and neuropathological changes in Alzheimerrsquos disease and dementia with Lewy bodies J Neural Transmission 2001 108 (10) 1149-1157
14 Caselli R Beach T Sue L Connor DJ Sabbagh MN Progressive Aphasia with Lewy Bodies
Dementia and Geriatric Cognitive Disorders 2002 14 (2) 55-58
15 Sabbagh M Silverberg N Majeed B Samant S Sparks DL Seward J Connor DJ Length of stay in skilled nursing facilities is longer for patients with dementia J Alz Dis 2003 5(1) 57-63
16 Smith RG Roher A Appel SH Doody RS Killian DM Corey-Bloom J Sabbagh MN Autonomic
sudomotor dysfunction discriminates Alzheimerrsquos disease and non-demented control individuals Current Medicinal Chemistry Immunology Endocrine and Metabolic Agents 2003 3233-243
17 Reid RT Sabbagh MN Effects of Donepezil Treatment on Rat Nicotinic Acetylcholine Receptor
Levels In Vivo and In Vitro Journal of Alzheimerrsquos Disease 2003 5(6) 429-436
18 Caviness JN Adler CH Sabbagh M Connor DJ Hernandez JL Lagerlund T Abnormal Cortico-muscular Coherence is associated with the small amplitude cortical myoclonus in Parkinsonrsquos Disease Movement Disorders 2003 18 (10) 1157-62
19 Beach TG Sue L Scott S Layne K Newell A Walker D Baker M Sahara N Yen S-H Hutton M
Caselli R Adler C Connor D Sabbagh M Hippocampal Sclerosis Dementia with Tauopathy Brain Pathology 2003 13 263-278
20 Sparks DL Lopez J Sabbagh M Connor D Seward J Browne P A position paper based on
observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the AD Cholesterol-Lowering Treatment Trial J Molecular Neuroscience 2003 20 407-410
21 Caselli RJ Beach TG Sue LI Connor DJ Sabbagh MN Progressive aphasia with Lewy bodies
Dementia Review Series 2003 4 10-11
22 Sabbagh MN Thompson N Tweedy D Stipho-Majeed S Kawas C Connor DJ Successful and Unsuccessful Recruitment and Retention Strategies for Alzheimerrsquos Disease Clinical Trials Pharmaceutical Regulation and Development 2003 1(4) 269-276
11 23 Johnson SC Baxter LC Susskind-Wilder L Connor DJ Sabbagh MN Caselli RJ Hippocampal
Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment Neuropsychologia 2004 42(7) 980-989
24 Li R Lindholm K Yang LB Yue X Citron M Yan R Beach T Sue L Sabbagh M Cai H Wong P
Price D Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimers disease patients Proc Natl Acad Sci U S A 2004 Mar 9 101(10)3632-3637
25 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A Masliah E Alford M Thal
LJ Corey-Bloom J Alzheimerrsquos disease without neocortical neurofibrillary tangles ldquoa second lookrdquo Neurology 2004 621141-1147
26 Davie JE Azuma T Goldinger SD Connor DJ Sabbagh MN Silverberg N Sensitivity to Expectancy
Violations in Healthy Aging and Mild Cognitive Impairment Neuropsychology 2004 18(2) 269-275
27 Sabbagh MN Silverberg NB Descheny RL Baxter LC Connor DJ Crocker-Sabbagh IP Dementia with Lewy bodies in a Native American Alzheimerrsquos Disease and Associated Disorders 2004 18 (4)259-261
28 Sabbagh MN Zahiri HR Ceimo J Cooper K Gaul W Connor DJ Sparks DL Is there a characteristic
lipid profile in Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2004 6 (6) 585-589
29 Sabbagh MN Tyas SL Emery SC Hansen LA Alford MF Reid RT Tiraboschi P Thal LJ Smoking Affects the Phenotype of Alzheimerrsquos Disease Neurology 2005 Apr 1264(7)1301-3
30 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Petanceska S Browne P Wassar D Johnson-Traver S Lochhead J Ziolwolski C Benefit of Atorvastatin in the treatment of mild to moderate Alzheimerrsquos disease results from the Alzheimerrsquos disease cholesterol lowering treatment (ADCLT) trial Archives of Neurology 2005 62753-757
31 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Browne P Johnson-Traver S Lochhead J
Ziolwolski C Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD Current Alzheimerrsquos Research 2005 Jul2(3)343-53
32 Sabbagh MN Silverberg N Bircea S Majeed B Samant S Caviness JN Reisberg B Adler CH Is
the functional decline in PD similar to the functional decline of AD Parkinsonism and Related Disorders 2005 11 311-315
33 Sabbagh MN Hake AM Ahmed S Farlow MR The use of memantine in Dementia with Lewy Bodies
Journal of Alzheimerrsquos Disease 2005 7(4) 285-289
34 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C rols MCI AD and the AD Cholesterol
Lowering Treatment Trial Current Alzheimerrsquos Research 2005 2527-539
35 Rogers J Li R Mastroeni D Grover A Leonard B Ahern G Cao P Kolody H Vedders L Kolb WP Sabbagh M Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes Neurobiology of Aging 2006 271733-1739
36 Caviness JN Shill HA Sabbagh MN Evidente VGH Hernandez J Adler CH Cortico-Muscular
coherence is increased in the small postural tremor of Parkinsonrsquos disease Movement Disorders 2006 21 (4)492-499
37 Sabbagh MN Sandhu S Lahti T Kolody H Silverberg NB Sparks DL What is the effect of the
apolipoprotein E genotype on the lipid profile in Alzheimerrsquos disease Current Alzheimerrsquos Research 2006 3(2) 157-160
38 Sparks DL Connor DJ Sabbagh MN Petersen RB Lopez J Browne P Circulating cholesterol
levels apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
2 UCSD Medical Center San Diego CA Staff Physician (1995-2000) Alzheimers Disease Research Center (ADRC) University of California San Diego San Diego CA Assistant Clinical Professor of Pharmacy Practice (1998-2000) Western College of Pharmacy Pomona CA Volunteer Physician (1995-2000) St Vincent De Paul Medical Clinic San Diego CA Volunteer Physician (2000-2005) St Vincent De Paul Clinic Phoenix AZ
Staff Neurologist (2003-2007) Phoenix Indian Medical Center Phoenix AZ Visiting Scientist (2000-2006) Department of Neurology Mayo Clinic Scottsdale Scottsdale AZ Adjunct Professor (2004-2009) College of Nursing Arizona State University Tempe AZ Adjunct Professor (2003-2008) Physician Assistant Osteopathic and Podiatry Programs Midwestern University Glendale AZ Clinical Instructor (2000-2008) Geriatric Fellowship Program Sun Health St Josephrsquos Hospitals Phoenix AZ
Board of Directors (2005-2011) Chairman of Medical-Scientific Advisory Committee Desert Southwest Chapter Alzheimerrsquos Association Phoenix AZ Co-Director (2007-2010) Clinical Therapeutics Core Arizona Alzheimerrsquos Registry Arizona Alzheimerrsquos Consortium Chairman-Scientific Advisory Board (2008-2012) Amerisciences Incorporated Houston TX TRAINING Fellowship (Geriatric Neurology amp Dementia) 1995-1997 under the mentorship of Drs Leon Thal and Robert Katzman Department of Neurosciences
3 University of California San Diego School of Medicine San Diego California Residency (Neurology) 1992-1995 Baylor College of Medicine Houston Texas Internship (Internal Medicine) 1991-1992 Good Samaritan Regional Medical Center Phoenix Arizona EDUCATION MD - University of Arizona College of Medicine 1991 BA - University of California - Berkeley 1987 HONORSAWARDS Student Summer Fellow Arizona Cancer Society 1988
Student Representative to the Western Federation of Clinical Research University of Arizona 1990
Allistair Karmody Award Finalist 1991 Travel Fellowship Award Recipient American Neurological Association 1996 Peter F Drucker Award Co-recipient 1998 Dystonia Doctor of Excellence San Diego County 2000 Life Member of the National Registry of Whorsquos Who 172142 2001 Arizona Business Journal Healthcare Hero Finalist 2004 Fellow of the American Academy of Neurology 2004 WestMarc Innovator Award 2015 BOARDS Diplomate of the National Board of Medical Examiners 1992 Certificate 407526 Diplomate of the American Board of Psychiatry and Neurology 1996 Certificate 43257 Recertified in 2007 Certified Clinical Research Investigator 03-F052 Diplomate of the UCNS Board of Geriatric Neurology LICENSES Arizona Medical License 1994 (AZ22378) California Medical License 1995 (CAG08170) Medicare UPING13648 AHCCCS540113 HOSPITAL AFFILIATIONS Saint Josephrsquos Hospital and Medical Center Phoenix AZ MEMBERSHIPS American Medical Association 1988-1993 American Federation of Clinical Research 1988-1991 American College of Physicians 1991-1997 American Academy of Neurology 1992-Present San Diego Neurological Society 1995-2000 Society for Neuroscience 1997- 2005 Arizona Geriatric Society 2001-Present Society for Behavioral and Cognitive Neurology 2001-2008 EDITOR FOR Neurology and Therapy (editor-in-chief) Journal of Alzheimerrsquos Disease (associate editor) BMC Neurology (section editor-dementia) Expert Opinion on Investigational Drugs (editorial board)
Alzheimerrsquos and Dementia Translational Research and Clinical Interventions (editorial board)
AD HOC REVIEWER FOR The Journal of Neuropsychiatry and Clinical Neuroscience Physiology and Behavior Grants Committee - Alzheimerrsquos Association Brain Research
4 Neurobiology of Aging Neurology Archives of Neurology Clinical Neurosciences and Disease Study Section CND-1 NIH Neuropharmacology Small Business ZRG1 BDCN-A (11) B CSR NIH Emerging Technology and Training in Neuroscience ETTN CSR NIH Aging Program Project Review ZRG1 BDCN-L 42P Alzheimers Disease Pilot Clinical Trials ZRG1 BBBP-V (55) R European Archives of Psychiatry and Clinical Neurosciences Journal of Clinical Psychiatry Neuroscience Letters Neuroepidemiology Biological Psychiatry International Journal of Geriatric Psychiatry Annals of Neurology PUBLICATIONS (Google scholar h-index 61) Books 1 Sabbagh MN The Alzheimerrsquos Answer Reduce Your Risk and Keep Your Brain Healthy 2008 2010
(paperback) John Wiley and Sons Hoboken New Jersey 2 Sabbagh MN Alzheimer Guia practica Respuestas a las cuestiones fundamentales desde su
diagnostico hsta como se aplica el tratamiento (Spanish Edition) 2010 RobinBooks Barcelona Spain 3 Martin G Sabbagh MN (eds) Palliative Care For Advanced Alzheimerrsquos and Dementia Guidelines and
Standards for Evidence Based Care 2010 Springer Publishing Company New York NY
4 Sabbagh M MacMillan B The Alzheimerrsquos Prevention Cookbook Recipes to Boost Brain Health 2012 TenSpeed Press Emeryville California
5 Nair A Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford United Kingdom Invited Chapters 1 Smith RG Sabbagh M White P Brod S Oral tolerance therapy of autoimmune disease In Appel SH
(ed) Current Neurology 1996 Mosby New York 16165-189 2 Shaibani AT Sabbagh MN Khan B Pathological Human Crying In Ad JJM Vingerhoets Randolph R
Cornelius (eds) Adult Crying A Biopsychosocial Approach 2002 Brunner-Routledge East Sussex UK
3 Sparks DL Connor DJ Browne PJ Wasser DR Lopez JE Sabbagh MN The Alzheimerrsquos disease atorvastatin treatment trial scientific basis and position on the use of the HMG-CoA reductase inhibitors (statins) that do or do not cross the blood-brain barrier In Fillit H OrsquoConnell AW Drug Discovery and Drug Development for Alzheimerrsquos Disease 2002 Springer Publishing Company New York 244-252
4 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C Lochhead J
Browne P Cholesterol copper and statin therapy in AD In Gauthier S Schelten P Cummings J Alzheimerrsquos Disease and Related Disorders Annual 5 2005 Taylor and Francis London 89-110
5 Reisberg B Weigel J Franssen E Kadiyala S Auer S Souren L Sabbagh M Golomb J Clinical features
of severe dementia-staging In Burns A Winblad B (eds) Severe Dementia 2006 John Wiley and Sons Hoboken New Jersey 95-127
6 McCarthy M Gallagher M Sabbagh M Appropriate use of medications in advanced dementia In Long C
(ed) Palliative Care for Advanced Dementia Guidelines and Standards 2006 Alzheimerrsquos Association Desert Southwest Chapter Phoenix AZ 40-51
7 Rogers J Beach T Li R Liang Z Lue L-F Roher A Sabbagh M Shen Y Strohmeyer R Walker D
Inflammatory mechanisms in Alzheimers disease and other neurodegenerative disorders In Chemistry and Molecular Aspects of Drug Design and Action (Kourounakis and Rekka eds) CRC Press (Boca Raton FL) pp 3-12 2007
5 8 Barry Reisberg Jerzy Wegiel Emile Franssen Sridhar Kadiyala Stefanie Auer Liduiumln Souren Marwan
Sabbagh and James Golomb Clinical Features of Severe Dementia Staging in Severe Dementia (Burns and Winblad eds) 2010 John Wiley and Sons Hoboken NJ Chapter 8
9 Reisberg B Jamil IA Khan S Monteiro I Torossian C Ferris S Sabbagh M Gauthier S Auer
S Shulman MB Kluger A Franssen E and Wegiel J Staging dementia In Principles and Practice of Geriatric Psychiatry 3rd edition M T Abou-Saleh C Katona and A Kumar (Eds) Chichester England Wiley-Blackwell 2010 p 162-169
10 Belden CM Burciu C Sabbagh M (2014) Global Deterioration Scale (Individuals) In Michalos AC (Ed)
Encyclopedia of Quality of Life and Well-Being Research Springer Dordrecht Netherlands Springer pp 2562-2564
11 Sabbagh MN Nair AK Approach to the Geriatric Neurology Patient The Neurologic Examination In Nair A
Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p71-84
12 Nair AK Sabbagh MN Amyloid imaging In Nair A Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p 162-169
13 Singh J Sabbagh MN Nair AK Evidence based pharmacological treatment of dementia In Nair A
Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p 557-573
14 Decourt B1 Macias M
1 Berk C
1 Sabbagh M
1 Adem A
2 BACE1 inhibitors attractive therapeutics for
Alzheimerrsquos disease In Ur-Rahman A Choudhary MI Frontiers in Drug Design and Discovery 2014 Bentham Science p518-546
Invited Reviews and Editorials 1 Taher A Sabbagh M Doody R Laughter and crying in neurologic disorders Neuropsychiatry
Neuropsychology amp Behavioral Neurology 7(4) 243-250 1994 2 Sabbagh MN Galasko D Thal LJ Beta amyloid and treatment opportunities for Alzheimers disease
Alzheimers Disease Reviews 1998 31-19 3 Shaibani AT Sabbagh MN Pseudo-Neurologic Syndromes Recognition and Diagnosis American Family
Physician 1998 57(10) 2485-2494 4 Sabbagh MN Application of the Changing Therapies for Alzheimerrsquos Disease in Clinical Practice
American Speech and Language Association 1998 3(1) 7-12
5 Sabbagh MN Galasko D Koo E Thal LJ -amyloid and treatment opportunities for Alzheimers disease Journal of Alzheimers Disease 2000 2(3-4) 231-259
6 Sparks DL Connor DJ Browne PJ Lopez JE Sabbagh MN HMG-CoA reductase inhibitors (statins) in
the treatment of Alzheimerrsquos disease and why it would be ill-advised to use one that crosses the blood-brain barrier Journal of Nutrition Health and Aging 2002 6(5) 324-330
7 Sparks DL Connor DJ Browne P and Sabbagh MN Should the guidelines for monitoring serum
cholesterol levels in the elderly be re-evaluated Journal of Molecular Neuroscience 2002 19 209-212 8 Sabbagh MN Lukas RJ Sparks DL Reid RT The nicotinic acetylcholine receptor smoking and
Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2002 4 (4) 317-325 9 Sparks DL Sabbagh MN Breitner JCS Hunsaker J Is cholesterol a culprit in AD International
Psychogeriatrics 2003 15 (suppl1) 153-159 10 Sabbagh MN Farlow MR Relkin NR Beach TG Do cholinergic therapies have disease modifying effects
in Alzheimerrsquos disease Alzheimerrsquos and Dementia 20062(2) 118-125 11 Sparks DL Sabbagh M Connor D Soares H Lopez J Stankovic G Johnson-Traver S Ziolkowski C
Browne P Statin therapy in AD Acta Neurologica Scandinavica 2006 185S78-86
6 12 Thind K Sabbagh MN Pathological Correlates of Cognitive Decline in Alzheimerrsquos Disease PanMinerva
Medica 2007 49(4)191-195 13 Beach TG Sue LI Walker DG Roher AE Lue LF Vedders L Connor DJ Sabbagh M Rogers J The
Sun Health Research Institute Brain Donation Program Description and Experience 1987-2007 Cell Tissue Bank 2008 Mar 18 [Epub ahead of print]
14 Sabbagh MN Richardson S Relkin N Disease modifying approaches to Alzheimers disease Challenges
and opportunities Lessons from donepezil therapyrdquo Alzheimerrsquos and Dementia 2008 4(1) S109-S118 15 Sabbagh MN Commentary on the baseline data of the atorvastatindonepezil study for Alzheimerrsquos
disease Alzheimerrsquos and Dementia 2008 4 (3)174-175 16 Khatchaturian ZS Petersen RC Gauthier S Buckholtz N Corey-Bloom J Evans B Fillit H Foster N
Greenberg B Grundman M Sano M Simpkins J Schneider LS Weiner MW Galasko D Hyman B Kuller L Schenk D Snyder S Thomas RG Tuszinski MH Vellas B Wurtman RJ Snyder PJ Frank RA Albert M Doody R Ferris S Kaye J Koo E Morrison-Bogorad M Reisberg B Salmon DP Gilman S Mohs R Aisen PS Breitner JCS Cummings JL Kawas C Phelps C Poirier J Sabbagh M Touchon J Khatchaturian AS Bain L A roadmap for the prevention of dementia the inaugural Leon Thal Symposium Alzheimerrsquos and Dementia 2008 4 (3)156-163
17 Rogers J Sabbagh MN Relationships of strokes and non-steroidal anti-inflammatory drug use to
apolipoprotein E4-conferred of Alzheimerrsquos disease and dementia Neurology 2008 702-4 18 Quinn J Sabbagh MN Editorial Biochemical Markers in Persons with Pre-Clinical Familial Alzheimers
Disease Neurology 2008 7178-79 19 Jacobson S Sabbagh MN Donepezil potential neuroprotective and disease modifying effects Expert
Opinion on Drug Metabolism and Toxicology 2008 4(10)1363-1369 20 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathologica 2008 Nov 4 [epub ahead of print] 21 Lue LF Jacobson S Walker D Sabbagh MN The receptor for advanced glycation end-products its role
in Alzheimerrsquos and other diseases Future Neurology 2009 4(2) 167-177 22 Sabbagh MN Tariot PN Commentary on A roadmap for the prevention of dementia II Leon Thal
Symposium 2008 A national registry to identify a cohort for Alzheimerrsquos disease prevention studies Alzheimerrsquos and Dementia 20095 128-129
23 Khachaturian ZS Snyder PJ Doody RS Aisen P Comer M Dwyer J Frank RA Holzapfel A
Khachaturian AS Korczyn AD Phelps C Roses A Simpkins JW Schneider LS Albert MS Egge R Deves A Ferris S Greenberg BD Johnson C Kukull WA Poirier J Schenk D Thies W Gauthier S Gilman S Bernick C Cummings JL Fillit H Grundman M Kaye J Mucke L Reisberg B Sano M Pickeral O Petersen RC Mohs RC Buckholtz N Carrillo M Corey-Bloom JP Foster NL Jacobsen S Lee V Potter WZ Sabbagh MN Salmon D Trojanowski JQ Wexler N Bain LJ A roadmap for the prevention of dementia II Leon Thal Symposium 2008 Alzheimerrsquos and Dementia 2009 585-92
24 Sabbagh MN Drug Development for Alzheimerrsquos Disease Where Are We Now and Where Are We
Headed American Journal of Geriatric Pharmacotherapy 2009 7(3) 167-185 25 Sabbagh MN Thind K Sparks DL On cholesterol levels and statins in Alzheimerrsquos disease and cognitive
decline progress and setbacks Alzheimerrsquos Disease and Associated Disorders 2009 (Oct-Dec) 23(4)303-305
26 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathol 2009 Feb117(2)217-218
7 27 Sabbagh MN Shill HA Dimebon (latrepirdine) a potential treatment with a novel mechanism of action for
the treatment of Alzheimers disease and Huntington disease Current Opinion in Investigational Drugs 2010 Curr Opin Investig Drugs 2010 Jan11(1)80-91
28 Arab L Sabbagh MN Lifestyle changes do they lower Alzheimerrsquos risk Journal of Alzheimerrsquos Disease
201020(3)785-94 Review PubMedPMID 20182018
29 Sabbagh MN Commentary On The Perspective Design Of Comprehensive Alzheimers Disease Centers To Address Unmet National Needs by JQ Trojanowski et al Alzheimerrsquos and Dementia 2010 Mar6(2)156-7 No abstract available
30 Khachaturian AS Sabbagh M Commentary on Developing a national strategy to prevent dementia
Leon Thal Symposium 2009 Creating a national database for successful aging Alzheimers Dement 2010 Mar6(2)132-4 No abstract available
31 Zaven Khachaturian [Convener ndash Facilitator] - Presenters Deborah Barnes Richard Einstein Sterling
Johnson Virginia Lee Allen Roses Mark A Sager William R Shankle Peter J Snyder Ronald C Petersen Gerard Schellenberg and John Trojanowski - Discussants Paul Aisen Marilyn S Albert Charles Bernick John C S Breitner Neil Buckholtz Maria Carrillo Steven Ferris Barry D Greenberg Michael Grundman Ara S Khachaturian Lewis H Kuller Oscar L Lopez Paul Maruff Richard C Mohs Marcelle Morrison-Bogorad Creighton Phelps Michael Phillips Stephen Rao Eric Reiman Marwan Sabbagh Mary Sano Randy Schiffer Lon S Schneider Eric Siemers Pierre Tariot Jacques Touchon Bruno Vellas Reporter Lisa J Bain Developing a National Strategy to Prevent Dementia Alzheimerrsquos and Dementia 2010 Mar6(2)89-97
32 Sabbagh MN Berk C Latrepirdine for Alzheimerrsquos disease trials and tribulations Future Neurology 2010
September 2010 Vol 5 No 5 Pages 645-651
33 Sabbagh MN Cummings J Progressive Cholinergic Decline in Alzheimerrsquos Disease Consideration for Treatment With Donepezil 23 mg in Patients With Moderate to Severe Symptomatology BMC Neurology 2011 1121
34 DeCourt B Sabbagh MN BACE1 as a potential biomarker for Alzheimerrsquos disease Journal of
Alzheimerrsquos Disease 201124 Suppl 253-9]
35 Jacobson SA Sabbagh MN Investigational drugs for the treatment of Alzheimerrsquos disease failed trials Alzheimerrsquos Research and Therapy 2011 Apr 153(2)14 [Epub ahead of print]
36 Patel S Shah R Coleman P Sabbagh MN Potential Peripheral Biomarkers for the Diagnosis of
Alzheimerrsquos Disease International Journal of Alzheimerrsquos Disease 2011572495 Epub 2011 Oct 23
37 Mehta M Adem A Sabbagh MN The nicotinic receptor smoking and Alzheimerrsquos revisited Frontiers in Bioscience E4 169-180 January 1 2012
38 Sabbagh MN Berk C Appraisal of higher doses of donepezil in the treatment of mild moderate and
severe Alzheimers disease International Journal of Alzheimerrsquos Disease 20122012707468 Epub 2011 Dec 1
39 Arab L Sadeghi R Walker DG Lue LF Sabbagh MN Consequences of aberrant insulin regulation in the
brain Can treating diabetes be effective for Alzheimerrsquos Disease Current Neuropharmacology 2011 9(4) 693-705
40 Mehta M Adem A Sabbagh MN New acetylcholinesterase inhibitors for Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 728983 8 pages doi1011552012728983
41 Sabbagh MN Sparks DL Statins to treat Alzheimerrsquos an incomplete story Expert Review in
Neurotherapeutics January 2012 Vol 12 No 1 Pages 27-30
8 42 Sabbagh MN Porsteinsson AP Nair A Adem A Novel Therapeutics in Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 207969 2 pages
43 Sabbagh MN Geula C Messis C Friedland R Conference Report on the 5th International Conference on
Alzheimerrsquos Disease in the Middle East May 7-9 2009 Limmassol Cyprus Journal of Alzheimerrsquos Disease 2012 May 21Epub ahead of print] No abstract available PMID22614876
44 Lue LF Andrade C Sabbagh MN Walker DG Is there inflammatory synergy in type II diabetes mellitus
and Alzheimerrsquos disease International Journal of Alzheimerrsquos Disease 2012918680 Epub 2012 Jun 21
45 Sabbagh MN Ahmadi MM Belden C The Use of Informant-Based Questionnaires in Differentiating Mild Cognitive Impairment from Normal Aging Expert Review of Neurotherapeutics 2012 Jun12(6)637-9
46 Jeffrey L Cummings1 David Geldmacher
2 Martin Farlow
3 Marwan Sabbagh
4 Daniel Christensen
5 amp
Peter Betz6 for the Donepezil 23 mg Expert Working Group High-Dose Donepezil (23 mgday) for the
Treatment of Moderate and Severe Alzheimerrsquos Disease Drug Profile and Clinical Guidelines CNS Neurosci Ther 2013 Mar 6 doi 101111cns12076 [Epub ahead of print]
47 DeCourt B Mobley W Reiman E Shah RJ Sabbagh MN Recent perspectives on Alzheimerrsquos disease pathological changes in Down syndromerdquo J Alzheimers Dis Parkinsonism 2013 S7 httpdxdoiorg 1041722161-0460S7-002
48 Adem A El-Agnaf O Sabbagh MN Neurodegeneration The first IBRO-Middle East Neuroscience
Conference Current Alzheimerrsquos Research 2013 10 (6)557-8
49 Berk C Sabbagh MN Drugs in Late Stage Development for Alzheimerrsquos Disease Drugs Aging 2013 Aug 14 [Epub ahead of print]
50 Berk C Paul G Sabbagh MN Investigational Drugs in Alzheimerrsquos Disease Current Progress Expert
Opinion on Investigational Drugs 2014 Expert Opin Investig Drugs 2014 Jun23(6)837-46 doi 101517135437842014905542 Epub 2014 Apr 5
51 Richards D Sabbagh MN Florbetaben for PET Imaging of Neuritic Beta-Amyloid Plaques in the Brain
Neurology and Therapy 2014 DOI 101007s40120-014-0022-9
52 Hartley D Blumenthal T Carrillo M DiPaolo G Esralew L Gardiner K Granholm AC Iqbal K Krams M Lemere C Lott I Mobley W Ness S Nixon R Potter H Reeves R Sabbagh M Silverman W Tycko B Whitten M Wisniewski T Down syndrome and Alzheimers disease Common pathways common goals Alzheimers Dement 2014 Dec 12 pii S1552-5260(14)02860-X doi 101016jjalz201410007
53 Saunders KT Langbaum JB Holt CJ Chen W High N Langlois C Sabbagh M Tariot PN Arizona
Alzheimers Registry Strategy and Outcomes of a Statewide Research Recruitment Registry J Prev Alzheimers Dis 2014 Sep1(2)74-79
54 Walker DG Lue LF Paul G Patel A Sabbagh MN Advanced Glycation Endproduct Modulators A New
Therapeutic Target in Alzheimerrsquos Disease Expert Opinion in Investigational Drugs Posted online on January 14 2015 (doi1015171354378420151001490)
55 Malek-Ahmadi M Sabbagh MN Development and validation of the Alzheimerrsquos Questionnaire (AQ)
Journal of Nature and Science 20151(5)e104
56 Anand K Sabbagh MN Early investigational drugs targeting tau protein for the treatment of Alzheimers Disease Expert Opinion in Investigational Drugs 2015 24 (10)1-6
57 Sabbagh MN Edgin JO Clinical Assessment of Cognitive Decline in Adults with Down Syndrome
Current Alzheimerrsquos Research 2015 Sep 20 [epub ahead of print]
58 Arab L Sabbagh MNAre Certain Lifestyle Habits Associated with Lower Alzheimers Disease Risk J Alzheimers Dis 2015 Oct 148(3)877 doi 103233JAD-159004 No abstract available
9 59 Bahureska L Schwenk M Sabbagh M Mohler J Saleh A Najafi B The Impact of Mild Cognitive
Impairment on Balance and Gait a Systematic Review and Meta-Analysis Gerontology 2016 (DOI101159000445831)
60 Anand K Sabbagh MN Amyloid imaging poised for integration into medical practice Neurotherapeutics 2016 Aug 29 [Epub ahead of print] Review
61 Marwan Sabbagh1 SeolHeui Han
2 SangYun Kim
3 Hae-Ri Na
4 Jae-Hong Lee
5 Nagaendran Kandiah
6
Kammant Phanthumchinda7 Chuthamanee Suthisisang
8 Vorapun Senanarong
9 Ming-Chyi Pai
10 Diatri
Narilastri11
Ajit M Sowani12
Encarnita Ampil13
Amitabh Dash14
for the Asia Pacific EXpert Panel (APEX) for Donepezil 23 mg Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimerrsquos disease in the Asia-Pacific region Dement Geriatr Cogn Disord Extra 20166382-395 (DOI101159000448214)
62 Decourt B Lahiri DK Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimers Disease Curr Alzheimer Res 2016 Sep 30
63 Sabbagh MN Editorial Introduction Neurol Ther 2016 Nov 9 [Epub ahead of print]
64 Shefner JM Sabbagh MN An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases Editorial Introduction Neurotherapeutics 2016 Dec 8 [Epub ahead of print] No abstract available
65 Sabbagh MN DeCourt B Editorial Current and Emerging Therapeutics in AD Current Alzheimerrsquos Research 201714 (3) 354-355
66 DeCourt B Lahiri D Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimerrsquos Disease Current Alzheimerrsquos Research 201714 (3) 412-425
67 Mehta DG Paul G Shi J Sabbagh MN Why are drugs failing in Alzheimerrsquos disease 2010-2015 Expert Opin Investig Drugs 2017 May 2 doi 1010801354378420171323868 [Epub ahead of print]
68 Sabbagh MN Lue LF Fayard D Shi J Increasing precision of clinical diagnosis of AD using a combined algorithm incorporating clinical and novel biomarker data Neurology and Therapy 2017 (submitted)
69 Sabbagh MN Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimerrsquos Disease and Related Disorders Neurology and Therapy 2017 (submitted)
70 Sabbagh MN Editorial Clinical Effects of Oral Tramiprosate in APOE44 Homozygous Patients with Mild Alzheimerrsquos Disease Suggest Disease Modification JPAD 2017 (submitted)
71 Geidy Serrano Marwan S Sabbagh Michael Sierks Tyler A Kokjohn Thomas G Beach Chera L Maarouf Steven G Clarke4 Alex Roher APPAβ Structural Diversity and Alzheimerrsquos Disease Pathogenesis Neurochemistry International 2017 (submitted)
Peer-Reviewed Manuscripts
1 Adem A Sabbagh M Nordberg A Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex Journal of Neural Transmission 1988 7211-18
2 Sabbagh M Garza J Patten B Thoracoscopic thymectomy in myasthenia gravis Muscle amp Nerve
1995 181475-1477
3 Sabbagh M Lynn P Jhingran S et al Correlation of SPECT Regional cerebral blood flow defects to psychometric testing in patients with Alzheimers disease Journal of Neuropsychiatry and Clinical Neurosciences 1997 9 68-74
4 Corey-Bloom J Sabbagh MN Bondi MW Hansen L Alford MF Thal LJ Hippocampal sclerosis
contributes to dementia in the elderly Neurology 1997 48(1) 154-160
5 Olichney J Sabbagh M Hofstetter RC Galasko D Grundman M Katzman R Thal L The impact of
apolipoprotein 4 on the cause of death in Alzheimerrsquos disease Neurology 1997 49(1) 76-81
10 6 Olichney J Ellis R Katzman R Sabbagh M Hansen L Types of cerebrovascular lesions associated
with severe cerebral amyloid angiopathy in Alzheimers disease Annals of the New York Academy of Sciences 1997 826 493-497
7 Sabbagh MN Reid R Corey-Bloom J Rao T Lloyd K Hansen L Alford M Masliah E Adem A Thal
LJ Correlation of nicotinic binding to neurochemical markers in Alzheimerrsquos disease Journal of Neural Transmission 1998105(7) 709-717
8 Sabbagh MN Corey-Bloom J Tiraboschi P Thomas R Masliah E Thal LJ Neurochemical markers
do not correlate with cognitive decline in the Lewy Body Variant of Alzheimerrsquos disease Archives of Neurology 1999 56(12) 1568-1572
9 Tiraboschi P Hansen LA Sabbagh MN Schoos B Alford M Masliah E Thal LJ Corey-Bloom J
Cholinergic dysfunction in diseases with Lewy bodies Neurology 2000 54407-411
10 Corey-Bloom J Tiraboschi P Hansen LA Schoos B Alford M Sabbagh MN Masliah E Thal LJ E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimerrsquos disease Neurology 2000 54403-406
11 Reid RT Sabbagh MN Corey-Bloom J Tiraboschi P Thal LJ Nicotinic receptor in dementia with
Lewy Bodies comparisons with Alzheimerrsquos disease Neurobiology of Aging 2000 21 (5) 741-746
12 ReidRT Sabbagh MN Thal LJ Does apolipoprotein e (apo e) genotype influence nicotinic receptor binding in Alzheimers disease J Neural Transmission 2001 108(8-9) 1043-1050
13 Sabbagh MN Reid RT Hansen LA Alford M Thal LJ Correlation of nicotinic receptor binding with
clinical and neuropathological changes in Alzheimerrsquos disease and dementia with Lewy bodies J Neural Transmission 2001 108 (10) 1149-1157
14 Caselli R Beach T Sue L Connor DJ Sabbagh MN Progressive Aphasia with Lewy Bodies
Dementia and Geriatric Cognitive Disorders 2002 14 (2) 55-58
15 Sabbagh M Silverberg N Majeed B Samant S Sparks DL Seward J Connor DJ Length of stay in skilled nursing facilities is longer for patients with dementia J Alz Dis 2003 5(1) 57-63
16 Smith RG Roher A Appel SH Doody RS Killian DM Corey-Bloom J Sabbagh MN Autonomic
sudomotor dysfunction discriminates Alzheimerrsquos disease and non-demented control individuals Current Medicinal Chemistry Immunology Endocrine and Metabolic Agents 2003 3233-243
17 Reid RT Sabbagh MN Effects of Donepezil Treatment on Rat Nicotinic Acetylcholine Receptor
Levels In Vivo and In Vitro Journal of Alzheimerrsquos Disease 2003 5(6) 429-436
18 Caviness JN Adler CH Sabbagh M Connor DJ Hernandez JL Lagerlund T Abnormal Cortico-muscular Coherence is associated with the small amplitude cortical myoclonus in Parkinsonrsquos Disease Movement Disorders 2003 18 (10) 1157-62
19 Beach TG Sue L Scott S Layne K Newell A Walker D Baker M Sahara N Yen S-H Hutton M
Caselli R Adler C Connor D Sabbagh M Hippocampal Sclerosis Dementia with Tauopathy Brain Pathology 2003 13 263-278
20 Sparks DL Lopez J Sabbagh M Connor D Seward J Browne P A position paper based on
observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the AD Cholesterol-Lowering Treatment Trial J Molecular Neuroscience 2003 20 407-410
21 Caselli RJ Beach TG Sue LI Connor DJ Sabbagh MN Progressive aphasia with Lewy bodies
Dementia Review Series 2003 4 10-11
22 Sabbagh MN Thompson N Tweedy D Stipho-Majeed S Kawas C Connor DJ Successful and Unsuccessful Recruitment and Retention Strategies for Alzheimerrsquos Disease Clinical Trials Pharmaceutical Regulation and Development 2003 1(4) 269-276
11 23 Johnson SC Baxter LC Susskind-Wilder L Connor DJ Sabbagh MN Caselli RJ Hippocampal
Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment Neuropsychologia 2004 42(7) 980-989
24 Li R Lindholm K Yang LB Yue X Citron M Yan R Beach T Sue L Sabbagh M Cai H Wong P
Price D Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimers disease patients Proc Natl Acad Sci U S A 2004 Mar 9 101(10)3632-3637
25 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A Masliah E Alford M Thal
LJ Corey-Bloom J Alzheimerrsquos disease without neocortical neurofibrillary tangles ldquoa second lookrdquo Neurology 2004 621141-1147
26 Davie JE Azuma T Goldinger SD Connor DJ Sabbagh MN Silverberg N Sensitivity to Expectancy
Violations in Healthy Aging and Mild Cognitive Impairment Neuropsychology 2004 18(2) 269-275
27 Sabbagh MN Silverberg NB Descheny RL Baxter LC Connor DJ Crocker-Sabbagh IP Dementia with Lewy bodies in a Native American Alzheimerrsquos Disease and Associated Disorders 2004 18 (4)259-261
28 Sabbagh MN Zahiri HR Ceimo J Cooper K Gaul W Connor DJ Sparks DL Is there a characteristic
lipid profile in Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2004 6 (6) 585-589
29 Sabbagh MN Tyas SL Emery SC Hansen LA Alford MF Reid RT Tiraboschi P Thal LJ Smoking Affects the Phenotype of Alzheimerrsquos Disease Neurology 2005 Apr 1264(7)1301-3
30 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Petanceska S Browne P Wassar D Johnson-Traver S Lochhead J Ziolwolski C Benefit of Atorvastatin in the treatment of mild to moderate Alzheimerrsquos disease results from the Alzheimerrsquos disease cholesterol lowering treatment (ADCLT) trial Archives of Neurology 2005 62753-757
31 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Browne P Johnson-Traver S Lochhead J
Ziolwolski C Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD Current Alzheimerrsquos Research 2005 Jul2(3)343-53
32 Sabbagh MN Silverberg N Bircea S Majeed B Samant S Caviness JN Reisberg B Adler CH Is
the functional decline in PD similar to the functional decline of AD Parkinsonism and Related Disorders 2005 11 311-315
33 Sabbagh MN Hake AM Ahmed S Farlow MR The use of memantine in Dementia with Lewy Bodies
Journal of Alzheimerrsquos Disease 2005 7(4) 285-289
34 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C rols MCI AD and the AD Cholesterol
Lowering Treatment Trial Current Alzheimerrsquos Research 2005 2527-539
35 Rogers J Li R Mastroeni D Grover A Leonard B Ahern G Cao P Kolody H Vedders L Kolb WP Sabbagh M Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes Neurobiology of Aging 2006 271733-1739
36 Caviness JN Shill HA Sabbagh MN Evidente VGH Hernandez J Adler CH Cortico-Muscular
coherence is increased in the small postural tremor of Parkinsonrsquos disease Movement Disorders 2006 21 (4)492-499
37 Sabbagh MN Sandhu S Lahti T Kolody H Silverberg NB Sparks DL What is the effect of the
apolipoprotein E genotype on the lipid profile in Alzheimerrsquos disease Current Alzheimerrsquos Research 2006 3(2) 157-160
38 Sparks DL Connor DJ Sabbagh MN Petersen RB Lopez J Browne P Circulating cholesterol
levels apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
3 University of California San Diego School of Medicine San Diego California Residency (Neurology) 1992-1995 Baylor College of Medicine Houston Texas Internship (Internal Medicine) 1991-1992 Good Samaritan Regional Medical Center Phoenix Arizona EDUCATION MD - University of Arizona College of Medicine 1991 BA - University of California - Berkeley 1987 HONORSAWARDS Student Summer Fellow Arizona Cancer Society 1988
Student Representative to the Western Federation of Clinical Research University of Arizona 1990
Allistair Karmody Award Finalist 1991 Travel Fellowship Award Recipient American Neurological Association 1996 Peter F Drucker Award Co-recipient 1998 Dystonia Doctor of Excellence San Diego County 2000 Life Member of the National Registry of Whorsquos Who 172142 2001 Arizona Business Journal Healthcare Hero Finalist 2004 Fellow of the American Academy of Neurology 2004 WestMarc Innovator Award 2015 BOARDS Diplomate of the National Board of Medical Examiners 1992 Certificate 407526 Diplomate of the American Board of Psychiatry and Neurology 1996 Certificate 43257 Recertified in 2007 Certified Clinical Research Investigator 03-F052 Diplomate of the UCNS Board of Geriatric Neurology LICENSES Arizona Medical License 1994 (AZ22378) California Medical License 1995 (CAG08170) Medicare UPING13648 AHCCCS540113 HOSPITAL AFFILIATIONS Saint Josephrsquos Hospital and Medical Center Phoenix AZ MEMBERSHIPS American Medical Association 1988-1993 American Federation of Clinical Research 1988-1991 American College of Physicians 1991-1997 American Academy of Neurology 1992-Present San Diego Neurological Society 1995-2000 Society for Neuroscience 1997- 2005 Arizona Geriatric Society 2001-Present Society for Behavioral and Cognitive Neurology 2001-2008 EDITOR FOR Neurology and Therapy (editor-in-chief) Journal of Alzheimerrsquos Disease (associate editor) BMC Neurology (section editor-dementia) Expert Opinion on Investigational Drugs (editorial board)
Alzheimerrsquos and Dementia Translational Research and Clinical Interventions (editorial board)
AD HOC REVIEWER FOR The Journal of Neuropsychiatry and Clinical Neuroscience Physiology and Behavior Grants Committee - Alzheimerrsquos Association Brain Research
4 Neurobiology of Aging Neurology Archives of Neurology Clinical Neurosciences and Disease Study Section CND-1 NIH Neuropharmacology Small Business ZRG1 BDCN-A (11) B CSR NIH Emerging Technology and Training in Neuroscience ETTN CSR NIH Aging Program Project Review ZRG1 BDCN-L 42P Alzheimers Disease Pilot Clinical Trials ZRG1 BBBP-V (55) R European Archives of Psychiatry and Clinical Neurosciences Journal of Clinical Psychiatry Neuroscience Letters Neuroepidemiology Biological Psychiatry International Journal of Geriatric Psychiatry Annals of Neurology PUBLICATIONS (Google scholar h-index 61) Books 1 Sabbagh MN The Alzheimerrsquos Answer Reduce Your Risk and Keep Your Brain Healthy 2008 2010
(paperback) John Wiley and Sons Hoboken New Jersey 2 Sabbagh MN Alzheimer Guia practica Respuestas a las cuestiones fundamentales desde su
diagnostico hsta como se aplica el tratamiento (Spanish Edition) 2010 RobinBooks Barcelona Spain 3 Martin G Sabbagh MN (eds) Palliative Care For Advanced Alzheimerrsquos and Dementia Guidelines and
Standards for Evidence Based Care 2010 Springer Publishing Company New York NY
4 Sabbagh M MacMillan B The Alzheimerrsquos Prevention Cookbook Recipes to Boost Brain Health 2012 TenSpeed Press Emeryville California
5 Nair A Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford United Kingdom Invited Chapters 1 Smith RG Sabbagh M White P Brod S Oral tolerance therapy of autoimmune disease In Appel SH
(ed) Current Neurology 1996 Mosby New York 16165-189 2 Shaibani AT Sabbagh MN Khan B Pathological Human Crying In Ad JJM Vingerhoets Randolph R
Cornelius (eds) Adult Crying A Biopsychosocial Approach 2002 Brunner-Routledge East Sussex UK
3 Sparks DL Connor DJ Browne PJ Wasser DR Lopez JE Sabbagh MN The Alzheimerrsquos disease atorvastatin treatment trial scientific basis and position on the use of the HMG-CoA reductase inhibitors (statins) that do or do not cross the blood-brain barrier In Fillit H OrsquoConnell AW Drug Discovery and Drug Development for Alzheimerrsquos Disease 2002 Springer Publishing Company New York 244-252
4 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C Lochhead J
Browne P Cholesterol copper and statin therapy in AD In Gauthier S Schelten P Cummings J Alzheimerrsquos Disease and Related Disorders Annual 5 2005 Taylor and Francis London 89-110
5 Reisberg B Weigel J Franssen E Kadiyala S Auer S Souren L Sabbagh M Golomb J Clinical features
of severe dementia-staging In Burns A Winblad B (eds) Severe Dementia 2006 John Wiley and Sons Hoboken New Jersey 95-127
6 McCarthy M Gallagher M Sabbagh M Appropriate use of medications in advanced dementia In Long C
(ed) Palliative Care for Advanced Dementia Guidelines and Standards 2006 Alzheimerrsquos Association Desert Southwest Chapter Phoenix AZ 40-51
7 Rogers J Beach T Li R Liang Z Lue L-F Roher A Sabbagh M Shen Y Strohmeyer R Walker D
Inflammatory mechanisms in Alzheimers disease and other neurodegenerative disorders In Chemistry and Molecular Aspects of Drug Design and Action (Kourounakis and Rekka eds) CRC Press (Boca Raton FL) pp 3-12 2007
5 8 Barry Reisberg Jerzy Wegiel Emile Franssen Sridhar Kadiyala Stefanie Auer Liduiumln Souren Marwan
Sabbagh and James Golomb Clinical Features of Severe Dementia Staging in Severe Dementia (Burns and Winblad eds) 2010 John Wiley and Sons Hoboken NJ Chapter 8
9 Reisberg B Jamil IA Khan S Monteiro I Torossian C Ferris S Sabbagh M Gauthier S Auer
S Shulman MB Kluger A Franssen E and Wegiel J Staging dementia In Principles and Practice of Geriatric Psychiatry 3rd edition M T Abou-Saleh C Katona and A Kumar (Eds) Chichester England Wiley-Blackwell 2010 p 162-169
10 Belden CM Burciu C Sabbagh M (2014) Global Deterioration Scale (Individuals) In Michalos AC (Ed)
Encyclopedia of Quality of Life and Well-Being Research Springer Dordrecht Netherlands Springer pp 2562-2564
11 Sabbagh MN Nair AK Approach to the Geriatric Neurology Patient The Neurologic Examination In Nair A
Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p71-84
12 Nair AK Sabbagh MN Amyloid imaging In Nair A Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p 162-169
13 Singh J Sabbagh MN Nair AK Evidence based pharmacological treatment of dementia In Nair A
Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p 557-573
14 Decourt B1 Macias M
1 Berk C
1 Sabbagh M
1 Adem A
2 BACE1 inhibitors attractive therapeutics for
Alzheimerrsquos disease In Ur-Rahman A Choudhary MI Frontiers in Drug Design and Discovery 2014 Bentham Science p518-546
Invited Reviews and Editorials 1 Taher A Sabbagh M Doody R Laughter and crying in neurologic disorders Neuropsychiatry
Neuropsychology amp Behavioral Neurology 7(4) 243-250 1994 2 Sabbagh MN Galasko D Thal LJ Beta amyloid and treatment opportunities for Alzheimers disease
Alzheimers Disease Reviews 1998 31-19 3 Shaibani AT Sabbagh MN Pseudo-Neurologic Syndromes Recognition and Diagnosis American Family
Physician 1998 57(10) 2485-2494 4 Sabbagh MN Application of the Changing Therapies for Alzheimerrsquos Disease in Clinical Practice
American Speech and Language Association 1998 3(1) 7-12
5 Sabbagh MN Galasko D Koo E Thal LJ -amyloid and treatment opportunities for Alzheimers disease Journal of Alzheimers Disease 2000 2(3-4) 231-259
6 Sparks DL Connor DJ Browne PJ Lopez JE Sabbagh MN HMG-CoA reductase inhibitors (statins) in
the treatment of Alzheimerrsquos disease and why it would be ill-advised to use one that crosses the blood-brain barrier Journal of Nutrition Health and Aging 2002 6(5) 324-330
7 Sparks DL Connor DJ Browne P and Sabbagh MN Should the guidelines for monitoring serum
cholesterol levels in the elderly be re-evaluated Journal of Molecular Neuroscience 2002 19 209-212 8 Sabbagh MN Lukas RJ Sparks DL Reid RT The nicotinic acetylcholine receptor smoking and
Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2002 4 (4) 317-325 9 Sparks DL Sabbagh MN Breitner JCS Hunsaker J Is cholesterol a culprit in AD International
Psychogeriatrics 2003 15 (suppl1) 153-159 10 Sabbagh MN Farlow MR Relkin NR Beach TG Do cholinergic therapies have disease modifying effects
in Alzheimerrsquos disease Alzheimerrsquos and Dementia 20062(2) 118-125 11 Sparks DL Sabbagh M Connor D Soares H Lopez J Stankovic G Johnson-Traver S Ziolkowski C
Browne P Statin therapy in AD Acta Neurologica Scandinavica 2006 185S78-86
6 12 Thind K Sabbagh MN Pathological Correlates of Cognitive Decline in Alzheimerrsquos Disease PanMinerva
Medica 2007 49(4)191-195 13 Beach TG Sue LI Walker DG Roher AE Lue LF Vedders L Connor DJ Sabbagh M Rogers J The
Sun Health Research Institute Brain Donation Program Description and Experience 1987-2007 Cell Tissue Bank 2008 Mar 18 [Epub ahead of print]
14 Sabbagh MN Richardson S Relkin N Disease modifying approaches to Alzheimers disease Challenges
and opportunities Lessons from donepezil therapyrdquo Alzheimerrsquos and Dementia 2008 4(1) S109-S118 15 Sabbagh MN Commentary on the baseline data of the atorvastatindonepezil study for Alzheimerrsquos
disease Alzheimerrsquos and Dementia 2008 4 (3)174-175 16 Khatchaturian ZS Petersen RC Gauthier S Buckholtz N Corey-Bloom J Evans B Fillit H Foster N
Greenberg B Grundman M Sano M Simpkins J Schneider LS Weiner MW Galasko D Hyman B Kuller L Schenk D Snyder S Thomas RG Tuszinski MH Vellas B Wurtman RJ Snyder PJ Frank RA Albert M Doody R Ferris S Kaye J Koo E Morrison-Bogorad M Reisberg B Salmon DP Gilman S Mohs R Aisen PS Breitner JCS Cummings JL Kawas C Phelps C Poirier J Sabbagh M Touchon J Khatchaturian AS Bain L A roadmap for the prevention of dementia the inaugural Leon Thal Symposium Alzheimerrsquos and Dementia 2008 4 (3)156-163
17 Rogers J Sabbagh MN Relationships of strokes and non-steroidal anti-inflammatory drug use to
apolipoprotein E4-conferred of Alzheimerrsquos disease and dementia Neurology 2008 702-4 18 Quinn J Sabbagh MN Editorial Biochemical Markers in Persons with Pre-Clinical Familial Alzheimers
Disease Neurology 2008 7178-79 19 Jacobson S Sabbagh MN Donepezil potential neuroprotective and disease modifying effects Expert
Opinion on Drug Metabolism and Toxicology 2008 4(10)1363-1369 20 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathologica 2008 Nov 4 [epub ahead of print] 21 Lue LF Jacobson S Walker D Sabbagh MN The receptor for advanced glycation end-products its role
in Alzheimerrsquos and other diseases Future Neurology 2009 4(2) 167-177 22 Sabbagh MN Tariot PN Commentary on A roadmap for the prevention of dementia II Leon Thal
Symposium 2008 A national registry to identify a cohort for Alzheimerrsquos disease prevention studies Alzheimerrsquos and Dementia 20095 128-129
23 Khachaturian ZS Snyder PJ Doody RS Aisen P Comer M Dwyer J Frank RA Holzapfel A
Khachaturian AS Korczyn AD Phelps C Roses A Simpkins JW Schneider LS Albert MS Egge R Deves A Ferris S Greenberg BD Johnson C Kukull WA Poirier J Schenk D Thies W Gauthier S Gilman S Bernick C Cummings JL Fillit H Grundman M Kaye J Mucke L Reisberg B Sano M Pickeral O Petersen RC Mohs RC Buckholtz N Carrillo M Corey-Bloom JP Foster NL Jacobsen S Lee V Potter WZ Sabbagh MN Salmon D Trojanowski JQ Wexler N Bain LJ A roadmap for the prevention of dementia II Leon Thal Symposium 2008 Alzheimerrsquos and Dementia 2009 585-92
24 Sabbagh MN Drug Development for Alzheimerrsquos Disease Where Are We Now and Where Are We
Headed American Journal of Geriatric Pharmacotherapy 2009 7(3) 167-185 25 Sabbagh MN Thind K Sparks DL On cholesterol levels and statins in Alzheimerrsquos disease and cognitive
decline progress and setbacks Alzheimerrsquos Disease and Associated Disorders 2009 (Oct-Dec) 23(4)303-305
26 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathol 2009 Feb117(2)217-218
7 27 Sabbagh MN Shill HA Dimebon (latrepirdine) a potential treatment with a novel mechanism of action for
the treatment of Alzheimers disease and Huntington disease Current Opinion in Investigational Drugs 2010 Curr Opin Investig Drugs 2010 Jan11(1)80-91
28 Arab L Sabbagh MN Lifestyle changes do they lower Alzheimerrsquos risk Journal of Alzheimerrsquos Disease
201020(3)785-94 Review PubMedPMID 20182018
29 Sabbagh MN Commentary On The Perspective Design Of Comprehensive Alzheimers Disease Centers To Address Unmet National Needs by JQ Trojanowski et al Alzheimerrsquos and Dementia 2010 Mar6(2)156-7 No abstract available
30 Khachaturian AS Sabbagh M Commentary on Developing a national strategy to prevent dementia
Leon Thal Symposium 2009 Creating a national database for successful aging Alzheimers Dement 2010 Mar6(2)132-4 No abstract available
31 Zaven Khachaturian [Convener ndash Facilitator] - Presenters Deborah Barnes Richard Einstein Sterling
Johnson Virginia Lee Allen Roses Mark A Sager William R Shankle Peter J Snyder Ronald C Petersen Gerard Schellenberg and John Trojanowski - Discussants Paul Aisen Marilyn S Albert Charles Bernick John C S Breitner Neil Buckholtz Maria Carrillo Steven Ferris Barry D Greenberg Michael Grundman Ara S Khachaturian Lewis H Kuller Oscar L Lopez Paul Maruff Richard C Mohs Marcelle Morrison-Bogorad Creighton Phelps Michael Phillips Stephen Rao Eric Reiman Marwan Sabbagh Mary Sano Randy Schiffer Lon S Schneider Eric Siemers Pierre Tariot Jacques Touchon Bruno Vellas Reporter Lisa J Bain Developing a National Strategy to Prevent Dementia Alzheimerrsquos and Dementia 2010 Mar6(2)89-97
32 Sabbagh MN Berk C Latrepirdine for Alzheimerrsquos disease trials and tribulations Future Neurology 2010
September 2010 Vol 5 No 5 Pages 645-651
33 Sabbagh MN Cummings J Progressive Cholinergic Decline in Alzheimerrsquos Disease Consideration for Treatment With Donepezil 23 mg in Patients With Moderate to Severe Symptomatology BMC Neurology 2011 1121
34 DeCourt B Sabbagh MN BACE1 as a potential biomarker for Alzheimerrsquos disease Journal of
Alzheimerrsquos Disease 201124 Suppl 253-9]
35 Jacobson SA Sabbagh MN Investigational drugs for the treatment of Alzheimerrsquos disease failed trials Alzheimerrsquos Research and Therapy 2011 Apr 153(2)14 [Epub ahead of print]
36 Patel S Shah R Coleman P Sabbagh MN Potential Peripheral Biomarkers for the Diagnosis of
Alzheimerrsquos Disease International Journal of Alzheimerrsquos Disease 2011572495 Epub 2011 Oct 23
37 Mehta M Adem A Sabbagh MN The nicotinic receptor smoking and Alzheimerrsquos revisited Frontiers in Bioscience E4 169-180 January 1 2012
38 Sabbagh MN Berk C Appraisal of higher doses of donepezil in the treatment of mild moderate and
severe Alzheimers disease International Journal of Alzheimerrsquos Disease 20122012707468 Epub 2011 Dec 1
39 Arab L Sadeghi R Walker DG Lue LF Sabbagh MN Consequences of aberrant insulin regulation in the
brain Can treating diabetes be effective for Alzheimerrsquos Disease Current Neuropharmacology 2011 9(4) 693-705
40 Mehta M Adem A Sabbagh MN New acetylcholinesterase inhibitors for Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 728983 8 pages doi1011552012728983
41 Sabbagh MN Sparks DL Statins to treat Alzheimerrsquos an incomplete story Expert Review in
Neurotherapeutics January 2012 Vol 12 No 1 Pages 27-30
8 42 Sabbagh MN Porsteinsson AP Nair A Adem A Novel Therapeutics in Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 207969 2 pages
43 Sabbagh MN Geula C Messis C Friedland R Conference Report on the 5th International Conference on
Alzheimerrsquos Disease in the Middle East May 7-9 2009 Limmassol Cyprus Journal of Alzheimerrsquos Disease 2012 May 21Epub ahead of print] No abstract available PMID22614876
44 Lue LF Andrade C Sabbagh MN Walker DG Is there inflammatory synergy in type II diabetes mellitus
and Alzheimerrsquos disease International Journal of Alzheimerrsquos Disease 2012918680 Epub 2012 Jun 21
45 Sabbagh MN Ahmadi MM Belden C The Use of Informant-Based Questionnaires in Differentiating Mild Cognitive Impairment from Normal Aging Expert Review of Neurotherapeutics 2012 Jun12(6)637-9
46 Jeffrey L Cummings1 David Geldmacher
2 Martin Farlow
3 Marwan Sabbagh
4 Daniel Christensen
5 amp
Peter Betz6 for the Donepezil 23 mg Expert Working Group High-Dose Donepezil (23 mgday) for the
Treatment of Moderate and Severe Alzheimerrsquos Disease Drug Profile and Clinical Guidelines CNS Neurosci Ther 2013 Mar 6 doi 101111cns12076 [Epub ahead of print]
47 DeCourt B Mobley W Reiman E Shah RJ Sabbagh MN Recent perspectives on Alzheimerrsquos disease pathological changes in Down syndromerdquo J Alzheimers Dis Parkinsonism 2013 S7 httpdxdoiorg 1041722161-0460S7-002
48 Adem A El-Agnaf O Sabbagh MN Neurodegeneration The first IBRO-Middle East Neuroscience
Conference Current Alzheimerrsquos Research 2013 10 (6)557-8
49 Berk C Sabbagh MN Drugs in Late Stage Development for Alzheimerrsquos Disease Drugs Aging 2013 Aug 14 [Epub ahead of print]
50 Berk C Paul G Sabbagh MN Investigational Drugs in Alzheimerrsquos Disease Current Progress Expert
Opinion on Investigational Drugs 2014 Expert Opin Investig Drugs 2014 Jun23(6)837-46 doi 101517135437842014905542 Epub 2014 Apr 5
51 Richards D Sabbagh MN Florbetaben for PET Imaging of Neuritic Beta-Amyloid Plaques in the Brain
Neurology and Therapy 2014 DOI 101007s40120-014-0022-9
52 Hartley D Blumenthal T Carrillo M DiPaolo G Esralew L Gardiner K Granholm AC Iqbal K Krams M Lemere C Lott I Mobley W Ness S Nixon R Potter H Reeves R Sabbagh M Silverman W Tycko B Whitten M Wisniewski T Down syndrome and Alzheimers disease Common pathways common goals Alzheimers Dement 2014 Dec 12 pii S1552-5260(14)02860-X doi 101016jjalz201410007
53 Saunders KT Langbaum JB Holt CJ Chen W High N Langlois C Sabbagh M Tariot PN Arizona
Alzheimers Registry Strategy and Outcomes of a Statewide Research Recruitment Registry J Prev Alzheimers Dis 2014 Sep1(2)74-79
54 Walker DG Lue LF Paul G Patel A Sabbagh MN Advanced Glycation Endproduct Modulators A New
Therapeutic Target in Alzheimerrsquos Disease Expert Opinion in Investigational Drugs Posted online on January 14 2015 (doi1015171354378420151001490)
55 Malek-Ahmadi M Sabbagh MN Development and validation of the Alzheimerrsquos Questionnaire (AQ)
Journal of Nature and Science 20151(5)e104
56 Anand K Sabbagh MN Early investigational drugs targeting tau protein for the treatment of Alzheimers Disease Expert Opinion in Investigational Drugs 2015 24 (10)1-6
57 Sabbagh MN Edgin JO Clinical Assessment of Cognitive Decline in Adults with Down Syndrome
Current Alzheimerrsquos Research 2015 Sep 20 [epub ahead of print]
58 Arab L Sabbagh MNAre Certain Lifestyle Habits Associated with Lower Alzheimers Disease Risk J Alzheimers Dis 2015 Oct 148(3)877 doi 103233JAD-159004 No abstract available
9 59 Bahureska L Schwenk M Sabbagh M Mohler J Saleh A Najafi B The Impact of Mild Cognitive
Impairment on Balance and Gait a Systematic Review and Meta-Analysis Gerontology 2016 (DOI101159000445831)
60 Anand K Sabbagh MN Amyloid imaging poised for integration into medical practice Neurotherapeutics 2016 Aug 29 [Epub ahead of print] Review
61 Marwan Sabbagh1 SeolHeui Han
2 SangYun Kim
3 Hae-Ri Na
4 Jae-Hong Lee
5 Nagaendran Kandiah
6
Kammant Phanthumchinda7 Chuthamanee Suthisisang
8 Vorapun Senanarong
9 Ming-Chyi Pai
10 Diatri
Narilastri11
Ajit M Sowani12
Encarnita Ampil13
Amitabh Dash14
for the Asia Pacific EXpert Panel (APEX) for Donepezil 23 mg Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimerrsquos disease in the Asia-Pacific region Dement Geriatr Cogn Disord Extra 20166382-395 (DOI101159000448214)
62 Decourt B Lahiri DK Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimers Disease Curr Alzheimer Res 2016 Sep 30
63 Sabbagh MN Editorial Introduction Neurol Ther 2016 Nov 9 [Epub ahead of print]
64 Shefner JM Sabbagh MN An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases Editorial Introduction Neurotherapeutics 2016 Dec 8 [Epub ahead of print] No abstract available
65 Sabbagh MN DeCourt B Editorial Current and Emerging Therapeutics in AD Current Alzheimerrsquos Research 201714 (3) 354-355
66 DeCourt B Lahiri D Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimerrsquos Disease Current Alzheimerrsquos Research 201714 (3) 412-425
67 Mehta DG Paul G Shi J Sabbagh MN Why are drugs failing in Alzheimerrsquos disease 2010-2015 Expert Opin Investig Drugs 2017 May 2 doi 1010801354378420171323868 [Epub ahead of print]
68 Sabbagh MN Lue LF Fayard D Shi J Increasing precision of clinical diagnosis of AD using a combined algorithm incorporating clinical and novel biomarker data Neurology and Therapy 2017 (submitted)
69 Sabbagh MN Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimerrsquos Disease and Related Disorders Neurology and Therapy 2017 (submitted)
70 Sabbagh MN Editorial Clinical Effects of Oral Tramiprosate in APOE44 Homozygous Patients with Mild Alzheimerrsquos Disease Suggest Disease Modification JPAD 2017 (submitted)
71 Geidy Serrano Marwan S Sabbagh Michael Sierks Tyler A Kokjohn Thomas G Beach Chera L Maarouf Steven G Clarke4 Alex Roher APPAβ Structural Diversity and Alzheimerrsquos Disease Pathogenesis Neurochemistry International 2017 (submitted)
Peer-Reviewed Manuscripts
1 Adem A Sabbagh M Nordberg A Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex Journal of Neural Transmission 1988 7211-18
2 Sabbagh M Garza J Patten B Thoracoscopic thymectomy in myasthenia gravis Muscle amp Nerve
1995 181475-1477
3 Sabbagh M Lynn P Jhingran S et al Correlation of SPECT Regional cerebral blood flow defects to psychometric testing in patients with Alzheimers disease Journal of Neuropsychiatry and Clinical Neurosciences 1997 9 68-74
4 Corey-Bloom J Sabbagh MN Bondi MW Hansen L Alford MF Thal LJ Hippocampal sclerosis
contributes to dementia in the elderly Neurology 1997 48(1) 154-160
5 Olichney J Sabbagh M Hofstetter RC Galasko D Grundman M Katzman R Thal L The impact of
apolipoprotein 4 on the cause of death in Alzheimerrsquos disease Neurology 1997 49(1) 76-81
10 6 Olichney J Ellis R Katzman R Sabbagh M Hansen L Types of cerebrovascular lesions associated
with severe cerebral amyloid angiopathy in Alzheimers disease Annals of the New York Academy of Sciences 1997 826 493-497
7 Sabbagh MN Reid R Corey-Bloom J Rao T Lloyd K Hansen L Alford M Masliah E Adem A Thal
LJ Correlation of nicotinic binding to neurochemical markers in Alzheimerrsquos disease Journal of Neural Transmission 1998105(7) 709-717
8 Sabbagh MN Corey-Bloom J Tiraboschi P Thomas R Masliah E Thal LJ Neurochemical markers
do not correlate with cognitive decline in the Lewy Body Variant of Alzheimerrsquos disease Archives of Neurology 1999 56(12) 1568-1572
9 Tiraboschi P Hansen LA Sabbagh MN Schoos B Alford M Masliah E Thal LJ Corey-Bloom J
Cholinergic dysfunction in diseases with Lewy bodies Neurology 2000 54407-411
10 Corey-Bloom J Tiraboschi P Hansen LA Schoos B Alford M Sabbagh MN Masliah E Thal LJ E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimerrsquos disease Neurology 2000 54403-406
11 Reid RT Sabbagh MN Corey-Bloom J Tiraboschi P Thal LJ Nicotinic receptor in dementia with
Lewy Bodies comparisons with Alzheimerrsquos disease Neurobiology of Aging 2000 21 (5) 741-746
12 ReidRT Sabbagh MN Thal LJ Does apolipoprotein e (apo e) genotype influence nicotinic receptor binding in Alzheimers disease J Neural Transmission 2001 108(8-9) 1043-1050
13 Sabbagh MN Reid RT Hansen LA Alford M Thal LJ Correlation of nicotinic receptor binding with
clinical and neuropathological changes in Alzheimerrsquos disease and dementia with Lewy bodies J Neural Transmission 2001 108 (10) 1149-1157
14 Caselli R Beach T Sue L Connor DJ Sabbagh MN Progressive Aphasia with Lewy Bodies
Dementia and Geriatric Cognitive Disorders 2002 14 (2) 55-58
15 Sabbagh M Silverberg N Majeed B Samant S Sparks DL Seward J Connor DJ Length of stay in skilled nursing facilities is longer for patients with dementia J Alz Dis 2003 5(1) 57-63
16 Smith RG Roher A Appel SH Doody RS Killian DM Corey-Bloom J Sabbagh MN Autonomic
sudomotor dysfunction discriminates Alzheimerrsquos disease and non-demented control individuals Current Medicinal Chemistry Immunology Endocrine and Metabolic Agents 2003 3233-243
17 Reid RT Sabbagh MN Effects of Donepezil Treatment on Rat Nicotinic Acetylcholine Receptor
Levels In Vivo and In Vitro Journal of Alzheimerrsquos Disease 2003 5(6) 429-436
18 Caviness JN Adler CH Sabbagh M Connor DJ Hernandez JL Lagerlund T Abnormal Cortico-muscular Coherence is associated with the small amplitude cortical myoclonus in Parkinsonrsquos Disease Movement Disorders 2003 18 (10) 1157-62
19 Beach TG Sue L Scott S Layne K Newell A Walker D Baker M Sahara N Yen S-H Hutton M
Caselli R Adler C Connor D Sabbagh M Hippocampal Sclerosis Dementia with Tauopathy Brain Pathology 2003 13 263-278
20 Sparks DL Lopez J Sabbagh M Connor D Seward J Browne P A position paper based on
observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the AD Cholesterol-Lowering Treatment Trial J Molecular Neuroscience 2003 20 407-410
21 Caselli RJ Beach TG Sue LI Connor DJ Sabbagh MN Progressive aphasia with Lewy bodies
Dementia Review Series 2003 4 10-11
22 Sabbagh MN Thompson N Tweedy D Stipho-Majeed S Kawas C Connor DJ Successful and Unsuccessful Recruitment and Retention Strategies for Alzheimerrsquos Disease Clinical Trials Pharmaceutical Regulation and Development 2003 1(4) 269-276
11 23 Johnson SC Baxter LC Susskind-Wilder L Connor DJ Sabbagh MN Caselli RJ Hippocampal
Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment Neuropsychologia 2004 42(7) 980-989
24 Li R Lindholm K Yang LB Yue X Citron M Yan R Beach T Sue L Sabbagh M Cai H Wong P
Price D Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimers disease patients Proc Natl Acad Sci U S A 2004 Mar 9 101(10)3632-3637
25 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A Masliah E Alford M Thal
LJ Corey-Bloom J Alzheimerrsquos disease without neocortical neurofibrillary tangles ldquoa second lookrdquo Neurology 2004 621141-1147
26 Davie JE Azuma T Goldinger SD Connor DJ Sabbagh MN Silverberg N Sensitivity to Expectancy
Violations in Healthy Aging and Mild Cognitive Impairment Neuropsychology 2004 18(2) 269-275
27 Sabbagh MN Silverberg NB Descheny RL Baxter LC Connor DJ Crocker-Sabbagh IP Dementia with Lewy bodies in a Native American Alzheimerrsquos Disease and Associated Disorders 2004 18 (4)259-261
28 Sabbagh MN Zahiri HR Ceimo J Cooper K Gaul W Connor DJ Sparks DL Is there a characteristic
lipid profile in Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2004 6 (6) 585-589
29 Sabbagh MN Tyas SL Emery SC Hansen LA Alford MF Reid RT Tiraboschi P Thal LJ Smoking Affects the Phenotype of Alzheimerrsquos Disease Neurology 2005 Apr 1264(7)1301-3
30 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Petanceska S Browne P Wassar D Johnson-Traver S Lochhead J Ziolwolski C Benefit of Atorvastatin in the treatment of mild to moderate Alzheimerrsquos disease results from the Alzheimerrsquos disease cholesterol lowering treatment (ADCLT) trial Archives of Neurology 2005 62753-757
31 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Browne P Johnson-Traver S Lochhead J
Ziolwolski C Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD Current Alzheimerrsquos Research 2005 Jul2(3)343-53
32 Sabbagh MN Silverberg N Bircea S Majeed B Samant S Caviness JN Reisberg B Adler CH Is
the functional decline in PD similar to the functional decline of AD Parkinsonism and Related Disorders 2005 11 311-315
33 Sabbagh MN Hake AM Ahmed S Farlow MR The use of memantine in Dementia with Lewy Bodies
Journal of Alzheimerrsquos Disease 2005 7(4) 285-289
34 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C rols MCI AD and the AD Cholesterol
Lowering Treatment Trial Current Alzheimerrsquos Research 2005 2527-539
35 Rogers J Li R Mastroeni D Grover A Leonard B Ahern G Cao P Kolody H Vedders L Kolb WP Sabbagh M Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes Neurobiology of Aging 2006 271733-1739
36 Caviness JN Shill HA Sabbagh MN Evidente VGH Hernandez J Adler CH Cortico-Muscular
coherence is increased in the small postural tremor of Parkinsonrsquos disease Movement Disorders 2006 21 (4)492-499
37 Sabbagh MN Sandhu S Lahti T Kolody H Silverberg NB Sparks DL What is the effect of the
apolipoprotein E genotype on the lipid profile in Alzheimerrsquos disease Current Alzheimerrsquos Research 2006 3(2) 157-160
38 Sparks DL Connor DJ Sabbagh MN Petersen RB Lopez J Browne P Circulating cholesterol
levels apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
4 Neurobiology of Aging Neurology Archives of Neurology Clinical Neurosciences and Disease Study Section CND-1 NIH Neuropharmacology Small Business ZRG1 BDCN-A (11) B CSR NIH Emerging Technology and Training in Neuroscience ETTN CSR NIH Aging Program Project Review ZRG1 BDCN-L 42P Alzheimers Disease Pilot Clinical Trials ZRG1 BBBP-V (55) R European Archives of Psychiatry and Clinical Neurosciences Journal of Clinical Psychiatry Neuroscience Letters Neuroepidemiology Biological Psychiatry International Journal of Geriatric Psychiatry Annals of Neurology PUBLICATIONS (Google scholar h-index 61) Books 1 Sabbagh MN The Alzheimerrsquos Answer Reduce Your Risk and Keep Your Brain Healthy 2008 2010
(paperback) John Wiley and Sons Hoboken New Jersey 2 Sabbagh MN Alzheimer Guia practica Respuestas a las cuestiones fundamentales desde su
diagnostico hsta como se aplica el tratamiento (Spanish Edition) 2010 RobinBooks Barcelona Spain 3 Martin G Sabbagh MN (eds) Palliative Care For Advanced Alzheimerrsquos and Dementia Guidelines and
Standards for Evidence Based Care 2010 Springer Publishing Company New York NY
4 Sabbagh M MacMillan B The Alzheimerrsquos Prevention Cookbook Recipes to Boost Brain Health 2012 TenSpeed Press Emeryville California
5 Nair A Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford United Kingdom Invited Chapters 1 Smith RG Sabbagh M White P Brod S Oral tolerance therapy of autoimmune disease In Appel SH
(ed) Current Neurology 1996 Mosby New York 16165-189 2 Shaibani AT Sabbagh MN Khan B Pathological Human Crying In Ad JJM Vingerhoets Randolph R
Cornelius (eds) Adult Crying A Biopsychosocial Approach 2002 Brunner-Routledge East Sussex UK
3 Sparks DL Connor DJ Browne PJ Wasser DR Lopez JE Sabbagh MN The Alzheimerrsquos disease atorvastatin treatment trial scientific basis and position on the use of the HMG-CoA reductase inhibitors (statins) that do or do not cross the blood-brain barrier In Fillit H OrsquoConnell AW Drug Discovery and Drug Development for Alzheimerrsquos Disease 2002 Springer Publishing Company New York 244-252
4 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C Lochhead J
Browne P Cholesterol copper and statin therapy in AD In Gauthier S Schelten P Cummings J Alzheimerrsquos Disease and Related Disorders Annual 5 2005 Taylor and Francis London 89-110
5 Reisberg B Weigel J Franssen E Kadiyala S Auer S Souren L Sabbagh M Golomb J Clinical features
of severe dementia-staging In Burns A Winblad B (eds) Severe Dementia 2006 John Wiley and Sons Hoboken New Jersey 95-127
6 McCarthy M Gallagher M Sabbagh M Appropriate use of medications in advanced dementia In Long C
(ed) Palliative Care for Advanced Dementia Guidelines and Standards 2006 Alzheimerrsquos Association Desert Southwest Chapter Phoenix AZ 40-51
7 Rogers J Beach T Li R Liang Z Lue L-F Roher A Sabbagh M Shen Y Strohmeyer R Walker D
Inflammatory mechanisms in Alzheimers disease and other neurodegenerative disorders In Chemistry and Molecular Aspects of Drug Design and Action (Kourounakis and Rekka eds) CRC Press (Boca Raton FL) pp 3-12 2007
5 8 Barry Reisberg Jerzy Wegiel Emile Franssen Sridhar Kadiyala Stefanie Auer Liduiumln Souren Marwan
Sabbagh and James Golomb Clinical Features of Severe Dementia Staging in Severe Dementia (Burns and Winblad eds) 2010 John Wiley and Sons Hoboken NJ Chapter 8
9 Reisberg B Jamil IA Khan S Monteiro I Torossian C Ferris S Sabbagh M Gauthier S Auer
S Shulman MB Kluger A Franssen E and Wegiel J Staging dementia In Principles and Practice of Geriatric Psychiatry 3rd edition M T Abou-Saleh C Katona and A Kumar (Eds) Chichester England Wiley-Blackwell 2010 p 162-169
10 Belden CM Burciu C Sabbagh M (2014) Global Deterioration Scale (Individuals) In Michalos AC (Ed)
Encyclopedia of Quality of Life and Well-Being Research Springer Dordrecht Netherlands Springer pp 2562-2564
11 Sabbagh MN Nair AK Approach to the Geriatric Neurology Patient The Neurologic Examination In Nair A
Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p71-84
12 Nair AK Sabbagh MN Amyloid imaging In Nair A Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p 162-169
13 Singh J Sabbagh MN Nair AK Evidence based pharmacological treatment of dementia In Nair A
Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p 557-573
14 Decourt B1 Macias M
1 Berk C
1 Sabbagh M
1 Adem A
2 BACE1 inhibitors attractive therapeutics for
Alzheimerrsquos disease In Ur-Rahman A Choudhary MI Frontiers in Drug Design and Discovery 2014 Bentham Science p518-546
Invited Reviews and Editorials 1 Taher A Sabbagh M Doody R Laughter and crying in neurologic disorders Neuropsychiatry
Neuropsychology amp Behavioral Neurology 7(4) 243-250 1994 2 Sabbagh MN Galasko D Thal LJ Beta amyloid and treatment opportunities for Alzheimers disease
Alzheimers Disease Reviews 1998 31-19 3 Shaibani AT Sabbagh MN Pseudo-Neurologic Syndromes Recognition and Diagnosis American Family
Physician 1998 57(10) 2485-2494 4 Sabbagh MN Application of the Changing Therapies for Alzheimerrsquos Disease in Clinical Practice
American Speech and Language Association 1998 3(1) 7-12
5 Sabbagh MN Galasko D Koo E Thal LJ -amyloid and treatment opportunities for Alzheimers disease Journal of Alzheimers Disease 2000 2(3-4) 231-259
6 Sparks DL Connor DJ Browne PJ Lopez JE Sabbagh MN HMG-CoA reductase inhibitors (statins) in
the treatment of Alzheimerrsquos disease and why it would be ill-advised to use one that crosses the blood-brain barrier Journal of Nutrition Health and Aging 2002 6(5) 324-330
7 Sparks DL Connor DJ Browne P and Sabbagh MN Should the guidelines for monitoring serum
cholesterol levels in the elderly be re-evaluated Journal of Molecular Neuroscience 2002 19 209-212 8 Sabbagh MN Lukas RJ Sparks DL Reid RT The nicotinic acetylcholine receptor smoking and
Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2002 4 (4) 317-325 9 Sparks DL Sabbagh MN Breitner JCS Hunsaker J Is cholesterol a culprit in AD International
Psychogeriatrics 2003 15 (suppl1) 153-159 10 Sabbagh MN Farlow MR Relkin NR Beach TG Do cholinergic therapies have disease modifying effects
in Alzheimerrsquos disease Alzheimerrsquos and Dementia 20062(2) 118-125 11 Sparks DL Sabbagh M Connor D Soares H Lopez J Stankovic G Johnson-Traver S Ziolkowski C
Browne P Statin therapy in AD Acta Neurologica Scandinavica 2006 185S78-86
6 12 Thind K Sabbagh MN Pathological Correlates of Cognitive Decline in Alzheimerrsquos Disease PanMinerva
Medica 2007 49(4)191-195 13 Beach TG Sue LI Walker DG Roher AE Lue LF Vedders L Connor DJ Sabbagh M Rogers J The
Sun Health Research Institute Brain Donation Program Description and Experience 1987-2007 Cell Tissue Bank 2008 Mar 18 [Epub ahead of print]
14 Sabbagh MN Richardson S Relkin N Disease modifying approaches to Alzheimers disease Challenges
and opportunities Lessons from donepezil therapyrdquo Alzheimerrsquos and Dementia 2008 4(1) S109-S118 15 Sabbagh MN Commentary on the baseline data of the atorvastatindonepezil study for Alzheimerrsquos
disease Alzheimerrsquos and Dementia 2008 4 (3)174-175 16 Khatchaturian ZS Petersen RC Gauthier S Buckholtz N Corey-Bloom J Evans B Fillit H Foster N
Greenberg B Grundman M Sano M Simpkins J Schneider LS Weiner MW Galasko D Hyman B Kuller L Schenk D Snyder S Thomas RG Tuszinski MH Vellas B Wurtman RJ Snyder PJ Frank RA Albert M Doody R Ferris S Kaye J Koo E Morrison-Bogorad M Reisberg B Salmon DP Gilman S Mohs R Aisen PS Breitner JCS Cummings JL Kawas C Phelps C Poirier J Sabbagh M Touchon J Khatchaturian AS Bain L A roadmap for the prevention of dementia the inaugural Leon Thal Symposium Alzheimerrsquos and Dementia 2008 4 (3)156-163
17 Rogers J Sabbagh MN Relationships of strokes and non-steroidal anti-inflammatory drug use to
apolipoprotein E4-conferred of Alzheimerrsquos disease and dementia Neurology 2008 702-4 18 Quinn J Sabbagh MN Editorial Biochemical Markers in Persons with Pre-Clinical Familial Alzheimers
Disease Neurology 2008 7178-79 19 Jacobson S Sabbagh MN Donepezil potential neuroprotective and disease modifying effects Expert
Opinion on Drug Metabolism and Toxicology 2008 4(10)1363-1369 20 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathologica 2008 Nov 4 [epub ahead of print] 21 Lue LF Jacobson S Walker D Sabbagh MN The receptor for advanced glycation end-products its role
in Alzheimerrsquos and other diseases Future Neurology 2009 4(2) 167-177 22 Sabbagh MN Tariot PN Commentary on A roadmap for the prevention of dementia II Leon Thal
Symposium 2008 A national registry to identify a cohort for Alzheimerrsquos disease prevention studies Alzheimerrsquos and Dementia 20095 128-129
23 Khachaturian ZS Snyder PJ Doody RS Aisen P Comer M Dwyer J Frank RA Holzapfel A
Khachaturian AS Korczyn AD Phelps C Roses A Simpkins JW Schneider LS Albert MS Egge R Deves A Ferris S Greenberg BD Johnson C Kukull WA Poirier J Schenk D Thies W Gauthier S Gilman S Bernick C Cummings JL Fillit H Grundman M Kaye J Mucke L Reisberg B Sano M Pickeral O Petersen RC Mohs RC Buckholtz N Carrillo M Corey-Bloom JP Foster NL Jacobsen S Lee V Potter WZ Sabbagh MN Salmon D Trojanowski JQ Wexler N Bain LJ A roadmap for the prevention of dementia II Leon Thal Symposium 2008 Alzheimerrsquos and Dementia 2009 585-92
24 Sabbagh MN Drug Development for Alzheimerrsquos Disease Where Are We Now and Where Are We
Headed American Journal of Geriatric Pharmacotherapy 2009 7(3) 167-185 25 Sabbagh MN Thind K Sparks DL On cholesterol levels and statins in Alzheimerrsquos disease and cognitive
decline progress and setbacks Alzheimerrsquos Disease and Associated Disorders 2009 (Oct-Dec) 23(4)303-305
26 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathol 2009 Feb117(2)217-218
7 27 Sabbagh MN Shill HA Dimebon (latrepirdine) a potential treatment with a novel mechanism of action for
the treatment of Alzheimers disease and Huntington disease Current Opinion in Investigational Drugs 2010 Curr Opin Investig Drugs 2010 Jan11(1)80-91
28 Arab L Sabbagh MN Lifestyle changes do they lower Alzheimerrsquos risk Journal of Alzheimerrsquos Disease
201020(3)785-94 Review PubMedPMID 20182018
29 Sabbagh MN Commentary On The Perspective Design Of Comprehensive Alzheimers Disease Centers To Address Unmet National Needs by JQ Trojanowski et al Alzheimerrsquos and Dementia 2010 Mar6(2)156-7 No abstract available
30 Khachaturian AS Sabbagh M Commentary on Developing a national strategy to prevent dementia
Leon Thal Symposium 2009 Creating a national database for successful aging Alzheimers Dement 2010 Mar6(2)132-4 No abstract available
31 Zaven Khachaturian [Convener ndash Facilitator] - Presenters Deborah Barnes Richard Einstein Sterling
Johnson Virginia Lee Allen Roses Mark A Sager William R Shankle Peter J Snyder Ronald C Petersen Gerard Schellenberg and John Trojanowski - Discussants Paul Aisen Marilyn S Albert Charles Bernick John C S Breitner Neil Buckholtz Maria Carrillo Steven Ferris Barry D Greenberg Michael Grundman Ara S Khachaturian Lewis H Kuller Oscar L Lopez Paul Maruff Richard C Mohs Marcelle Morrison-Bogorad Creighton Phelps Michael Phillips Stephen Rao Eric Reiman Marwan Sabbagh Mary Sano Randy Schiffer Lon S Schneider Eric Siemers Pierre Tariot Jacques Touchon Bruno Vellas Reporter Lisa J Bain Developing a National Strategy to Prevent Dementia Alzheimerrsquos and Dementia 2010 Mar6(2)89-97
32 Sabbagh MN Berk C Latrepirdine for Alzheimerrsquos disease trials and tribulations Future Neurology 2010
September 2010 Vol 5 No 5 Pages 645-651
33 Sabbagh MN Cummings J Progressive Cholinergic Decline in Alzheimerrsquos Disease Consideration for Treatment With Donepezil 23 mg in Patients With Moderate to Severe Symptomatology BMC Neurology 2011 1121
34 DeCourt B Sabbagh MN BACE1 as a potential biomarker for Alzheimerrsquos disease Journal of
Alzheimerrsquos Disease 201124 Suppl 253-9]
35 Jacobson SA Sabbagh MN Investigational drugs for the treatment of Alzheimerrsquos disease failed trials Alzheimerrsquos Research and Therapy 2011 Apr 153(2)14 [Epub ahead of print]
36 Patel S Shah R Coleman P Sabbagh MN Potential Peripheral Biomarkers for the Diagnosis of
Alzheimerrsquos Disease International Journal of Alzheimerrsquos Disease 2011572495 Epub 2011 Oct 23
37 Mehta M Adem A Sabbagh MN The nicotinic receptor smoking and Alzheimerrsquos revisited Frontiers in Bioscience E4 169-180 January 1 2012
38 Sabbagh MN Berk C Appraisal of higher doses of donepezil in the treatment of mild moderate and
severe Alzheimers disease International Journal of Alzheimerrsquos Disease 20122012707468 Epub 2011 Dec 1
39 Arab L Sadeghi R Walker DG Lue LF Sabbagh MN Consequences of aberrant insulin regulation in the
brain Can treating diabetes be effective for Alzheimerrsquos Disease Current Neuropharmacology 2011 9(4) 693-705
40 Mehta M Adem A Sabbagh MN New acetylcholinesterase inhibitors for Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 728983 8 pages doi1011552012728983
41 Sabbagh MN Sparks DL Statins to treat Alzheimerrsquos an incomplete story Expert Review in
Neurotherapeutics January 2012 Vol 12 No 1 Pages 27-30
8 42 Sabbagh MN Porsteinsson AP Nair A Adem A Novel Therapeutics in Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 207969 2 pages
43 Sabbagh MN Geula C Messis C Friedland R Conference Report on the 5th International Conference on
Alzheimerrsquos Disease in the Middle East May 7-9 2009 Limmassol Cyprus Journal of Alzheimerrsquos Disease 2012 May 21Epub ahead of print] No abstract available PMID22614876
44 Lue LF Andrade C Sabbagh MN Walker DG Is there inflammatory synergy in type II diabetes mellitus
and Alzheimerrsquos disease International Journal of Alzheimerrsquos Disease 2012918680 Epub 2012 Jun 21
45 Sabbagh MN Ahmadi MM Belden C The Use of Informant-Based Questionnaires in Differentiating Mild Cognitive Impairment from Normal Aging Expert Review of Neurotherapeutics 2012 Jun12(6)637-9
46 Jeffrey L Cummings1 David Geldmacher
2 Martin Farlow
3 Marwan Sabbagh
4 Daniel Christensen
5 amp
Peter Betz6 for the Donepezil 23 mg Expert Working Group High-Dose Donepezil (23 mgday) for the
Treatment of Moderate and Severe Alzheimerrsquos Disease Drug Profile and Clinical Guidelines CNS Neurosci Ther 2013 Mar 6 doi 101111cns12076 [Epub ahead of print]
47 DeCourt B Mobley W Reiman E Shah RJ Sabbagh MN Recent perspectives on Alzheimerrsquos disease pathological changes in Down syndromerdquo J Alzheimers Dis Parkinsonism 2013 S7 httpdxdoiorg 1041722161-0460S7-002
48 Adem A El-Agnaf O Sabbagh MN Neurodegeneration The first IBRO-Middle East Neuroscience
Conference Current Alzheimerrsquos Research 2013 10 (6)557-8
49 Berk C Sabbagh MN Drugs in Late Stage Development for Alzheimerrsquos Disease Drugs Aging 2013 Aug 14 [Epub ahead of print]
50 Berk C Paul G Sabbagh MN Investigational Drugs in Alzheimerrsquos Disease Current Progress Expert
Opinion on Investigational Drugs 2014 Expert Opin Investig Drugs 2014 Jun23(6)837-46 doi 101517135437842014905542 Epub 2014 Apr 5
51 Richards D Sabbagh MN Florbetaben for PET Imaging of Neuritic Beta-Amyloid Plaques in the Brain
Neurology and Therapy 2014 DOI 101007s40120-014-0022-9
52 Hartley D Blumenthal T Carrillo M DiPaolo G Esralew L Gardiner K Granholm AC Iqbal K Krams M Lemere C Lott I Mobley W Ness S Nixon R Potter H Reeves R Sabbagh M Silverman W Tycko B Whitten M Wisniewski T Down syndrome and Alzheimers disease Common pathways common goals Alzheimers Dement 2014 Dec 12 pii S1552-5260(14)02860-X doi 101016jjalz201410007
53 Saunders KT Langbaum JB Holt CJ Chen W High N Langlois C Sabbagh M Tariot PN Arizona
Alzheimers Registry Strategy and Outcomes of a Statewide Research Recruitment Registry J Prev Alzheimers Dis 2014 Sep1(2)74-79
54 Walker DG Lue LF Paul G Patel A Sabbagh MN Advanced Glycation Endproduct Modulators A New
Therapeutic Target in Alzheimerrsquos Disease Expert Opinion in Investigational Drugs Posted online on January 14 2015 (doi1015171354378420151001490)
55 Malek-Ahmadi M Sabbagh MN Development and validation of the Alzheimerrsquos Questionnaire (AQ)
Journal of Nature and Science 20151(5)e104
56 Anand K Sabbagh MN Early investigational drugs targeting tau protein for the treatment of Alzheimers Disease Expert Opinion in Investigational Drugs 2015 24 (10)1-6
57 Sabbagh MN Edgin JO Clinical Assessment of Cognitive Decline in Adults with Down Syndrome
Current Alzheimerrsquos Research 2015 Sep 20 [epub ahead of print]
58 Arab L Sabbagh MNAre Certain Lifestyle Habits Associated with Lower Alzheimers Disease Risk J Alzheimers Dis 2015 Oct 148(3)877 doi 103233JAD-159004 No abstract available
9 59 Bahureska L Schwenk M Sabbagh M Mohler J Saleh A Najafi B The Impact of Mild Cognitive
Impairment on Balance and Gait a Systematic Review and Meta-Analysis Gerontology 2016 (DOI101159000445831)
60 Anand K Sabbagh MN Amyloid imaging poised for integration into medical practice Neurotherapeutics 2016 Aug 29 [Epub ahead of print] Review
61 Marwan Sabbagh1 SeolHeui Han
2 SangYun Kim
3 Hae-Ri Na
4 Jae-Hong Lee
5 Nagaendran Kandiah
6
Kammant Phanthumchinda7 Chuthamanee Suthisisang
8 Vorapun Senanarong
9 Ming-Chyi Pai
10 Diatri
Narilastri11
Ajit M Sowani12
Encarnita Ampil13
Amitabh Dash14
for the Asia Pacific EXpert Panel (APEX) for Donepezil 23 mg Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimerrsquos disease in the Asia-Pacific region Dement Geriatr Cogn Disord Extra 20166382-395 (DOI101159000448214)
62 Decourt B Lahiri DK Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimers Disease Curr Alzheimer Res 2016 Sep 30
63 Sabbagh MN Editorial Introduction Neurol Ther 2016 Nov 9 [Epub ahead of print]
64 Shefner JM Sabbagh MN An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases Editorial Introduction Neurotherapeutics 2016 Dec 8 [Epub ahead of print] No abstract available
65 Sabbagh MN DeCourt B Editorial Current and Emerging Therapeutics in AD Current Alzheimerrsquos Research 201714 (3) 354-355
66 DeCourt B Lahiri D Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimerrsquos Disease Current Alzheimerrsquos Research 201714 (3) 412-425
67 Mehta DG Paul G Shi J Sabbagh MN Why are drugs failing in Alzheimerrsquos disease 2010-2015 Expert Opin Investig Drugs 2017 May 2 doi 1010801354378420171323868 [Epub ahead of print]
68 Sabbagh MN Lue LF Fayard D Shi J Increasing precision of clinical diagnosis of AD using a combined algorithm incorporating clinical and novel biomarker data Neurology and Therapy 2017 (submitted)
69 Sabbagh MN Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimerrsquos Disease and Related Disorders Neurology and Therapy 2017 (submitted)
70 Sabbagh MN Editorial Clinical Effects of Oral Tramiprosate in APOE44 Homozygous Patients with Mild Alzheimerrsquos Disease Suggest Disease Modification JPAD 2017 (submitted)
71 Geidy Serrano Marwan S Sabbagh Michael Sierks Tyler A Kokjohn Thomas G Beach Chera L Maarouf Steven G Clarke4 Alex Roher APPAβ Structural Diversity and Alzheimerrsquos Disease Pathogenesis Neurochemistry International 2017 (submitted)
Peer-Reviewed Manuscripts
1 Adem A Sabbagh M Nordberg A Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex Journal of Neural Transmission 1988 7211-18
2 Sabbagh M Garza J Patten B Thoracoscopic thymectomy in myasthenia gravis Muscle amp Nerve
1995 181475-1477
3 Sabbagh M Lynn P Jhingran S et al Correlation of SPECT Regional cerebral blood flow defects to psychometric testing in patients with Alzheimers disease Journal of Neuropsychiatry and Clinical Neurosciences 1997 9 68-74
4 Corey-Bloom J Sabbagh MN Bondi MW Hansen L Alford MF Thal LJ Hippocampal sclerosis
contributes to dementia in the elderly Neurology 1997 48(1) 154-160
5 Olichney J Sabbagh M Hofstetter RC Galasko D Grundman M Katzman R Thal L The impact of
apolipoprotein 4 on the cause of death in Alzheimerrsquos disease Neurology 1997 49(1) 76-81
10 6 Olichney J Ellis R Katzman R Sabbagh M Hansen L Types of cerebrovascular lesions associated
with severe cerebral amyloid angiopathy in Alzheimers disease Annals of the New York Academy of Sciences 1997 826 493-497
7 Sabbagh MN Reid R Corey-Bloom J Rao T Lloyd K Hansen L Alford M Masliah E Adem A Thal
LJ Correlation of nicotinic binding to neurochemical markers in Alzheimerrsquos disease Journal of Neural Transmission 1998105(7) 709-717
8 Sabbagh MN Corey-Bloom J Tiraboschi P Thomas R Masliah E Thal LJ Neurochemical markers
do not correlate with cognitive decline in the Lewy Body Variant of Alzheimerrsquos disease Archives of Neurology 1999 56(12) 1568-1572
9 Tiraboschi P Hansen LA Sabbagh MN Schoos B Alford M Masliah E Thal LJ Corey-Bloom J
Cholinergic dysfunction in diseases with Lewy bodies Neurology 2000 54407-411
10 Corey-Bloom J Tiraboschi P Hansen LA Schoos B Alford M Sabbagh MN Masliah E Thal LJ E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimerrsquos disease Neurology 2000 54403-406
11 Reid RT Sabbagh MN Corey-Bloom J Tiraboschi P Thal LJ Nicotinic receptor in dementia with
Lewy Bodies comparisons with Alzheimerrsquos disease Neurobiology of Aging 2000 21 (5) 741-746
12 ReidRT Sabbagh MN Thal LJ Does apolipoprotein e (apo e) genotype influence nicotinic receptor binding in Alzheimers disease J Neural Transmission 2001 108(8-9) 1043-1050
13 Sabbagh MN Reid RT Hansen LA Alford M Thal LJ Correlation of nicotinic receptor binding with
clinical and neuropathological changes in Alzheimerrsquos disease and dementia with Lewy bodies J Neural Transmission 2001 108 (10) 1149-1157
14 Caselli R Beach T Sue L Connor DJ Sabbagh MN Progressive Aphasia with Lewy Bodies
Dementia and Geriatric Cognitive Disorders 2002 14 (2) 55-58
15 Sabbagh M Silverberg N Majeed B Samant S Sparks DL Seward J Connor DJ Length of stay in skilled nursing facilities is longer for patients with dementia J Alz Dis 2003 5(1) 57-63
16 Smith RG Roher A Appel SH Doody RS Killian DM Corey-Bloom J Sabbagh MN Autonomic
sudomotor dysfunction discriminates Alzheimerrsquos disease and non-demented control individuals Current Medicinal Chemistry Immunology Endocrine and Metabolic Agents 2003 3233-243
17 Reid RT Sabbagh MN Effects of Donepezil Treatment on Rat Nicotinic Acetylcholine Receptor
Levels In Vivo and In Vitro Journal of Alzheimerrsquos Disease 2003 5(6) 429-436
18 Caviness JN Adler CH Sabbagh M Connor DJ Hernandez JL Lagerlund T Abnormal Cortico-muscular Coherence is associated with the small amplitude cortical myoclonus in Parkinsonrsquos Disease Movement Disorders 2003 18 (10) 1157-62
19 Beach TG Sue L Scott S Layne K Newell A Walker D Baker M Sahara N Yen S-H Hutton M
Caselli R Adler C Connor D Sabbagh M Hippocampal Sclerosis Dementia with Tauopathy Brain Pathology 2003 13 263-278
20 Sparks DL Lopez J Sabbagh M Connor D Seward J Browne P A position paper based on
observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the AD Cholesterol-Lowering Treatment Trial J Molecular Neuroscience 2003 20 407-410
21 Caselli RJ Beach TG Sue LI Connor DJ Sabbagh MN Progressive aphasia with Lewy bodies
Dementia Review Series 2003 4 10-11
22 Sabbagh MN Thompson N Tweedy D Stipho-Majeed S Kawas C Connor DJ Successful and Unsuccessful Recruitment and Retention Strategies for Alzheimerrsquos Disease Clinical Trials Pharmaceutical Regulation and Development 2003 1(4) 269-276
11 23 Johnson SC Baxter LC Susskind-Wilder L Connor DJ Sabbagh MN Caselli RJ Hippocampal
Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment Neuropsychologia 2004 42(7) 980-989
24 Li R Lindholm K Yang LB Yue X Citron M Yan R Beach T Sue L Sabbagh M Cai H Wong P
Price D Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimers disease patients Proc Natl Acad Sci U S A 2004 Mar 9 101(10)3632-3637
25 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A Masliah E Alford M Thal
LJ Corey-Bloom J Alzheimerrsquos disease without neocortical neurofibrillary tangles ldquoa second lookrdquo Neurology 2004 621141-1147
26 Davie JE Azuma T Goldinger SD Connor DJ Sabbagh MN Silverberg N Sensitivity to Expectancy
Violations in Healthy Aging and Mild Cognitive Impairment Neuropsychology 2004 18(2) 269-275
27 Sabbagh MN Silverberg NB Descheny RL Baxter LC Connor DJ Crocker-Sabbagh IP Dementia with Lewy bodies in a Native American Alzheimerrsquos Disease and Associated Disorders 2004 18 (4)259-261
28 Sabbagh MN Zahiri HR Ceimo J Cooper K Gaul W Connor DJ Sparks DL Is there a characteristic
lipid profile in Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2004 6 (6) 585-589
29 Sabbagh MN Tyas SL Emery SC Hansen LA Alford MF Reid RT Tiraboschi P Thal LJ Smoking Affects the Phenotype of Alzheimerrsquos Disease Neurology 2005 Apr 1264(7)1301-3
30 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Petanceska S Browne P Wassar D Johnson-Traver S Lochhead J Ziolwolski C Benefit of Atorvastatin in the treatment of mild to moderate Alzheimerrsquos disease results from the Alzheimerrsquos disease cholesterol lowering treatment (ADCLT) trial Archives of Neurology 2005 62753-757
31 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Browne P Johnson-Traver S Lochhead J
Ziolwolski C Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD Current Alzheimerrsquos Research 2005 Jul2(3)343-53
32 Sabbagh MN Silverberg N Bircea S Majeed B Samant S Caviness JN Reisberg B Adler CH Is
the functional decline in PD similar to the functional decline of AD Parkinsonism and Related Disorders 2005 11 311-315
33 Sabbagh MN Hake AM Ahmed S Farlow MR The use of memantine in Dementia with Lewy Bodies
Journal of Alzheimerrsquos Disease 2005 7(4) 285-289
34 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C rols MCI AD and the AD Cholesterol
Lowering Treatment Trial Current Alzheimerrsquos Research 2005 2527-539
35 Rogers J Li R Mastroeni D Grover A Leonard B Ahern G Cao P Kolody H Vedders L Kolb WP Sabbagh M Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes Neurobiology of Aging 2006 271733-1739
36 Caviness JN Shill HA Sabbagh MN Evidente VGH Hernandez J Adler CH Cortico-Muscular
coherence is increased in the small postural tremor of Parkinsonrsquos disease Movement Disorders 2006 21 (4)492-499
37 Sabbagh MN Sandhu S Lahti T Kolody H Silverberg NB Sparks DL What is the effect of the
apolipoprotein E genotype on the lipid profile in Alzheimerrsquos disease Current Alzheimerrsquos Research 2006 3(2) 157-160
38 Sparks DL Connor DJ Sabbagh MN Petersen RB Lopez J Browne P Circulating cholesterol
levels apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
5 8 Barry Reisberg Jerzy Wegiel Emile Franssen Sridhar Kadiyala Stefanie Auer Liduiumln Souren Marwan
Sabbagh and James Golomb Clinical Features of Severe Dementia Staging in Severe Dementia (Burns and Winblad eds) 2010 John Wiley and Sons Hoboken NJ Chapter 8
9 Reisberg B Jamil IA Khan S Monteiro I Torossian C Ferris S Sabbagh M Gauthier S Auer
S Shulman MB Kluger A Franssen E and Wegiel J Staging dementia In Principles and Practice of Geriatric Psychiatry 3rd edition M T Abou-Saleh C Katona and A Kumar (Eds) Chichester England Wiley-Blackwell 2010 p 162-169
10 Belden CM Burciu C Sabbagh M (2014) Global Deterioration Scale (Individuals) In Michalos AC (Ed)
Encyclopedia of Quality of Life and Well-Being Research Springer Dordrecht Netherlands Springer pp 2562-2564
11 Sabbagh MN Nair AK Approach to the Geriatric Neurology Patient The Neurologic Examination In Nair A
Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p71-84
12 Nair AK Sabbagh MN Amyloid imaging In Nair A Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p 162-169
13 Singh J Sabbagh MN Nair AK Evidence based pharmacological treatment of dementia In Nair A
Sabbagh MN (eds) Geriatric Neurology 2014 Wiley Oxford p 557-573
14 Decourt B1 Macias M
1 Berk C
1 Sabbagh M
1 Adem A
2 BACE1 inhibitors attractive therapeutics for
Alzheimerrsquos disease In Ur-Rahman A Choudhary MI Frontiers in Drug Design and Discovery 2014 Bentham Science p518-546
Invited Reviews and Editorials 1 Taher A Sabbagh M Doody R Laughter and crying in neurologic disorders Neuropsychiatry
Neuropsychology amp Behavioral Neurology 7(4) 243-250 1994 2 Sabbagh MN Galasko D Thal LJ Beta amyloid and treatment opportunities for Alzheimers disease
Alzheimers Disease Reviews 1998 31-19 3 Shaibani AT Sabbagh MN Pseudo-Neurologic Syndromes Recognition and Diagnosis American Family
Physician 1998 57(10) 2485-2494 4 Sabbagh MN Application of the Changing Therapies for Alzheimerrsquos Disease in Clinical Practice
American Speech and Language Association 1998 3(1) 7-12
5 Sabbagh MN Galasko D Koo E Thal LJ -amyloid and treatment opportunities for Alzheimers disease Journal of Alzheimers Disease 2000 2(3-4) 231-259
6 Sparks DL Connor DJ Browne PJ Lopez JE Sabbagh MN HMG-CoA reductase inhibitors (statins) in
the treatment of Alzheimerrsquos disease and why it would be ill-advised to use one that crosses the blood-brain barrier Journal of Nutrition Health and Aging 2002 6(5) 324-330
7 Sparks DL Connor DJ Browne P and Sabbagh MN Should the guidelines for monitoring serum
cholesterol levels in the elderly be re-evaluated Journal of Molecular Neuroscience 2002 19 209-212 8 Sabbagh MN Lukas RJ Sparks DL Reid RT The nicotinic acetylcholine receptor smoking and
Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2002 4 (4) 317-325 9 Sparks DL Sabbagh MN Breitner JCS Hunsaker J Is cholesterol a culprit in AD International
Psychogeriatrics 2003 15 (suppl1) 153-159 10 Sabbagh MN Farlow MR Relkin NR Beach TG Do cholinergic therapies have disease modifying effects
in Alzheimerrsquos disease Alzheimerrsquos and Dementia 20062(2) 118-125 11 Sparks DL Sabbagh M Connor D Soares H Lopez J Stankovic G Johnson-Traver S Ziolkowski C
Browne P Statin therapy in AD Acta Neurologica Scandinavica 2006 185S78-86
6 12 Thind K Sabbagh MN Pathological Correlates of Cognitive Decline in Alzheimerrsquos Disease PanMinerva
Medica 2007 49(4)191-195 13 Beach TG Sue LI Walker DG Roher AE Lue LF Vedders L Connor DJ Sabbagh M Rogers J The
Sun Health Research Institute Brain Donation Program Description and Experience 1987-2007 Cell Tissue Bank 2008 Mar 18 [Epub ahead of print]
14 Sabbagh MN Richardson S Relkin N Disease modifying approaches to Alzheimers disease Challenges
and opportunities Lessons from donepezil therapyrdquo Alzheimerrsquos and Dementia 2008 4(1) S109-S118 15 Sabbagh MN Commentary on the baseline data of the atorvastatindonepezil study for Alzheimerrsquos
disease Alzheimerrsquos and Dementia 2008 4 (3)174-175 16 Khatchaturian ZS Petersen RC Gauthier S Buckholtz N Corey-Bloom J Evans B Fillit H Foster N
Greenberg B Grundman M Sano M Simpkins J Schneider LS Weiner MW Galasko D Hyman B Kuller L Schenk D Snyder S Thomas RG Tuszinski MH Vellas B Wurtman RJ Snyder PJ Frank RA Albert M Doody R Ferris S Kaye J Koo E Morrison-Bogorad M Reisberg B Salmon DP Gilman S Mohs R Aisen PS Breitner JCS Cummings JL Kawas C Phelps C Poirier J Sabbagh M Touchon J Khatchaturian AS Bain L A roadmap for the prevention of dementia the inaugural Leon Thal Symposium Alzheimerrsquos and Dementia 2008 4 (3)156-163
17 Rogers J Sabbagh MN Relationships of strokes and non-steroidal anti-inflammatory drug use to
apolipoprotein E4-conferred of Alzheimerrsquos disease and dementia Neurology 2008 702-4 18 Quinn J Sabbagh MN Editorial Biochemical Markers in Persons with Pre-Clinical Familial Alzheimers
Disease Neurology 2008 7178-79 19 Jacobson S Sabbagh MN Donepezil potential neuroprotective and disease modifying effects Expert
Opinion on Drug Metabolism and Toxicology 2008 4(10)1363-1369 20 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathologica 2008 Nov 4 [epub ahead of print] 21 Lue LF Jacobson S Walker D Sabbagh MN The receptor for advanced glycation end-products its role
in Alzheimerrsquos and other diseases Future Neurology 2009 4(2) 167-177 22 Sabbagh MN Tariot PN Commentary on A roadmap for the prevention of dementia II Leon Thal
Symposium 2008 A national registry to identify a cohort for Alzheimerrsquos disease prevention studies Alzheimerrsquos and Dementia 20095 128-129
23 Khachaturian ZS Snyder PJ Doody RS Aisen P Comer M Dwyer J Frank RA Holzapfel A
Khachaturian AS Korczyn AD Phelps C Roses A Simpkins JW Schneider LS Albert MS Egge R Deves A Ferris S Greenberg BD Johnson C Kukull WA Poirier J Schenk D Thies W Gauthier S Gilman S Bernick C Cummings JL Fillit H Grundman M Kaye J Mucke L Reisberg B Sano M Pickeral O Petersen RC Mohs RC Buckholtz N Carrillo M Corey-Bloom JP Foster NL Jacobsen S Lee V Potter WZ Sabbagh MN Salmon D Trojanowski JQ Wexler N Bain LJ A roadmap for the prevention of dementia II Leon Thal Symposium 2008 Alzheimerrsquos and Dementia 2009 585-92
24 Sabbagh MN Drug Development for Alzheimerrsquos Disease Where Are We Now and Where Are We
Headed American Journal of Geriatric Pharmacotherapy 2009 7(3) 167-185 25 Sabbagh MN Thind K Sparks DL On cholesterol levels and statins in Alzheimerrsquos disease and cognitive
decline progress and setbacks Alzheimerrsquos Disease and Associated Disorders 2009 (Oct-Dec) 23(4)303-305
26 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathol 2009 Feb117(2)217-218
7 27 Sabbagh MN Shill HA Dimebon (latrepirdine) a potential treatment with a novel mechanism of action for
the treatment of Alzheimers disease and Huntington disease Current Opinion in Investigational Drugs 2010 Curr Opin Investig Drugs 2010 Jan11(1)80-91
28 Arab L Sabbagh MN Lifestyle changes do they lower Alzheimerrsquos risk Journal of Alzheimerrsquos Disease
201020(3)785-94 Review PubMedPMID 20182018
29 Sabbagh MN Commentary On The Perspective Design Of Comprehensive Alzheimers Disease Centers To Address Unmet National Needs by JQ Trojanowski et al Alzheimerrsquos and Dementia 2010 Mar6(2)156-7 No abstract available
30 Khachaturian AS Sabbagh M Commentary on Developing a national strategy to prevent dementia
Leon Thal Symposium 2009 Creating a national database for successful aging Alzheimers Dement 2010 Mar6(2)132-4 No abstract available
31 Zaven Khachaturian [Convener ndash Facilitator] - Presenters Deborah Barnes Richard Einstein Sterling
Johnson Virginia Lee Allen Roses Mark A Sager William R Shankle Peter J Snyder Ronald C Petersen Gerard Schellenberg and John Trojanowski - Discussants Paul Aisen Marilyn S Albert Charles Bernick John C S Breitner Neil Buckholtz Maria Carrillo Steven Ferris Barry D Greenberg Michael Grundman Ara S Khachaturian Lewis H Kuller Oscar L Lopez Paul Maruff Richard C Mohs Marcelle Morrison-Bogorad Creighton Phelps Michael Phillips Stephen Rao Eric Reiman Marwan Sabbagh Mary Sano Randy Schiffer Lon S Schneider Eric Siemers Pierre Tariot Jacques Touchon Bruno Vellas Reporter Lisa J Bain Developing a National Strategy to Prevent Dementia Alzheimerrsquos and Dementia 2010 Mar6(2)89-97
32 Sabbagh MN Berk C Latrepirdine for Alzheimerrsquos disease trials and tribulations Future Neurology 2010
September 2010 Vol 5 No 5 Pages 645-651
33 Sabbagh MN Cummings J Progressive Cholinergic Decline in Alzheimerrsquos Disease Consideration for Treatment With Donepezil 23 mg in Patients With Moderate to Severe Symptomatology BMC Neurology 2011 1121
34 DeCourt B Sabbagh MN BACE1 as a potential biomarker for Alzheimerrsquos disease Journal of
Alzheimerrsquos Disease 201124 Suppl 253-9]
35 Jacobson SA Sabbagh MN Investigational drugs for the treatment of Alzheimerrsquos disease failed trials Alzheimerrsquos Research and Therapy 2011 Apr 153(2)14 [Epub ahead of print]
36 Patel S Shah R Coleman P Sabbagh MN Potential Peripheral Biomarkers for the Diagnosis of
Alzheimerrsquos Disease International Journal of Alzheimerrsquos Disease 2011572495 Epub 2011 Oct 23
37 Mehta M Adem A Sabbagh MN The nicotinic receptor smoking and Alzheimerrsquos revisited Frontiers in Bioscience E4 169-180 January 1 2012
38 Sabbagh MN Berk C Appraisal of higher doses of donepezil in the treatment of mild moderate and
severe Alzheimers disease International Journal of Alzheimerrsquos Disease 20122012707468 Epub 2011 Dec 1
39 Arab L Sadeghi R Walker DG Lue LF Sabbagh MN Consequences of aberrant insulin regulation in the
brain Can treating diabetes be effective for Alzheimerrsquos Disease Current Neuropharmacology 2011 9(4) 693-705
40 Mehta M Adem A Sabbagh MN New acetylcholinesterase inhibitors for Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 728983 8 pages doi1011552012728983
41 Sabbagh MN Sparks DL Statins to treat Alzheimerrsquos an incomplete story Expert Review in
Neurotherapeutics January 2012 Vol 12 No 1 Pages 27-30
8 42 Sabbagh MN Porsteinsson AP Nair A Adem A Novel Therapeutics in Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 207969 2 pages
43 Sabbagh MN Geula C Messis C Friedland R Conference Report on the 5th International Conference on
Alzheimerrsquos Disease in the Middle East May 7-9 2009 Limmassol Cyprus Journal of Alzheimerrsquos Disease 2012 May 21Epub ahead of print] No abstract available PMID22614876
44 Lue LF Andrade C Sabbagh MN Walker DG Is there inflammatory synergy in type II diabetes mellitus
and Alzheimerrsquos disease International Journal of Alzheimerrsquos Disease 2012918680 Epub 2012 Jun 21
45 Sabbagh MN Ahmadi MM Belden C The Use of Informant-Based Questionnaires in Differentiating Mild Cognitive Impairment from Normal Aging Expert Review of Neurotherapeutics 2012 Jun12(6)637-9
46 Jeffrey L Cummings1 David Geldmacher
2 Martin Farlow
3 Marwan Sabbagh
4 Daniel Christensen
5 amp
Peter Betz6 for the Donepezil 23 mg Expert Working Group High-Dose Donepezil (23 mgday) for the
Treatment of Moderate and Severe Alzheimerrsquos Disease Drug Profile and Clinical Guidelines CNS Neurosci Ther 2013 Mar 6 doi 101111cns12076 [Epub ahead of print]
47 DeCourt B Mobley W Reiman E Shah RJ Sabbagh MN Recent perspectives on Alzheimerrsquos disease pathological changes in Down syndromerdquo J Alzheimers Dis Parkinsonism 2013 S7 httpdxdoiorg 1041722161-0460S7-002
48 Adem A El-Agnaf O Sabbagh MN Neurodegeneration The first IBRO-Middle East Neuroscience
Conference Current Alzheimerrsquos Research 2013 10 (6)557-8
49 Berk C Sabbagh MN Drugs in Late Stage Development for Alzheimerrsquos Disease Drugs Aging 2013 Aug 14 [Epub ahead of print]
50 Berk C Paul G Sabbagh MN Investigational Drugs in Alzheimerrsquos Disease Current Progress Expert
Opinion on Investigational Drugs 2014 Expert Opin Investig Drugs 2014 Jun23(6)837-46 doi 101517135437842014905542 Epub 2014 Apr 5
51 Richards D Sabbagh MN Florbetaben for PET Imaging of Neuritic Beta-Amyloid Plaques in the Brain
Neurology and Therapy 2014 DOI 101007s40120-014-0022-9
52 Hartley D Blumenthal T Carrillo M DiPaolo G Esralew L Gardiner K Granholm AC Iqbal K Krams M Lemere C Lott I Mobley W Ness S Nixon R Potter H Reeves R Sabbagh M Silverman W Tycko B Whitten M Wisniewski T Down syndrome and Alzheimers disease Common pathways common goals Alzheimers Dement 2014 Dec 12 pii S1552-5260(14)02860-X doi 101016jjalz201410007
53 Saunders KT Langbaum JB Holt CJ Chen W High N Langlois C Sabbagh M Tariot PN Arizona
Alzheimers Registry Strategy and Outcomes of a Statewide Research Recruitment Registry J Prev Alzheimers Dis 2014 Sep1(2)74-79
54 Walker DG Lue LF Paul G Patel A Sabbagh MN Advanced Glycation Endproduct Modulators A New
Therapeutic Target in Alzheimerrsquos Disease Expert Opinion in Investigational Drugs Posted online on January 14 2015 (doi1015171354378420151001490)
55 Malek-Ahmadi M Sabbagh MN Development and validation of the Alzheimerrsquos Questionnaire (AQ)
Journal of Nature and Science 20151(5)e104
56 Anand K Sabbagh MN Early investigational drugs targeting tau protein for the treatment of Alzheimers Disease Expert Opinion in Investigational Drugs 2015 24 (10)1-6
57 Sabbagh MN Edgin JO Clinical Assessment of Cognitive Decline in Adults with Down Syndrome
Current Alzheimerrsquos Research 2015 Sep 20 [epub ahead of print]
58 Arab L Sabbagh MNAre Certain Lifestyle Habits Associated with Lower Alzheimers Disease Risk J Alzheimers Dis 2015 Oct 148(3)877 doi 103233JAD-159004 No abstract available
9 59 Bahureska L Schwenk M Sabbagh M Mohler J Saleh A Najafi B The Impact of Mild Cognitive
Impairment on Balance and Gait a Systematic Review and Meta-Analysis Gerontology 2016 (DOI101159000445831)
60 Anand K Sabbagh MN Amyloid imaging poised for integration into medical practice Neurotherapeutics 2016 Aug 29 [Epub ahead of print] Review
61 Marwan Sabbagh1 SeolHeui Han
2 SangYun Kim
3 Hae-Ri Na
4 Jae-Hong Lee
5 Nagaendran Kandiah
6
Kammant Phanthumchinda7 Chuthamanee Suthisisang
8 Vorapun Senanarong
9 Ming-Chyi Pai
10 Diatri
Narilastri11
Ajit M Sowani12
Encarnita Ampil13
Amitabh Dash14
for the Asia Pacific EXpert Panel (APEX) for Donepezil 23 mg Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimerrsquos disease in the Asia-Pacific region Dement Geriatr Cogn Disord Extra 20166382-395 (DOI101159000448214)
62 Decourt B Lahiri DK Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimers Disease Curr Alzheimer Res 2016 Sep 30
63 Sabbagh MN Editorial Introduction Neurol Ther 2016 Nov 9 [Epub ahead of print]
64 Shefner JM Sabbagh MN An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases Editorial Introduction Neurotherapeutics 2016 Dec 8 [Epub ahead of print] No abstract available
65 Sabbagh MN DeCourt B Editorial Current and Emerging Therapeutics in AD Current Alzheimerrsquos Research 201714 (3) 354-355
66 DeCourt B Lahiri D Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimerrsquos Disease Current Alzheimerrsquos Research 201714 (3) 412-425
67 Mehta DG Paul G Shi J Sabbagh MN Why are drugs failing in Alzheimerrsquos disease 2010-2015 Expert Opin Investig Drugs 2017 May 2 doi 1010801354378420171323868 [Epub ahead of print]
68 Sabbagh MN Lue LF Fayard D Shi J Increasing precision of clinical diagnosis of AD using a combined algorithm incorporating clinical and novel biomarker data Neurology and Therapy 2017 (submitted)
69 Sabbagh MN Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimerrsquos Disease and Related Disorders Neurology and Therapy 2017 (submitted)
70 Sabbagh MN Editorial Clinical Effects of Oral Tramiprosate in APOE44 Homozygous Patients with Mild Alzheimerrsquos Disease Suggest Disease Modification JPAD 2017 (submitted)
71 Geidy Serrano Marwan S Sabbagh Michael Sierks Tyler A Kokjohn Thomas G Beach Chera L Maarouf Steven G Clarke4 Alex Roher APPAβ Structural Diversity and Alzheimerrsquos Disease Pathogenesis Neurochemistry International 2017 (submitted)
Peer-Reviewed Manuscripts
1 Adem A Sabbagh M Nordberg A Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex Journal of Neural Transmission 1988 7211-18
2 Sabbagh M Garza J Patten B Thoracoscopic thymectomy in myasthenia gravis Muscle amp Nerve
1995 181475-1477
3 Sabbagh M Lynn P Jhingran S et al Correlation of SPECT Regional cerebral blood flow defects to psychometric testing in patients with Alzheimers disease Journal of Neuropsychiatry and Clinical Neurosciences 1997 9 68-74
4 Corey-Bloom J Sabbagh MN Bondi MW Hansen L Alford MF Thal LJ Hippocampal sclerosis
contributes to dementia in the elderly Neurology 1997 48(1) 154-160
5 Olichney J Sabbagh M Hofstetter RC Galasko D Grundman M Katzman R Thal L The impact of
apolipoprotein 4 on the cause of death in Alzheimerrsquos disease Neurology 1997 49(1) 76-81
10 6 Olichney J Ellis R Katzman R Sabbagh M Hansen L Types of cerebrovascular lesions associated
with severe cerebral amyloid angiopathy in Alzheimers disease Annals of the New York Academy of Sciences 1997 826 493-497
7 Sabbagh MN Reid R Corey-Bloom J Rao T Lloyd K Hansen L Alford M Masliah E Adem A Thal
LJ Correlation of nicotinic binding to neurochemical markers in Alzheimerrsquos disease Journal of Neural Transmission 1998105(7) 709-717
8 Sabbagh MN Corey-Bloom J Tiraboschi P Thomas R Masliah E Thal LJ Neurochemical markers
do not correlate with cognitive decline in the Lewy Body Variant of Alzheimerrsquos disease Archives of Neurology 1999 56(12) 1568-1572
9 Tiraboschi P Hansen LA Sabbagh MN Schoos B Alford M Masliah E Thal LJ Corey-Bloom J
Cholinergic dysfunction in diseases with Lewy bodies Neurology 2000 54407-411
10 Corey-Bloom J Tiraboschi P Hansen LA Schoos B Alford M Sabbagh MN Masliah E Thal LJ E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimerrsquos disease Neurology 2000 54403-406
11 Reid RT Sabbagh MN Corey-Bloom J Tiraboschi P Thal LJ Nicotinic receptor in dementia with
Lewy Bodies comparisons with Alzheimerrsquos disease Neurobiology of Aging 2000 21 (5) 741-746
12 ReidRT Sabbagh MN Thal LJ Does apolipoprotein e (apo e) genotype influence nicotinic receptor binding in Alzheimers disease J Neural Transmission 2001 108(8-9) 1043-1050
13 Sabbagh MN Reid RT Hansen LA Alford M Thal LJ Correlation of nicotinic receptor binding with
clinical and neuropathological changes in Alzheimerrsquos disease and dementia with Lewy bodies J Neural Transmission 2001 108 (10) 1149-1157
14 Caselli R Beach T Sue L Connor DJ Sabbagh MN Progressive Aphasia with Lewy Bodies
Dementia and Geriatric Cognitive Disorders 2002 14 (2) 55-58
15 Sabbagh M Silverberg N Majeed B Samant S Sparks DL Seward J Connor DJ Length of stay in skilled nursing facilities is longer for patients with dementia J Alz Dis 2003 5(1) 57-63
16 Smith RG Roher A Appel SH Doody RS Killian DM Corey-Bloom J Sabbagh MN Autonomic
sudomotor dysfunction discriminates Alzheimerrsquos disease and non-demented control individuals Current Medicinal Chemistry Immunology Endocrine and Metabolic Agents 2003 3233-243
17 Reid RT Sabbagh MN Effects of Donepezil Treatment on Rat Nicotinic Acetylcholine Receptor
Levels In Vivo and In Vitro Journal of Alzheimerrsquos Disease 2003 5(6) 429-436
18 Caviness JN Adler CH Sabbagh M Connor DJ Hernandez JL Lagerlund T Abnormal Cortico-muscular Coherence is associated with the small amplitude cortical myoclonus in Parkinsonrsquos Disease Movement Disorders 2003 18 (10) 1157-62
19 Beach TG Sue L Scott S Layne K Newell A Walker D Baker M Sahara N Yen S-H Hutton M
Caselli R Adler C Connor D Sabbagh M Hippocampal Sclerosis Dementia with Tauopathy Brain Pathology 2003 13 263-278
20 Sparks DL Lopez J Sabbagh M Connor D Seward J Browne P A position paper based on
observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the AD Cholesterol-Lowering Treatment Trial J Molecular Neuroscience 2003 20 407-410
21 Caselli RJ Beach TG Sue LI Connor DJ Sabbagh MN Progressive aphasia with Lewy bodies
Dementia Review Series 2003 4 10-11
22 Sabbagh MN Thompson N Tweedy D Stipho-Majeed S Kawas C Connor DJ Successful and Unsuccessful Recruitment and Retention Strategies for Alzheimerrsquos Disease Clinical Trials Pharmaceutical Regulation and Development 2003 1(4) 269-276
11 23 Johnson SC Baxter LC Susskind-Wilder L Connor DJ Sabbagh MN Caselli RJ Hippocampal
Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment Neuropsychologia 2004 42(7) 980-989
24 Li R Lindholm K Yang LB Yue X Citron M Yan R Beach T Sue L Sabbagh M Cai H Wong P
Price D Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimers disease patients Proc Natl Acad Sci U S A 2004 Mar 9 101(10)3632-3637
25 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A Masliah E Alford M Thal
LJ Corey-Bloom J Alzheimerrsquos disease without neocortical neurofibrillary tangles ldquoa second lookrdquo Neurology 2004 621141-1147
26 Davie JE Azuma T Goldinger SD Connor DJ Sabbagh MN Silverberg N Sensitivity to Expectancy
Violations in Healthy Aging and Mild Cognitive Impairment Neuropsychology 2004 18(2) 269-275
27 Sabbagh MN Silverberg NB Descheny RL Baxter LC Connor DJ Crocker-Sabbagh IP Dementia with Lewy bodies in a Native American Alzheimerrsquos Disease and Associated Disorders 2004 18 (4)259-261
28 Sabbagh MN Zahiri HR Ceimo J Cooper K Gaul W Connor DJ Sparks DL Is there a characteristic
lipid profile in Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2004 6 (6) 585-589
29 Sabbagh MN Tyas SL Emery SC Hansen LA Alford MF Reid RT Tiraboschi P Thal LJ Smoking Affects the Phenotype of Alzheimerrsquos Disease Neurology 2005 Apr 1264(7)1301-3
30 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Petanceska S Browne P Wassar D Johnson-Traver S Lochhead J Ziolwolski C Benefit of Atorvastatin in the treatment of mild to moderate Alzheimerrsquos disease results from the Alzheimerrsquos disease cholesterol lowering treatment (ADCLT) trial Archives of Neurology 2005 62753-757
31 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Browne P Johnson-Traver S Lochhead J
Ziolwolski C Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD Current Alzheimerrsquos Research 2005 Jul2(3)343-53
32 Sabbagh MN Silverberg N Bircea S Majeed B Samant S Caviness JN Reisberg B Adler CH Is
the functional decline in PD similar to the functional decline of AD Parkinsonism and Related Disorders 2005 11 311-315
33 Sabbagh MN Hake AM Ahmed S Farlow MR The use of memantine in Dementia with Lewy Bodies
Journal of Alzheimerrsquos Disease 2005 7(4) 285-289
34 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C rols MCI AD and the AD Cholesterol
Lowering Treatment Trial Current Alzheimerrsquos Research 2005 2527-539
35 Rogers J Li R Mastroeni D Grover A Leonard B Ahern G Cao P Kolody H Vedders L Kolb WP Sabbagh M Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes Neurobiology of Aging 2006 271733-1739
36 Caviness JN Shill HA Sabbagh MN Evidente VGH Hernandez J Adler CH Cortico-Muscular
coherence is increased in the small postural tremor of Parkinsonrsquos disease Movement Disorders 2006 21 (4)492-499
37 Sabbagh MN Sandhu S Lahti T Kolody H Silverberg NB Sparks DL What is the effect of the
apolipoprotein E genotype on the lipid profile in Alzheimerrsquos disease Current Alzheimerrsquos Research 2006 3(2) 157-160
38 Sparks DL Connor DJ Sabbagh MN Petersen RB Lopez J Browne P Circulating cholesterol
levels apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
6 12 Thind K Sabbagh MN Pathological Correlates of Cognitive Decline in Alzheimerrsquos Disease PanMinerva
Medica 2007 49(4)191-195 13 Beach TG Sue LI Walker DG Roher AE Lue LF Vedders L Connor DJ Sabbagh M Rogers J The
Sun Health Research Institute Brain Donation Program Description and Experience 1987-2007 Cell Tissue Bank 2008 Mar 18 [Epub ahead of print]
14 Sabbagh MN Richardson S Relkin N Disease modifying approaches to Alzheimers disease Challenges
and opportunities Lessons from donepezil therapyrdquo Alzheimerrsquos and Dementia 2008 4(1) S109-S118 15 Sabbagh MN Commentary on the baseline data of the atorvastatindonepezil study for Alzheimerrsquos
disease Alzheimerrsquos and Dementia 2008 4 (3)174-175 16 Khatchaturian ZS Petersen RC Gauthier S Buckholtz N Corey-Bloom J Evans B Fillit H Foster N
Greenberg B Grundman M Sano M Simpkins J Schneider LS Weiner MW Galasko D Hyman B Kuller L Schenk D Snyder S Thomas RG Tuszinski MH Vellas B Wurtman RJ Snyder PJ Frank RA Albert M Doody R Ferris S Kaye J Koo E Morrison-Bogorad M Reisberg B Salmon DP Gilman S Mohs R Aisen PS Breitner JCS Cummings JL Kawas C Phelps C Poirier J Sabbagh M Touchon J Khatchaturian AS Bain L A roadmap for the prevention of dementia the inaugural Leon Thal Symposium Alzheimerrsquos and Dementia 2008 4 (3)156-163
17 Rogers J Sabbagh MN Relationships of strokes and non-steroidal anti-inflammatory drug use to
apolipoprotein E4-conferred of Alzheimerrsquos disease and dementia Neurology 2008 702-4 18 Quinn J Sabbagh MN Editorial Biochemical Markers in Persons with Pre-Clinical Familial Alzheimers
Disease Neurology 2008 7178-79 19 Jacobson S Sabbagh MN Donepezil potential neuroprotective and disease modifying effects Expert
Opinion on Drug Metabolism and Toxicology 2008 4(10)1363-1369 20 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathologica 2008 Nov 4 [epub ahead of print] 21 Lue LF Jacobson S Walker D Sabbagh MN The receptor for advanced glycation end-products its role
in Alzheimerrsquos and other diseases Future Neurology 2009 4(2) 167-177 22 Sabbagh MN Tariot PN Commentary on A roadmap for the prevention of dementia II Leon Thal
Symposium 2008 A national registry to identify a cohort for Alzheimerrsquos disease prevention studies Alzheimerrsquos and Dementia 20095 128-129
23 Khachaturian ZS Snyder PJ Doody RS Aisen P Comer M Dwyer J Frank RA Holzapfel A
Khachaturian AS Korczyn AD Phelps C Roses A Simpkins JW Schneider LS Albert MS Egge R Deves A Ferris S Greenberg BD Johnson C Kukull WA Poirier J Schenk D Thies W Gauthier S Gilman S Bernick C Cummings JL Fillit H Grundman M Kaye J Mucke L Reisberg B Sano M Pickeral O Petersen RC Mohs RC Buckholtz N Carrillo M Corey-Bloom JP Foster NL Jacobsen S Lee V Potter WZ Sabbagh MN Salmon D Trojanowski JQ Wexler N Bain LJ A roadmap for the prevention of dementia II Leon Thal Symposium 2008 Alzheimerrsquos and Dementia 2009 585-92
24 Sabbagh MN Drug Development for Alzheimerrsquos Disease Where Are We Now and Where Are We
Headed American Journal of Geriatric Pharmacotherapy 2009 7(3) 167-185 25 Sabbagh MN Thind K Sparks DL On cholesterol levels and statins in Alzheimerrsquos disease and cognitive
decline progress and setbacks Alzheimerrsquos Disease and Associated Disorders 2009 (Oct-Dec) 23(4)303-305
26 Beach TG White CL Sabbagh MN Shill HA Adler CH Response to Parkinnen et al and Jellinger Acta
Neuropathol 2009 Feb117(2)217-218
7 27 Sabbagh MN Shill HA Dimebon (latrepirdine) a potential treatment with a novel mechanism of action for
the treatment of Alzheimers disease and Huntington disease Current Opinion in Investigational Drugs 2010 Curr Opin Investig Drugs 2010 Jan11(1)80-91
28 Arab L Sabbagh MN Lifestyle changes do they lower Alzheimerrsquos risk Journal of Alzheimerrsquos Disease
201020(3)785-94 Review PubMedPMID 20182018
29 Sabbagh MN Commentary On The Perspective Design Of Comprehensive Alzheimers Disease Centers To Address Unmet National Needs by JQ Trojanowski et al Alzheimerrsquos and Dementia 2010 Mar6(2)156-7 No abstract available
30 Khachaturian AS Sabbagh M Commentary on Developing a national strategy to prevent dementia
Leon Thal Symposium 2009 Creating a national database for successful aging Alzheimers Dement 2010 Mar6(2)132-4 No abstract available
31 Zaven Khachaturian [Convener ndash Facilitator] - Presenters Deborah Barnes Richard Einstein Sterling
Johnson Virginia Lee Allen Roses Mark A Sager William R Shankle Peter J Snyder Ronald C Petersen Gerard Schellenberg and John Trojanowski - Discussants Paul Aisen Marilyn S Albert Charles Bernick John C S Breitner Neil Buckholtz Maria Carrillo Steven Ferris Barry D Greenberg Michael Grundman Ara S Khachaturian Lewis H Kuller Oscar L Lopez Paul Maruff Richard C Mohs Marcelle Morrison-Bogorad Creighton Phelps Michael Phillips Stephen Rao Eric Reiman Marwan Sabbagh Mary Sano Randy Schiffer Lon S Schneider Eric Siemers Pierre Tariot Jacques Touchon Bruno Vellas Reporter Lisa J Bain Developing a National Strategy to Prevent Dementia Alzheimerrsquos and Dementia 2010 Mar6(2)89-97
32 Sabbagh MN Berk C Latrepirdine for Alzheimerrsquos disease trials and tribulations Future Neurology 2010
September 2010 Vol 5 No 5 Pages 645-651
33 Sabbagh MN Cummings J Progressive Cholinergic Decline in Alzheimerrsquos Disease Consideration for Treatment With Donepezil 23 mg in Patients With Moderate to Severe Symptomatology BMC Neurology 2011 1121
34 DeCourt B Sabbagh MN BACE1 as a potential biomarker for Alzheimerrsquos disease Journal of
Alzheimerrsquos Disease 201124 Suppl 253-9]
35 Jacobson SA Sabbagh MN Investigational drugs for the treatment of Alzheimerrsquos disease failed trials Alzheimerrsquos Research and Therapy 2011 Apr 153(2)14 [Epub ahead of print]
36 Patel S Shah R Coleman P Sabbagh MN Potential Peripheral Biomarkers for the Diagnosis of
Alzheimerrsquos Disease International Journal of Alzheimerrsquos Disease 2011572495 Epub 2011 Oct 23
37 Mehta M Adem A Sabbagh MN The nicotinic receptor smoking and Alzheimerrsquos revisited Frontiers in Bioscience E4 169-180 January 1 2012
38 Sabbagh MN Berk C Appraisal of higher doses of donepezil in the treatment of mild moderate and
severe Alzheimers disease International Journal of Alzheimerrsquos Disease 20122012707468 Epub 2011 Dec 1
39 Arab L Sadeghi R Walker DG Lue LF Sabbagh MN Consequences of aberrant insulin regulation in the
brain Can treating diabetes be effective for Alzheimerrsquos Disease Current Neuropharmacology 2011 9(4) 693-705
40 Mehta M Adem A Sabbagh MN New acetylcholinesterase inhibitors for Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 728983 8 pages doi1011552012728983
41 Sabbagh MN Sparks DL Statins to treat Alzheimerrsquos an incomplete story Expert Review in
Neurotherapeutics January 2012 Vol 12 No 1 Pages 27-30
8 42 Sabbagh MN Porsteinsson AP Nair A Adem A Novel Therapeutics in Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 207969 2 pages
43 Sabbagh MN Geula C Messis C Friedland R Conference Report on the 5th International Conference on
Alzheimerrsquos Disease in the Middle East May 7-9 2009 Limmassol Cyprus Journal of Alzheimerrsquos Disease 2012 May 21Epub ahead of print] No abstract available PMID22614876
44 Lue LF Andrade C Sabbagh MN Walker DG Is there inflammatory synergy in type II diabetes mellitus
and Alzheimerrsquos disease International Journal of Alzheimerrsquos Disease 2012918680 Epub 2012 Jun 21
45 Sabbagh MN Ahmadi MM Belden C The Use of Informant-Based Questionnaires in Differentiating Mild Cognitive Impairment from Normal Aging Expert Review of Neurotherapeutics 2012 Jun12(6)637-9
46 Jeffrey L Cummings1 David Geldmacher
2 Martin Farlow
3 Marwan Sabbagh
4 Daniel Christensen
5 amp
Peter Betz6 for the Donepezil 23 mg Expert Working Group High-Dose Donepezil (23 mgday) for the
Treatment of Moderate and Severe Alzheimerrsquos Disease Drug Profile and Clinical Guidelines CNS Neurosci Ther 2013 Mar 6 doi 101111cns12076 [Epub ahead of print]
47 DeCourt B Mobley W Reiman E Shah RJ Sabbagh MN Recent perspectives on Alzheimerrsquos disease pathological changes in Down syndromerdquo J Alzheimers Dis Parkinsonism 2013 S7 httpdxdoiorg 1041722161-0460S7-002
48 Adem A El-Agnaf O Sabbagh MN Neurodegeneration The first IBRO-Middle East Neuroscience
Conference Current Alzheimerrsquos Research 2013 10 (6)557-8
49 Berk C Sabbagh MN Drugs in Late Stage Development for Alzheimerrsquos Disease Drugs Aging 2013 Aug 14 [Epub ahead of print]
50 Berk C Paul G Sabbagh MN Investigational Drugs in Alzheimerrsquos Disease Current Progress Expert
Opinion on Investigational Drugs 2014 Expert Opin Investig Drugs 2014 Jun23(6)837-46 doi 101517135437842014905542 Epub 2014 Apr 5
51 Richards D Sabbagh MN Florbetaben for PET Imaging of Neuritic Beta-Amyloid Plaques in the Brain
Neurology and Therapy 2014 DOI 101007s40120-014-0022-9
52 Hartley D Blumenthal T Carrillo M DiPaolo G Esralew L Gardiner K Granholm AC Iqbal K Krams M Lemere C Lott I Mobley W Ness S Nixon R Potter H Reeves R Sabbagh M Silverman W Tycko B Whitten M Wisniewski T Down syndrome and Alzheimers disease Common pathways common goals Alzheimers Dement 2014 Dec 12 pii S1552-5260(14)02860-X doi 101016jjalz201410007
53 Saunders KT Langbaum JB Holt CJ Chen W High N Langlois C Sabbagh M Tariot PN Arizona
Alzheimers Registry Strategy and Outcomes of a Statewide Research Recruitment Registry J Prev Alzheimers Dis 2014 Sep1(2)74-79
54 Walker DG Lue LF Paul G Patel A Sabbagh MN Advanced Glycation Endproduct Modulators A New
Therapeutic Target in Alzheimerrsquos Disease Expert Opinion in Investigational Drugs Posted online on January 14 2015 (doi1015171354378420151001490)
55 Malek-Ahmadi M Sabbagh MN Development and validation of the Alzheimerrsquos Questionnaire (AQ)
Journal of Nature and Science 20151(5)e104
56 Anand K Sabbagh MN Early investigational drugs targeting tau protein for the treatment of Alzheimers Disease Expert Opinion in Investigational Drugs 2015 24 (10)1-6
57 Sabbagh MN Edgin JO Clinical Assessment of Cognitive Decline in Adults with Down Syndrome
Current Alzheimerrsquos Research 2015 Sep 20 [epub ahead of print]
58 Arab L Sabbagh MNAre Certain Lifestyle Habits Associated with Lower Alzheimers Disease Risk J Alzheimers Dis 2015 Oct 148(3)877 doi 103233JAD-159004 No abstract available
9 59 Bahureska L Schwenk M Sabbagh M Mohler J Saleh A Najafi B The Impact of Mild Cognitive
Impairment on Balance and Gait a Systematic Review and Meta-Analysis Gerontology 2016 (DOI101159000445831)
60 Anand K Sabbagh MN Amyloid imaging poised for integration into medical practice Neurotherapeutics 2016 Aug 29 [Epub ahead of print] Review
61 Marwan Sabbagh1 SeolHeui Han
2 SangYun Kim
3 Hae-Ri Na
4 Jae-Hong Lee
5 Nagaendran Kandiah
6
Kammant Phanthumchinda7 Chuthamanee Suthisisang
8 Vorapun Senanarong
9 Ming-Chyi Pai
10 Diatri
Narilastri11
Ajit M Sowani12
Encarnita Ampil13
Amitabh Dash14
for the Asia Pacific EXpert Panel (APEX) for Donepezil 23 mg Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimerrsquos disease in the Asia-Pacific region Dement Geriatr Cogn Disord Extra 20166382-395 (DOI101159000448214)
62 Decourt B Lahiri DK Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimers Disease Curr Alzheimer Res 2016 Sep 30
63 Sabbagh MN Editorial Introduction Neurol Ther 2016 Nov 9 [Epub ahead of print]
64 Shefner JM Sabbagh MN An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases Editorial Introduction Neurotherapeutics 2016 Dec 8 [Epub ahead of print] No abstract available
65 Sabbagh MN DeCourt B Editorial Current and Emerging Therapeutics in AD Current Alzheimerrsquos Research 201714 (3) 354-355
66 DeCourt B Lahiri D Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimerrsquos Disease Current Alzheimerrsquos Research 201714 (3) 412-425
67 Mehta DG Paul G Shi J Sabbagh MN Why are drugs failing in Alzheimerrsquos disease 2010-2015 Expert Opin Investig Drugs 2017 May 2 doi 1010801354378420171323868 [Epub ahead of print]
68 Sabbagh MN Lue LF Fayard D Shi J Increasing precision of clinical diagnosis of AD using a combined algorithm incorporating clinical and novel biomarker data Neurology and Therapy 2017 (submitted)
69 Sabbagh MN Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimerrsquos Disease and Related Disorders Neurology and Therapy 2017 (submitted)
70 Sabbagh MN Editorial Clinical Effects of Oral Tramiprosate in APOE44 Homozygous Patients with Mild Alzheimerrsquos Disease Suggest Disease Modification JPAD 2017 (submitted)
71 Geidy Serrano Marwan S Sabbagh Michael Sierks Tyler A Kokjohn Thomas G Beach Chera L Maarouf Steven G Clarke4 Alex Roher APPAβ Structural Diversity and Alzheimerrsquos Disease Pathogenesis Neurochemistry International 2017 (submitted)
Peer-Reviewed Manuscripts
1 Adem A Sabbagh M Nordberg A Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex Journal of Neural Transmission 1988 7211-18
2 Sabbagh M Garza J Patten B Thoracoscopic thymectomy in myasthenia gravis Muscle amp Nerve
1995 181475-1477
3 Sabbagh M Lynn P Jhingran S et al Correlation of SPECT Regional cerebral blood flow defects to psychometric testing in patients with Alzheimers disease Journal of Neuropsychiatry and Clinical Neurosciences 1997 9 68-74
4 Corey-Bloom J Sabbagh MN Bondi MW Hansen L Alford MF Thal LJ Hippocampal sclerosis
contributes to dementia in the elderly Neurology 1997 48(1) 154-160
5 Olichney J Sabbagh M Hofstetter RC Galasko D Grundman M Katzman R Thal L The impact of
apolipoprotein 4 on the cause of death in Alzheimerrsquos disease Neurology 1997 49(1) 76-81
10 6 Olichney J Ellis R Katzman R Sabbagh M Hansen L Types of cerebrovascular lesions associated
with severe cerebral amyloid angiopathy in Alzheimers disease Annals of the New York Academy of Sciences 1997 826 493-497
7 Sabbagh MN Reid R Corey-Bloom J Rao T Lloyd K Hansen L Alford M Masliah E Adem A Thal
LJ Correlation of nicotinic binding to neurochemical markers in Alzheimerrsquos disease Journal of Neural Transmission 1998105(7) 709-717
8 Sabbagh MN Corey-Bloom J Tiraboschi P Thomas R Masliah E Thal LJ Neurochemical markers
do not correlate with cognitive decline in the Lewy Body Variant of Alzheimerrsquos disease Archives of Neurology 1999 56(12) 1568-1572
9 Tiraboschi P Hansen LA Sabbagh MN Schoos B Alford M Masliah E Thal LJ Corey-Bloom J
Cholinergic dysfunction in diseases with Lewy bodies Neurology 2000 54407-411
10 Corey-Bloom J Tiraboschi P Hansen LA Schoos B Alford M Sabbagh MN Masliah E Thal LJ E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimerrsquos disease Neurology 2000 54403-406
11 Reid RT Sabbagh MN Corey-Bloom J Tiraboschi P Thal LJ Nicotinic receptor in dementia with
Lewy Bodies comparisons with Alzheimerrsquos disease Neurobiology of Aging 2000 21 (5) 741-746
12 ReidRT Sabbagh MN Thal LJ Does apolipoprotein e (apo e) genotype influence nicotinic receptor binding in Alzheimers disease J Neural Transmission 2001 108(8-9) 1043-1050
13 Sabbagh MN Reid RT Hansen LA Alford M Thal LJ Correlation of nicotinic receptor binding with
clinical and neuropathological changes in Alzheimerrsquos disease and dementia with Lewy bodies J Neural Transmission 2001 108 (10) 1149-1157
14 Caselli R Beach T Sue L Connor DJ Sabbagh MN Progressive Aphasia with Lewy Bodies
Dementia and Geriatric Cognitive Disorders 2002 14 (2) 55-58
15 Sabbagh M Silverberg N Majeed B Samant S Sparks DL Seward J Connor DJ Length of stay in skilled nursing facilities is longer for patients with dementia J Alz Dis 2003 5(1) 57-63
16 Smith RG Roher A Appel SH Doody RS Killian DM Corey-Bloom J Sabbagh MN Autonomic
sudomotor dysfunction discriminates Alzheimerrsquos disease and non-demented control individuals Current Medicinal Chemistry Immunology Endocrine and Metabolic Agents 2003 3233-243
17 Reid RT Sabbagh MN Effects of Donepezil Treatment on Rat Nicotinic Acetylcholine Receptor
Levels In Vivo and In Vitro Journal of Alzheimerrsquos Disease 2003 5(6) 429-436
18 Caviness JN Adler CH Sabbagh M Connor DJ Hernandez JL Lagerlund T Abnormal Cortico-muscular Coherence is associated with the small amplitude cortical myoclonus in Parkinsonrsquos Disease Movement Disorders 2003 18 (10) 1157-62
19 Beach TG Sue L Scott S Layne K Newell A Walker D Baker M Sahara N Yen S-H Hutton M
Caselli R Adler C Connor D Sabbagh M Hippocampal Sclerosis Dementia with Tauopathy Brain Pathology 2003 13 263-278
20 Sparks DL Lopez J Sabbagh M Connor D Seward J Browne P A position paper based on
observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the AD Cholesterol-Lowering Treatment Trial J Molecular Neuroscience 2003 20 407-410
21 Caselli RJ Beach TG Sue LI Connor DJ Sabbagh MN Progressive aphasia with Lewy bodies
Dementia Review Series 2003 4 10-11
22 Sabbagh MN Thompson N Tweedy D Stipho-Majeed S Kawas C Connor DJ Successful and Unsuccessful Recruitment and Retention Strategies for Alzheimerrsquos Disease Clinical Trials Pharmaceutical Regulation and Development 2003 1(4) 269-276
11 23 Johnson SC Baxter LC Susskind-Wilder L Connor DJ Sabbagh MN Caselli RJ Hippocampal
Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment Neuropsychologia 2004 42(7) 980-989
24 Li R Lindholm K Yang LB Yue X Citron M Yan R Beach T Sue L Sabbagh M Cai H Wong P
Price D Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimers disease patients Proc Natl Acad Sci U S A 2004 Mar 9 101(10)3632-3637
25 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A Masliah E Alford M Thal
LJ Corey-Bloom J Alzheimerrsquos disease without neocortical neurofibrillary tangles ldquoa second lookrdquo Neurology 2004 621141-1147
26 Davie JE Azuma T Goldinger SD Connor DJ Sabbagh MN Silverberg N Sensitivity to Expectancy
Violations in Healthy Aging and Mild Cognitive Impairment Neuropsychology 2004 18(2) 269-275
27 Sabbagh MN Silverberg NB Descheny RL Baxter LC Connor DJ Crocker-Sabbagh IP Dementia with Lewy bodies in a Native American Alzheimerrsquos Disease and Associated Disorders 2004 18 (4)259-261
28 Sabbagh MN Zahiri HR Ceimo J Cooper K Gaul W Connor DJ Sparks DL Is there a characteristic
lipid profile in Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2004 6 (6) 585-589
29 Sabbagh MN Tyas SL Emery SC Hansen LA Alford MF Reid RT Tiraboschi P Thal LJ Smoking Affects the Phenotype of Alzheimerrsquos Disease Neurology 2005 Apr 1264(7)1301-3
30 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Petanceska S Browne P Wassar D Johnson-Traver S Lochhead J Ziolwolski C Benefit of Atorvastatin in the treatment of mild to moderate Alzheimerrsquos disease results from the Alzheimerrsquos disease cholesterol lowering treatment (ADCLT) trial Archives of Neurology 2005 62753-757
31 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Browne P Johnson-Traver S Lochhead J
Ziolwolski C Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD Current Alzheimerrsquos Research 2005 Jul2(3)343-53
32 Sabbagh MN Silverberg N Bircea S Majeed B Samant S Caviness JN Reisberg B Adler CH Is
the functional decline in PD similar to the functional decline of AD Parkinsonism and Related Disorders 2005 11 311-315
33 Sabbagh MN Hake AM Ahmed S Farlow MR The use of memantine in Dementia with Lewy Bodies
Journal of Alzheimerrsquos Disease 2005 7(4) 285-289
34 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C rols MCI AD and the AD Cholesterol
Lowering Treatment Trial Current Alzheimerrsquos Research 2005 2527-539
35 Rogers J Li R Mastroeni D Grover A Leonard B Ahern G Cao P Kolody H Vedders L Kolb WP Sabbagh M Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes Neurobiology of Aging 2006 271733-1739
36 Caviness JN Shill HA Sabbagh MN Evidente VGH Hernandez J Adler CH Cortico-Muscular
coherence is increased in the small postural tremor of Parkinsonrsquos disease Movement Disorders 2006 21 (4)492-499
37 Sabbagh MN Sandhu S Lahti T Kolody H Silverberg NB Sparks DL What is the effect of the
apolipoprotein E genotype on the lipid profile in Alzheimerrsquos disease Current Alzheimerrsquos Research 2006 3(2) 157-160
38 Sparks DL Connor DJ Sabbagh MN Petersen RB Lopez J Browne P Circulating cholesterol
levels apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
7 27 Sabbagh MN Shill HA Dimebon (latrepirdine) a potential treatment with a novel mechanism of action for
the treatment of Alzheimers disease and Huntington disease Current Opinion in Investigational Drugs 2010 Curr Opin Investig Drugs 2010 Jan11(1)80-91
28 Arab L Sabbagh MN Lifestyle changes do they lower Alzheimerrsquos risk Journal of Alzheimerrsquos Disease
201020(3)785-94 Review PubMedPMID 20182018
29 Sabbagh MN Commentary On The Perspective Design Of Comprehensive Alzheimers Disease Centers To Address Unmet National Needs by JQ Trojanowski et al Alzheimerrsquos and Dementia 2010 Mar6(2)156-7 No abstract available
30 Khachaturian AS Sabbagh M Commentary on Developing a national strategy to prevent dementia
Leon Thal Symposium 2009 Creating a national database for successful aging Alzheimers Dement 2010 Mar6(2)132-4 No abstract available
31 Zaven Khachaturian [Convener ndash Facilitator] - Presenters Deborah Barnes Richard Einstein Sterling
Johnson Virginia Lee Allen Roses Mark A Sager William R Shankle Peter J Snyder Ronald C Petersen Gerard Schellenberg and John Trojanowski - Discussants Paul Aisen Marilyn S Albert Charles Bernick John C S Breitner Neil Buckholtz Maria Carrillo Steven Ferris Barry D Greenberg Michael Grundman Ara S Khachaturian Lewis H Kuller Oscar L Lopez Paul Maruff Richard C Mohs Marcelle Morrison-Bogorad Creighton Phelps Michael Phillips Stephen Rao Eric Reiman Marwan Sabbagh Mary Sano Randy Schiffer Lon S Schneider Eric Siemers Pierre Tariot Jacques Touchon Bruno Vellas Reporter Lisa J Bain Developing a National Strategy to Prevent Dementia Alzheimerrsquos and Dementia 2010 Mar6(2)89-97
32 Sabbagh MN Berk C Latrepirdine for Alzheimerrsquos disease trials and tribulations Future Neurology 2010
September 2010 Vol 5 No 5 Pages 645-651
33 Sabbagh MN Cummings J Progressive Cholinergic Decline in Alzheimerrsquos Disease Consideration for Treatment With Donepezil 23 mg in Patients With Moderate to Severe Symptomatology BMC Neurology 2011 1121
34 DeCourt B Sabbagh MN BACE1 as a potential biomarker for Alzheimerrsquos disease Journal of
Alzheimerrsquos Disease 201124 Suppl 253-9]
35 Jacobson SA Sabbagh MN Investigational drugs for the treatment of Alzheimerrsquos disease failed trials Alzheimerrsquos Research and Therapy 2011 Apr 153(2)14 [Epub ahead of print]
36 Patel S Shah R Coleman P Sabbagh MN Potential Peripheral Biomarkers for the Diagnosis of
Alzheimerrsquos Disease International Journal of Alzheimerrsquos Disease 2011572495 Epub 2011 Oct 23
37 Mehta M Adem A Sabbagh MN The nicotinic receptor smoking and Alzheimerrsquos revisited Frontiers in Bioscience E4 169-180 January 1 2012
38 Sabbagh MN Berk C Appraisal of higher doses of donepezil in the treatment of mild moderate and
severe Alzheimers disease International Journal of Alzheimerrsquos Disease 20122012707468 Epub 2011 Dec 1
39 Arab L Sadeghi R Walker DG Lue LF Sabbagh MN Consequences of aberrant insulin regulation in the
brain Can treating diabetes be effective for Alzheimerrsquos Disease Current Neuropharmacology 2011 9(4) 693-705
40 Mehta M Adem A Sabbagh MN New acetylcholinesterase inhibitors for Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 728983 8 pages doi1011552012728983
41 Sabbagh MN Sparks DL Statins to treat Alzheimerrsquos an incomplete story Expert Review in
Neurotherapeutics January 2012 Vol 12 No 1 Pages 27-30
8 42 Sabbagh MN Porsteinsson AP Nair A Adem A Novel Therapeutics in Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 207969 2 pages
43 Sabbagh MN Geula C Messis C Friedland R Conference Report on the 5th International Conference on
Alzheimerrsquos Disease in the Middle East May 7-9 2009 Limmassol Cyprus Journal of Alzheimerrsquos Disease 2012 May 21Epub ahead of print] No abstract available PMID22614876
44 Lue LF Andrade C Sabbagh MN Walker DG Is there inflammatory synergy in type II diabetes mellitus
and Alzheimerrsquos disease International Journal of Alzheimerrsquos Disease 2012918680 Epub 2012 Jun 21
45 Sabbagh MN Ahmadi MM Belden C The Use of Informant-Based Questionnaires in Differentiating Mild Cognitive Impairment from Normal Aging Expert Review of Neurotherapeutics 2012 Jun12(6)637-9
46 Jeffrey L Cummings1 David Geldmacher
2 Martin Farlow
3 Marwan Sabbagh
4 Daniel Christensen
5 amp
Peter Betz6 for the Donepezil 23 mg Expert Working Group High-Dose Donepezil (23 mgday) for the
Treatment of Moderate and Severe Alzheimerrsquos Disease Drug Profile and Clinical Guidelines CNS Neurosci Ther 2013 Mar 6 doi 101111cns12076 [Epub ahead of print]
47 DeCourt B Mobley W Reiman E Shah RJ Sabbagh MN Recent perspectives on Alzheimerrsquos disease pathological changes in Down syndromerdquo J Alzheimers Dis Parkinsonism 2013 S7 httpdxdoiorg 1041722161-0460S7-002
48 Adem A El-Agnaf O Sabbagh MN Neurodegeneration The first IBRO-Middle East Neuroscience
Conference Current Alzheimerrsquos Research 2013 10 (6)557-8
49 Berk C Sabbagh MN Drugs in Late Stage Development for Alzheimerrsquos Disease Drugs Aging 2013 Aug 14 [Epub ahead of print]
50 Berk C Paul G Sabbagh MN Investigational Drugs in Alzheimerrsquos Disease Current Progress Expert
Opinion on Investigational Drugs 2014 Expert Opin Investig Drugs 2014 Jun23(6)837-46 doi 101517135437842014905542 Epub 2014 Apr 5
51 Richards D Sabbagh MN Florbetaben for PET Imaging of Neuritic Beta-Amyloid Plaques in the Brain
Neurology and Therapy 2014 DOI 101007s40120-014-0022-9
52 Hartley D Blumenthal T Carrillo M DiPaolo G Esralew L Gardiner K Granholm AC Iqbal K Krams M Lemere C Lott I Mobley W Ness S Nixon R Potter H Reeves R Sabbagh M Silverman W Tycko B Whitten M Wisniewski T Down syndrome and Alzheimers disease Common pathways common goals Alzheimers Dement 2014 Dec 12 pii S1552-5260(14)02860-X doi 101016jjalz201410007
53 Saunders KT Langbaum JB Holt CJ Chen W High N Langlois C Sabbagh M Tariot PN Arizona
Alzheimers Registry Strategy and Outcomes of a Statewide Research Recruitment Registry J Prev Alzheimers Dis 2014 Sep1(2)74-79
54 Walker DG Lue LF Paul G Patel A Sabbagh MN Advanced Glycation Endproduct Modulators A New
Therapeutic Target in Alzheimerrsquos Disease Expert Opinion in Investigational Drugs Posted online on January 14 2015 (doi1015171354378420151001490)
55 Malek-Ahmadi M Sabbagh MN Development and validation of the Alzheimerrsquos Questionnaire (AQ)
Journal of Nature and Science 20151(5)e104
56 Anand K Sabbagh MN Early investigational drugs targeting tau protein for the treatment of Alzheimers Disease Expert Opinion in Investigational Drugs 2015 24 (10)1-6
57 Sabbagh MN Edgin JO Clinical Assessment of Cognitive Decline in Adults with Down Syndrome
Current Alzheimerrsquos Research 2015 Sep 20 [epub ahead of print]
58 Arab L Sabbagh MNAre Certain Lifestyle Habits Associated with Lower Alzheimers Disease Risk J Alzheimers Dis 2015 Oct 148(3)877 doi 103233JAD-159004 No abstract available
9 59 Bahureska L Schwenk M Sabbagh M Mohler J Saleh A Najafi B The Impact of Mild Cognitive
Impairment on Balance and Gait a Systematic Review and Meta-Analysis Gerontology 2016 (DOI101159000445831)
60 Anand K Sabbagh MN Amyloid imaging poised for integration into medical practice Neurotherapeutics 2016 Aug 29 [Epub ahead of print] Review
61 Marwan Sabbagh1 SeolHeui Han
2 SangYun Kim
3 Hae-Ri Na
4 Jae-Hong Lee
5 Nagaendran Kandiah
6
Kammant Phanthumchinda7 Chuthamanee Suthisisang
8 Vorapun Senanarong
9 Ming-Chyi Pai
10 Diatri
Narilastri11
Ajit M Sowani12
Encarnita Ampil13
Amitabh Dash14
for the Asia Pacific EXpert Panel (APEX) for Donepezil 23 mg Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimerrsquos disease in the Asia-Pacific region Dement Geriatr Cogn Disord Extra 20166382-395 (DOI101159000448214)
62 Decourt B Lahiri DK Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimers Disease Curr Alzheimer Res 2016 Sep 30
63 Sabbagh MN Editorial Introduction Neurol Ther 2016 Nov 9 [Epub ahead of print]
64 Shefner JM Sabbagh MN An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases Editorial Introduction Neurotherapeutics 2016 Dec 8 [Epub ahead of print] No abstract available
65 Sabbagh MN DeCourt B Editorial Current and Emerging Therapeutics in AD Current Alzheimerrsquos Research 201714 (3) 354-355
66 DeCourt B Lahiri D Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimerrsquos Disease Current Alzheimerrsquos Research 201714 (3) 412-425
67 Mehta DG Paul G Shi J Sabbagh MN Why are drugs failing in Alzheimerrsquos disease 2010-2015 Expert Opin Investig Drugs 2017 May 2 doi 1010801354378420171323868 [Epub ahead of print]
68 Sabbagh MN Lue LF Fayard D Shi J Increasing precision of clinical diagnosis of AD using a combined algorithm incorporating clinical and novel biomarker data Neurology and Therapy 2017 (submitted)
69 Sabbagh MN Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimerrsquos Disease and Related Disorders Neurology and Therapy 2017 (submitted)
70 Sabbagh MN Editorial Clinical Effects of Oral Tramiprosate in APOE44 Homozygous Patients with Mild Alzheimerrsquos Disease Suggest Disease Modification JPAD 2017 (submitted)
71 Geidy Serrano Marwan S Sabbagh Michael Sierks Tyler A Kokjohn Thomas G Beach Chera L Maarouf Steven G Clarke4 Alex Roher APPAβ Structural Diversity and Alzheimerrsquos Disease Pathogenesis Neurochemistry International 2017 (submitted)
Peer-Reviewed Manuscripts
1 Adem A Sabbagh M Nordberg A Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex Journal of Neural Transmission 1988 7211-18
2 Sabbagh M Garza J Patten B Thoracoscopic thymectomy in myasthenia gravis Muscle amp Nerve
1995 181475-1477
3 Sabbagh M Lynn P Jhingran S et al Correlation of SPECT Regional cerebral blood flow defects to psychometric testing in patients with Alzheimers disease Journal of Neuropsychiatry and Clinical Neurosciences 1997 9 68-74
4 Corey-Bloom J Sabbagh MN Bondi MW Hansen L Alford MF Thal LJ Hippocampal sclerosis
contributes to dementia in the elderly Neurology 1997 48(1) 154-160
5 Olichney J Sabbagh M Hofstetter RC Galasko D Grundman M Katzman R Thal L The impact of
apolipoprotein 4 on the cause of death in Alzheimerrsquos disease Neurology 1997 49(1) 76-81
10 6 Olichney J Ellis R Katzman R Sabbagh M Hansen L Types of cerebrovascular lesions associated
with severe cerebral amyloid angiopathy in Alzheimers disease Annals of the New York Academy of Sciences 1997 826 493-497
7 Sabbagh MN Reid R Corey-Bloom J Rao T Lloyd K Hansen L Alford M Masliah E Adem A Thal
LJ Correlation of nicotinic binding to neurochemical markers in Alzheimerrsquos disease Journal of Neural Transmission 1998105(7) 709-717
8 Sabbagh MN Corey-Bloom J Tiraboschi P Thomas R Masliah E Thal LJ Neurochemical markers
do not correlate with cognitive decline in the Lewy Body Variant of Alzheimerrsquos disease Archives of Neurology 1999 56(12) 1568-1572
9 Tiraboschi P Hansen LA Sabbagh MN Schoos B Alford M Masliah E Thal LJ Corey-Bloom J
Cholinergic dysfunction in diseases with Lewy bodies Neurology 2000 54407-411
10 Corey-Bloom J Tiraboschi P Hansen LA Schoos B Alford M Sabbagh MN Masliah E Thal LJ E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimerrsquos disease Neurology 2000 54403-406
11 Reid RT Sabbagh MN Corey-Bloom J Tiraboschi P Thal LJ Nicotinic receptor in dementia with
Lewy Bodies comparisons with Alzheimerrsquos disease Neurobiology of Aging 2000 21 (5) 741-746
12 ReidRT Sabbagh MN Thal LJ Does apolipoprotein e (apo e) genotype influence nicotinic receptor binding in Alzheimers disease J Neural Transmission 2001 108(8-9) 1043-1050
13 Sabbagh MN Reid RT Hansen LA Alford M Thal LJ Correlation of nicotinic receptor binding with
clinical and neuropathological changes in Alzheimerrsquos disease and dementia with Lewy bodies J Neural Transmission 2001 108 (10) 1149-1157
14 Caselli R Beach T Sue L Connor DJ Sabbagh MN Progressive Aphasia with Lewy Bodies
Dementia and Geriatric Cognitive Disorders 2002 14 (2) 55-58
15 Sabbagh M Silverberg N Majeed B Samant S Sparks DL Seward J Connor DJ Length of stay in skilled nursing facilities is longer for patients with dementia J Alz Dis 2003 5(1) 57-63
16 Smith RG Roher A Appel SH Doody RS Killian DM Corey-Bloom J Sabbagh MN Autonomic
sudomotor dysfunction discriminates Alzheimerrsquos disease and non-demented control individuals Current Medicinal Chemistry Immunology Endocrine and Metabolic Agents 2003 3233-243
17 Reid RT Sabbagh MN Effects of Donepezil Treatment on Rat Nicotinic Acetylcholine Receptor
Levels In Vivo and In Vitro Journal of Alzheimerrsquos Disease 2003 5(6) 429-436
18 Caviness JN Adler CH Sabbagh M Connor DJ Hernandez JL Lagerlund T Abnormal Cortico-muscular Coherence is associated with the small amplitude cortical myoclonus in Parkinsonrsquos Disease Movement Disorders 2003 18 (10) 1157-62
19 Beach TG Sue L Scott S Layne K Newell A Walker D Baker M Sahara N Yen S-H Hutton M
Caselli R Adler C Connor D Sabbagh M Hippocampal Sclerosis Dementia with Tauopathy Brain Pathology 2003 13 263-278
20 Sparks DL Lopez J Sabbagh M Connor D Seward J Browne P A position paper based on
observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the AD Cholesterol-Lowering Treatment Trial J Molecular Neuroscience 2003 20 407-410
21 Caselli RJ Beach TG Sue LI Connor DJ Sabbagh MN Progressive aphasia with Lewy bodies
Dementia Review Series 2003 4 10-11
22 Sabbagh MN Thompson N Tweedy D Stipho-Majeed S Kawas C Connor DJ Successful and Unsuccessful Recruitment and Retention Strategies for Alzheimerrsquos Disease Clinical Trials Pharmaceutical Regulation and Development 2003 1(4) 269-276
11 23 Johnson SC Baxter LC Susskind-Wilder L Connor DJ Sabbagh MN Caselli RJ Hippocampal
Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment Neuropsychologia 2004 42(7) 980-989
24 Li R Lindholm K Yang LB Yue X Citron M Yan R Beach T Sue L Sabbagh M Cai H Wong P
Price D Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimers disease patients Proc Natl Acad Sci U S A 2004 Mar 9 101(10)3632-3637
25 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A Masliah E Alford M Thal
LJ Corey-Bloom J Alzheimerrsquos disease without neocortical neurofibrillary tangles ldquoa second lookrdquo Neurology 2004 621141-1147
26 Davie JE Azuma T Goldinger SD Connor DJ Sabbagh MN Silverberg N Sensitivity to Expectancy
Violations in Healthy Aging and Mild Cognitive Impairment Neuropsychology 2004 18(2) 269-275
27 Sabbagh MN Silverberg NB Descheny RL Baxter LC Connor DJ Crocker-Sabbagh IP Dementia with Lewy bodies in a Native American Alzheimerrsquos Disease and Associated Disorders 2004 18 (4)259-261
28 Sabbagh MN Zahiri HR Ceimo J Cooper K Gaul W Connor DJ Sparks DL Is there a characteristic
lipid profile in Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2004 6 (6) 585-589
29 Sabbagh MN Tyas SL Emery SC Hansen LA Alford MF Reid RT Tiraboschi P Thal LJ Smoking Affects the Phenotype of Alzheimerrsquos Disease Neurology 2005 Apr 1264(7)1301-3
30 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Petanceska S Browne P Wassar D Johnson-Traver S Lochhead J Ziolwolski C Benefit of Atorvastatin in the treatment of mild to moderate Alzheimerrsquos disease results from the Alzheimerrsquos disease cholesterol lowering treatment (ADCLT) trial Archives of Neurology 2005 62753-757
31 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Browne P Johnson-Traver S Lochhead J
Ziolwolski C Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD Current Alzheimerrsquos Research 2005 Jul2(3)343-53
32 Sabbagh MN Silverberg N Bircea S Majeed B Samant S Caviness JN Reisberg B Adler CH Is
the functional decline in PD similar to the functional decline of AD Parkinsonism and Related Disorders 2005 11 311-315
33 Sabbagh MN Hake AM Ahmed S Farlow MR The use of memantine in Dementia with Lewy Bodies
Journal of Alzheimerrsquos Disease 2005 7(4) 285-289
34 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C rols MCI AD and the AD Cholesterol
Lowering Treatment Trial Current Alzheimerrsquos Research 2005 2527-539
35 Rogers J Li R Mastroeni D Grover A Leonard B Ahern G Cao P Kolody H Vedders L Kolb WP Sabbagh M Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes Neurobiology of Aging 2006 271733-1739
36 Caviness JN Shill HA Sabbagh MN Evidente VGH Hernandez J Adler CH Cortico-Muscular
coherence is increased in the small postural tremor of Parkinsonrsquos disease Movement Disorders 2006 21 (4)492-499
37 Sabbagh MN Sandhu S Lahti T Kolody H Silverberg NB Sparks DL What is the effect of the
apolipoprotein E genotype on the lipid profile in Alzheimerrsquos disease Current Alzheimerrsquos Research 2006 3(2) 157-160
38 Sparks DL Connor DJ Sabbagh MN Petersen RB Lopez J Browne P Circulating cholesterol
levels apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
8 42 Sabbagh MN Porsteinsson AP Nair A Adem A Novel Therapeutics in Alzheimers Disease
International Journal on Alzheimerrsquos Disease Volume 2012 (2012) Article ID 207969 2 pages
43 Sabbagh MN Geula C Messis C Friedland R Conference Report on the 5th International Conference on
Alzheimerrsquos Disease in the Middle East May 7-9 2009 Limmassol Cyprus Journal of Alzheimerrsquos Disease 2012 May 21Epub ahead of print] No abstract available PMID22614876
44 Lue LF Andrade C Sabbagh MN Walker DG Is there inflammatory synergy in type II diabetes mellitus
and Alzheimerrsquos disease International Journal of Alzheimerrsquos Disease 2012918680 Epub 2012 Jun 21
45 Sabbagh MN Ahmadi MM Belden C The Use of Informant-Based Questionnaires in Differentiating Mild Cognitive Impairment from Normal Aging Expert Review of Neurotherapeutics 2012 Jun12(6)637-9
46 Jeffrey L Cummings1 David Geldmacher
2 Martin Farlow
3 Marwan Sabbagh
4 Daniel Christensen
5 amp
Peter Betz6 for the Donepezil 23 mg Expert Working Group High-Dose Donepezil (23 mgday) for the
Treatment of Moderate and Severe Alzheimerrsquos Disease Drug Profile and Clinical Guidelines CNS Neurosci Ther 2013 Mar 6 doi 101111cns12076 [Epub ahead of print]
47 DeCourt B Mobley W Reiman E Shah RJ Sabbagh MN Recent perspectives on Alzheimerrsquos disease pathological changes in Down syndromerdquo J Alzheimers Dis Parkinsonism 2013 S7 httpdxdoiorg 1041722161-0460S7-002
48 Adem A El-Agnaf O Sabbagh MN Neurodegeneration The first IBRO-Middle East Neuroscience
Conference Current Alzheimerrsquos Research 2013 10 (6)557-8
49 Berk C Sabbagh MN Drugs in Late Stage Development for Alzheimerrsquos Disease Drugs Aging 2013 Aug 14 [Epub ahead of print]
50 Berk C Paul G Sabbagh MN Investigational Drugs in Alzheimerrsquos Disease Current Progress Expert
Opinion on Investigational Drugs 2014 Expert Opin Investig Drugs 2014 Jun23(6)837-46 doi 101517135437842014905542 Epub 2014 Apr 5
51 Richards D Sabbagh MN Florbetaben for PET Imaging of Neuritic Beta-Amyloid Plaques in the Brain
Neurology and Therapy 2014 DOI 101007s40120-014-0022-9
52 Hartley D Blumenthal T Carrillo M DiPaolo G Esralew L Gardiner K Granholm AC Iqbal K Krams M Lemere C Lott I Mobley W Ness S Nixon R Potter H Reeves R Sabbagh M Silverman W Tycko B Whitten M Wisniewski T Down syndrome and Alzheimers disease Common pathways common goals Alzheimers Dement 2014 Dec 12 pii S1552-5260(14)02860-X doi 101016jjalz201410007
53 Saunders KT Langbaum JB Holt CJ Chen W High N Langlois C Sabbagh M Tariot PN Arizona
Alzheimers Registry Strategy and Outcomes of a Statewide Research Recruitment Registry J Prev Alzheimers Dis 2014 Sep1(2)74-79
54 Walker DG Lue LF Paul G Patel A Sabbagh MN Advanced Glycation Endproduct Modulators A New
Therapeutic Target in Alzheimerrsquos Disease Expert Opinion in Investigational Drugs Posted online on January 14 2015 (doi1015171354378420151001490)
55 Malek-Ahmadi M Sabbagh MN Development and validation of the Alzheimerrsquos Questionnaire (AQ)
Journal of Nature and Science 20151(5)e104
56 Anand K Sabbagh MN Early investigational drugs targeting tau protein for the treatment of Alzheimers Disease Expert Opinion in Investigational Drugs 2015 24 (10)1-6
57 Sabbagh MN Edgin JO Clinical Assessment of Cognitive Decline in Adults with Down Syndrome
Current Alzheimerrsquos Research 2015 Sep 20 [epub ahead of print]
58 Arab L Sabbagh MNAre Certain Lifestyle Habits Associated with Lower Alzheimers Disease Risk J Alzheimers Dis 2015 Oct 148(3)877 doi 103233JAD-159004 No abstract available
9 59 Bahureska L Schwenk M Sabbagh M Mohler J Saleh A Najafi B The Impact of Mild Cognitive
Impairment on Balance and Gait a Systematic Review and Meta-Analysis Gerontology 2016 (DOI101159000445831)
60 Anand K Sabbagh MN Amyloid imaging poised for integration into medical practice Neurotherapeutics 2016 Aug 29 [Epub ahead of print] Review
61 Marwan Sabbagh1 SeolHeui Han
2 SangYun Kim
3 Hae-Ri Na
4 Jae-Hong Lee
5 Nagaendran Kandiah
6
Kammant Phanthumchinda7 Chuthamanee Suthisisang
8 Vorapun Senanarong
9 Ming-Chyi Pai
10 Diatri
Narilastri11
Ajit M Sowani12
Encarnita Ampil13
Amitabh Dash14
for the Asia Pacific EXpert Panel (APEX) for Donepezil 23 mg Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimerrsquos disease in the Asia-Pacific region Dement Geriatr Cogn Disord Extra 20166382-395 (DOI101159000448214)
62 Decourt B Lahiri DK Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimers Disease Curr Alzheimer Res 2016 Sep 30
63 Sabbagh MN Editorial Introduction Neurol Ther 2016 Nov 9 [Epub ahead of print]
64 Shefner JM Sabbagh MN An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases Editorial Introduction Neurotherapeutics 2016 Dec 8 [Epub ahead of print] No abstract available
65 Sabbagh MN DeCourt B Editorial Current and Emerging Therapeutics in AD Current Alzheimerrsquos Research 201714 (3) 354-355
66 DeCourt B Lahiri D Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimerrsquos Disease Current Alzheimerrsquos Research 201714 (3) 412-425
67 Mehta DG Paul G Shi J Sabbagh MN Why are drugs failing in Alzheimerrsquos disease 2010-2015 Expert Opin Investig Drugs 2017 May 2 doi 1010801354378420171323868 [Epub ahead of print]
68 Sabbagh MN Lue LF Fayard D Shi J Increasing precision of clinical diagnosis of AD using a combined algorithm incorporating clinical and novel biomarker data Neurology and Therapy 2017 (submitted)
69 Sabbagh MN Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimerrsquos Disease and Related Disorders Neurology and Therapy 2017 (submitted)
70 Sabbagh MN Editorial Clinical Effects of Oral Tramiprosate in APOE44 Homozygous Patients with Mild Alzheimerrsquos Disease Suggest Disease Modification JPAD 2017 (submitted)
71 Geidy Serrano Marwan S Sabbagh Michael Sierks Tyler A Kokjohn Thomas G Beach Chera L Maarouf Steven G Clarke4 Alex Roher APPAβ Structural Diversity and Alzheimerrsquos Disease Pathogenesis Neurochemistry International 2017 (submitted)
Peer-Reviewed Manuscripts
1 Adem A Sabbagh M Nordberg A Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex Journal of Neural Transmission 1988 7211-18
2 Sabbagh M Garza J Patten B Thoracoscopic thymectomy in myasthenia gravis Muscle amp Nerve
1995 181475-1477
3 Sabbagh M Lynn P Jhingran S et al Correlation of SPECT Regional cerebral blood flow defects to psychometric testing in patients with Alzheimers disease Journal of Neuropsychiatry and Clinical Neurosciences 1997 9 68-74
4 Corey-Bloom J Sabbagh MN Bondi MW Hansen L Alford MF Thal LJ Hippocampal sclerosis
contributes to dementia in the elderly Neurology 1997 48(1) 154-160
5 Olichney J Sabbagh M Hofstetter RC Galasko D Grundman M Katzman R Thal L The impact of
apolipoprotein 4 on the cause of death in Alzheimerrsquos disease Neurology 1997 49(1) 76-81
10 6 Olichney J Ellis R Katzman R Sabbagh M Hansen L Types of cerebrovascular lesions associated
with severe cerebral amyloid angiopathy in Alzheimers disease Annals of the New York Academy of Sciences 1997 826 493-497
7 Sabbagh MN Reid R Corey-Bloom J Rao T Lloyd K Hansen L Alford M Masliah E Adem A Thal
LJ Correlation of nicotinic binding to neurochemical markers in Alzheimerrsquos disease Journal of Neural Transmission 1998105(7) 709-717
8 Sabbagh MN Corey-Bloom J Tiraboschi P Thomas R Masliah E Thal LJ Neurochemical markers
do not correlate with cognitive decline in the Lewy Body Variant of Alzheimerrsquos disease Archives of Neurology 1999 56(12) 1568-1572
9 Tiraboschi P Hansen LA Sabbagh MN Schoos B Alford M Masliah E Thal LJ Corey-Bloom J
Cholinergic dysfunction in diseases with Lewy bodies Neurology 2000 54407-411
10 Corey-Bloom J Tiraboschi P Hansen LA Schoos B Alford M Sabbagh MN Masliah E Thal LJ E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimerrsquos disease Neurology 2000 54403-406
11 Reid RT Sabbagh MN Corey-Bloom J Tiraboschi P Thal LJ Nicotinic receptor in dementia with
Lewy Bodies comparisons with Alzheimerrsquos disease Neurobiology of Aging 2000 21 (5) 741-746
12 ReidRT Sabbagh MN Thal LJ Does apolipoprotein e (apo e) genotype influence nicotinic receptor binding in Alzheimers disease J Neural Transmission 2001 108(8-9) 1043-1050
13 Sabbagh MN Reid RT Hansen LA Alford M Thal LJ Correlation of nicotinic receptor binding with
clinical and neuropathological changes in Alzheimerrsquos disease and dementia with Lewy bodies J Neural Transmission 2001 108 (10) 1149-1157
14 Caselli R Beach T Sue L Connor DJ Sabbagh MN Progressive Aphasia with Lewy Bodies
Dementia and Geriatric Cognitive Disorders 2002 14 (2) 55-58
15 Sabbagh M Silverberg N Majeed B Samant S Sparks DL Seward J Connor DJ Length of stay in skilled nursing facilities is longer for patients with dementia J Alz Dis 2003 5(1) 57-63
16 Smith RG Roher A Appel SH Doody RS Killian DM Corey-Bloom J Sabbagh MN Autonomic
sudomotor dysfunction discriminates Alzheimerrsquos disease and non-demented control individuals Current Medicinal Chemistry Immunology Endocrine and Metabolic Agents 2003 3233-243
17 Reid RT Sabbagh MN Effects of Donepezil Treatment on Rat Nicotinic Acetylcholine Receptor
Levels In Vivo and In Vitro Journal of Alzheimerrsquos Disease 2003 5(6) 429-436
18 Caviness JN Adler CH Sabbagh M Connor DJ Hernandez JL Lagerlund T Abnormal Cortico-muscular Coherence is associated with the small amplitude cortical myoclonus in Parkinsonrsquos Disease Movement Disorders 2003 18 (10) 1157-62
19 Beach TG Sue L Scott S Layne K Newell A Walker D Baker M Sahara N Yen S-H Hutton M
Caselli R Adler C Connor D Sabbagh M Hippocampal Sclerosis Dementia with Tauopathy Brain Pathology 2003 13 263-278
20 Sparks DL Lopez J Sabbagh M Connor D Seward J Browne P A position paper based on
observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the AD Cholesterol-Lowering Treatment Trial J Molecular Neuroscience 2003 20 407-410
21 Caselli RJ Beach TG Sue LI Connor DJ Sabbagh MN Progressive aphasia with Lewy bodies
Dementia Review Series 2003 4 10-11
22 Sabbagh MN Thompson N Tweedy D Stipho-Majeed S Kawas C Connor DJ Successful and Unsuccessful Recruitment and Retention Strategies for Alzheimerrsquos Disease Clinical Trials Pharmaceutical Regulation and Development 2003 1(4) 269-276
11 23 Johnson SC Baxter LC Susskind-Wilder L Connor DJ Sabbagh MN Caselli RJ Hippocampal
Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment Neuropsychologia 2004 42(7) 980-989
24 Li R Lindholm K Yang LB Yue X Citron M Yan R Beach T Sue L Sabbagh M Cai H Wong P
Price D Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimers disease patients Proc Natl Acad Sci U S A 2004 Mar 9 101(10)3632-3637
25 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A Masliah E Alford M Thal
LJ Corey-Bloom J Alzheimerrsquos disease without neocortical neurofibrillary tangles ldquoa second lookrdquo Neurology 2004 621141-1147
26 Davie JE Azuma T Goldinger SD Connor DJ Sabbagh MN Silverberg N Sensitivity to Expectancy
Violations in Healthy Aging and Mild Cognitive Impairment Neuropsychology 2004 18(2) 269-275
27 Sabbagh MN Silverberg NB Descheny RL Baxter LC Connor DJ Crocker-Sabbagh IP Dementia with Lewy bodies in a Native American Alzheimerrsquos Disease and Associated Disorders 2004 18 (4)259-261
28 Sabbagh MN Zahiri HR Ceimo J Cooper K Gaul W Connor DJ Sparks DL Is there a characteristic
lipid profile in Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2004 6 (6) 585-589
29 Sabbagh MN Tyas SL Emery SC Hansen LA Alford MF Reid RT Tiraboschi P Thal LJ Smoking Affects the Phenotype of Alzheimerrsquos Disease Neurology 2005 Apr 1264(7)1301-3
30 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Petanceska S Browne P Wassar D Johnson-Traver S Lochhead J Ziolwolski C Benefit of Atorvastatin in the treatment of mild to moderate Alzheimerrsquos disease results from the Alzheimerrsquos disease cholesterol lowering treatment (ADCLT) trial Archives of Neurology 2005 62753-757
31 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Browne P Johnson-Traver S Lochhead J
Ziolwolski C Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD Current Alzheimerrsquos Research 2005 Jul2(3)343-53
32 Sabbagh MN Silverberg N Bircea S Majeed B Samant S Caviness JN Reisberg B Adler CH Is
the functional decline in PD similar to the functional decline of AD Parkinsonism and Related Disorders 2005 11 311-315
33 Sabbagh MN Hake AM Ahmed S Farlow MR The use of memantine in Dementia with Lewy Bodies
Journal of Alzheimerrsquos Disease 2005 7(4) 285-289
34 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C rols MCI AD and the AD Cholesterol
Lowering Treatment Trial Current Alzheimerrsquos Research 2005 2527-539
35 Rogers J Li R Mastroeni D Grover A Leonard B Ahern G Cao P Kolody H Vedders L Kolb WP Sabbagh M Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes Neurobiology of Aging 2006 271733-1739
36 Caviness JN Shill HA Sabbagh MN Evidente VGH Hernandez J Adler CH Cortico-Muscular
coherence is increased in the small postural tremor of Parkinsonrsquos disease Movement Disorders 2006 21 (4)492-499
37 Sabbagh MN Sandhu S Lahti T Kolody H Silverberg NB Sparks DL What is the effect of the
apolipoprotein E genotype on the lipid profile in Alzheimerrsquos disease Current Alzheimerrsquos Research 2006 3(2) 157-160
38 Sparks DL Connor DJ Sabbagh MN Petersen RB Lopez J Browne P Circulating cholesterol
levels apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
9 59 Bahureska L Schwenk M Sabbagh M Mohler J Saleh A Najafi B The Impact of Mild Cognitive
Impairment on Balance and Gait a Systematic Review and Meta-Analysis Gerontology 2016 (DOI101159000445831)
60 Anand K Sabbagh MN Amyloid imaging poised for integration into medical practice Neurotherapeutics 2016 Aug 29 [Epub ahead of print] Review
61 Marwan Sabbagh1 SeolHeui Han
2 SangYun Kim
3 Hae-Ri Na
4 Jae-Hong Lee
5 Nagaendran Kandiah
6
Kammant Phanthumchinda7 Chuthamanee Suthisisang
8 Vorapun Senanarong
9 Ming-Chyi Pai
10 Diatri
Narilastri11
Ajit M Sowani12
Encarnita Ampil13
Amitabh Dash14
for the Asia Pacific EXpert Panel (APEX) for Donepezil 23 mg Clinical recommendations for the use of donepezil 23 mg in moderate-to-severe Alzheimerrsquos disease in the Asia-Pacific region Dement Geriatr Cogn Disord Extra 20166382-395 (DOI101159000448214)
62 Decourt B Lahiri DK Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimers Disease Curr Alzheimer Res 2016 Sep 30
63 Sabbagh MN Editorial Introduction Neurol Ther 2016 Nov 9 [Epub ahead of print]
64 Shefner JM Sabbagh MN An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases Editorial Introduction Neurotherapeutics 2016 Dec 8 [Epub ahead of print] No abstract available
65 Sabbagh MN DeCourt B Editorial Current and Emerging Therapeutics in AD Current Alzheimerrsquos Research 201714 (3) 354-355
66 DeCourt B Lahiri D Sabbagh MN Targeting Tumor Necrosis Factor Alpha for Alzheimerrsquos Disease Current Alzheimerrsquos Research 201714 (3) 412-425
67 Mehta DG Paul G Shi J Sabbagh MN Why are drugs failing in Alzheimerrsquos disease 2010-2015 Expert Opin Investig Drugs 2017 May 2 doi 1010801354378420171323868 [Epub ahead of print]
68 Sabbagh MN Lue LF Fayard D Shi J Increasing precision of clinical diagnosis of AD using a combined algorithm incorporating clinical and novel biomarker data Neurology and Therapy 2017 (submitted)
69 Sabbagh MN Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimerrsquos Disease and Related Disorders Neurology and Therapy 2017 (submitted)
70 Sabbagh MN Editorial Clinical Effects of Oral Tramiprosate in APOE44 Homozygous Patients with Mild Alzheimerrsquos Disease Suggest Disease Modification JPAD 2017 (submitted)
71 Geidy Serrano Marwan S Sabbagh Michael Sierks Tyler A Kokjohn Thomas G Beach Chera L Maarouf Steven G Clarke4 Alex Roher APPAβ Structural Diversity and Alzheimerrsquos Disease Pathogenesis Neurochemistry International 2017 (submitted)
Peer-Reviewed Manuscripts
1 Adem A Sabbagh M Nordberg A Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex Journal of Neural Transmission 1988 7211-18
2 Sabbagh M Garza J Patten B Thoracoscopic thymectomy in myasthenia gravis Muscle amp Nerve
1995 181475-1477
3 Sabbagh M Lynn P Jhingran S et al Correlation of SPECT Regional cerebral blood flow defects to psychometric testing in patients with Alzheimers disease Journal of Neuropsychiatry and Clinical Neurosciences 1997 9 68-74
4 Corey-Bloom J Sabbagh MN Bondi MW Hansen L Alford MF Thal LJ Hippocampal sclerosis
contributes to dementia in the elderly Neurology 1997 48(1) 154-160
5 Olichney J Sabbagh M Hofstetter RC Galasko D Grundman M Katzman R Thal L The impact of
apolipoprotein 4 on the cause of death in Alzheimerrsquos disease Neurology 1997 49(1) 76-81
10 6 Olichney J Ellis R Katzman R Sabbagh M Hansen L Types of cerebrovascular lesions associated
with severe cerebral amyloid angiopathy in Alzheimers disease Annals of the New York Academy of Sciences 1997 826 493-497
7 Sabbagh MN Reid R Corey-Bloom J Rao T Lloyd K Hansen L Alford M Masliah E Adem A Thal
LJ Correlation of nicotinic binding to neurochemical markers in Alzheimerrsquos disease Journal of Neural Transmission 1998105(7) 709-717
8 Sabbagh MN Corey-Bloom J Tiraboschi P Thomas R Masliah E Thal LJ Neurochemical markers
do not correlate with cognitive decline in the Lewy Body Variant of Alzheimerrsquos disease Archives of Neurology 1999 56(12) 1568-1572
9 Tiraboschi P Hansen LA Sabbagh MN Schoos B Alford M Masliah E Thal LJ Corey-Bloom J
Cholinergic dysfunction in diseases with Lewy bodies Neurology 2000 54407-411
10 Corey-Bloom J Tiraboschi P Hansen LA Schoos B Alford M Sabbagh MN Masliah E Thal LJ E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimerrsquos disease Neurology 2000 54403-406
11 Reid RT Sabbagh MN Corey-Bloom J Tiraboschi P Thal LJ Nicotinic receptor in dementia with
Lewy Bodies comparisons with Alzheimerrsquos disease Neurobiology of Aging 2000 21 (5) 741-746
12 ReidRT Sabbagh MN Thal LJ Does apolipoprotein e (apo e) genotype influence nicotinic receptor binding in Alzheimers disease J Neural Transmission 2001 108(8-9) 1043-1050
13 Sabbagh MN Reid RT Hansen LA Alford M Thal LJ Correlation of nicotinic receptor binding with
clinical and neuropathological changes in Alzheimerrsquos disease and dementia with Lewy bodies J Neural Transmission 2001 108 (10) 1149-1157
14 Caselli R Beach T Sue L Connor DJ Sabbagh MN Progressive Aphasia with Lewy Bodies
Dementia and Geriatric Cognitive Disorders 2002 14 (2) 55-58
15 Sabbagh M Silverberg N Majeed B Samant S Sparks DL Seward J Connor DJ Length of stay in skilled nursing facilities is longer for patients with dementia J Alz Dis 2003 5(1) 57-63
16 Smith RG Roher A Appel SH Doody RS Killian DM Corey-Bloom J Sabbagh MN Autonomic
sudomotor dysfunction discriminates Alzheimerrsquos disease and non-demented control individuals Current Medicinal Chemistry Immunology Endocrine and Metabolic Agents 2003 3233-243
17 Reid RT Sabbagh MN Effects of Donepezil Treatment on Rat Nicotinic Acetylcholine Receptor
Levels In Vivo and In Vitro Journal of Alzheimerrsquos Disease 2003 5(6) 429-436
18 Caviness JN Adler CH Sabbagh M Connor DJ Hernandez JL Lagerlund T Abnormal Cortico-muscular Coherence is associated with the small amplitude cortical myoclonus in Parkinsonrsquos Disease Movement Disorders 2003 18 (10) 1157-62
19 Beach TG Sue L Scott S Layne K Newell A Walker D Baker M Sahara N Yen S-H Hutton M
Caselli R Adler C Connor D Sabbagh M Hippocampal Sclerosis Dementia with Tauopathy Brain Pathology 2003 13 263-278
20 Sparks DL Lopez J Sabbagh M Connor D Seward J Browne P A position paper based on
observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the AD Cholesterol-Lowering Treatment Trial J Molecular Neuroscience 2003 20 407-410
21 Caselli RJ Beach TG Sue LI Connor DJ Sabbagh MN Progressive aphasia with Lewy bodies
Dementia Review Series 2003 4 10-11
22 Sabbagh MN Thompson N Tweedy D Stipho-Majeed S Kawas C Connor DJ Successful and Unsuccessful Recruitment and Retention Strategies for Alzheimerrsquos Disease Clinical Trials Pharmaceutical Regulation and Development 2003 1(4) 269-276
11 23 Johnson SC Baxter LC Susskind-Wilder L Connor DJ Sabbagh MN Caselli RJ Hippocampal
Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment Neuropsychologia 2004 42(7) 980-989
24 Li R Lindholm K Yang LB Yue X Citron M Yan R Beach T Sue L Sabbagh M Cai H Wong P
Price D Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimers disease patients Proc Natl Acad Sci U S A 2004 Mar 9 101(10)3632-3637
25 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A Masliah E Alford M Thal
LJ Corey-Bloom J Alzheimerrsquos disease without neocortical neurofibrillary tangles ldquoa second lookrdquo Neurology 2004 621141-1147
26 Davie JE Azuma T Goldinger SD Connor DJ Sabbagh MN Silverberg N Sensitivity to Expectancy
Violations in Healthy Aging and Mild Cognitive Impairment Neuropsychology 2004 18(2) 269-275
27 Sabbagh MN Silverberg NB Descheny RL Baxter LC Connor DJ Crocker-Sabbagh IP Dementia with Lewy bodies in a Native American Alzheimerrsquos Disease and Associated Disorders 2004 18 (4)259-261
28 Sabbagh MN Zahiri HR Ceimo J Cooper K Gaul W Connor DJ Sparks DL Is there a characteristic
lipid profile in Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2004 6 (6) 585-589
29 Sabbagh MN Tyas SL Emery SC Hansen LA Alford MF Reid RT Tiraboschi P Thal LJ Smoking Affects the Phenotype of Alzheimerrsquos Disease Neurology 2005 Apr 1264(7)1301-3
30 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Petanceska S Browne P Wassar D Johnson-Traver S Lochhead J Ziolwolski C Benefit of Atorvastatin in the treatment of mild to moderate Alzheimerrsquos disease results from the Alzheimerrsquos disease cholesterol lowering treatment (ADCLT) trial Archives of Neurology 2005 62753-757
31 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Browne P Johnson-Traver S Lochhead J
Ziolwolski C Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD Current Alzheimerrsquos Research 2005 Jul2(3)343-53
32 Sabbagh MN Silverberg N Bircea S Majeed B Samant S Caviness JN Reisberg B Adler CH Is
the functional decline in PD similar to the functional decline of AD Parkinsonism and Related Disorders 2005 11 311-315
33 Sabbagh MN Hake AM Ahmed S Farlow MR The use of memantine in Dementia with Lewy Bodies
Journal of Alzheimerrsquos Disease 2005 7(4) 285-289
34 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C rols MCI AD and the AD Cholesterol
Lowering Treatment Trial Current Alzheimerrsquos Research 2005 2527-539
35 Rogers J Li R Mastroeni D Grover A Leonard B Ahern G Cao P Kolody H Vedders L Kolb WP Sabbagh M Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes Neurobiology of Aging 2006 271733-1739
36 Caviness JN Shill HA Sabbagh MN Evidente VGH Hernandez J Adler CH Cortico-Muscular
coherence is increased in the small postural tremor of Parkinsonrsquos disease Movement Disorders 2006 21 (4)492-499
37 Sabbagh MN Sandhu S Lahti T Kolody H Silverberg NB Sparks DL What is the effect of the
apolipoprotein E genotype on the lipid profile in Alzheimerrsquos disease Current Alzheimerrsquos Research 2006 3(2) 157-160
38 Sparks DL Connor DJ Sabbagh MN Petersen RB Lopez J Browne P Circulating cholesterol
levels apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
10 6 Olichney J Ellis R Katzman R Sabbagh M Hansen L Types of cerebrovascular lesions associated
with severe cerebral amyloid angiopathy in Alzheimers disease Annals of the New York Academy of Sciences 1997 826 493-497
7 Sabbagh MN Reid R Corey-Bloom J Rao T Lloyd K Hansen L Alford M Masliah E Adem A Thal
LJ Correlation of nicotinic binding to neurochemical markers in Alzheimerrsquos disease Journal of Neural Transmission 1998105(7) 709-717
8 Sabbagh MN Corey-Bloom J Tiraboschi P Thomas R Masliah E Thal LJ Neurochemical markers
do not correlate with cognitive decline in the Lewy Body Variant of Alzheimerrsquos disease Archives of Neurology 1999 56(12) 1568-1572
9 Tiraboschi P Hansen LA Sabbagh MN Schoos B Alford M Masliah E Thal LJ Corey-Bloom J
Cholinergic dysfunction in diseases with Lewy bodies Neurology 2000 54407-411
10 Corey-Bloom J Tiraboschi P Hansen LA Schoos B Alford M Sabbagh MN Masliah E Thal LJ E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimerrsquos disease Neurology 2000 54403-406
11 Reid RT Sabbagh MN Corey-Bloom J Tiraboschi P Thal LJ Nicotinic receptor in dementia with
Lewy Bodies comparisons with Alzheimerrsquos disease Neurobiology of Aging 2000 21 (5) 741-746
12 ReidRT Sabbagh MN Thal LJ Does apolipoprotein e (apo e) genotype influence nicotinic receptor binding in Alzheimers disease J Neural Transmission 2001 108(8-9) 1043-1050
13 Sabbagh MN Reid RT Hansen LA Alford M Thal LJ Correlation of nicotinic receptor binding with
clinical and neuropathological changes in Alzheimerrsquos disease and dementia with Lewy bodies J Neural Transmission 2001 108 (10) 1149-1157
14 Caselli R Beach T Sue L Connor DJ Sabbagh MN Progressive Aphasia with Lewy Bodies
Dementia and Geriatric Cognitive Disorders 2002 14 (2) 55-58
15 Sabbagh M Silverberg N Majeed B Samant S Sparks DL Seward J Connor DJ Length of stay in skilled nursing facilities is longer for patients with dementia J Alz Dis 2003 5(1) 57-63
16 Smith RG Roher A Appel SH Doody RS Killian DM Corey-Bloom J Sabbagh MN Autonomic
sudomotor dysfunction discriminates Alzheimerrsquos disease and non-demented control individuals Current Medicinal Chemistry Immunology Endocrine and Metabolic Agents 2003 3233-243
17 Reid RT Sabbagh MN Effects of Donepezil Treatment on Rat Nicotinic Acetylcholine Receptor
Levels In Vivo and In Vitro Journal of Alzheimerrsquos Disease 2003 5(6) 429-436
18 Caviness JN Adler CH Sabbagh M Connor DJ Hernandez JL Lagerlund T Abnormal Cortico-muscular Coherence is associated with the small amplitude cortical myoclonus in Parkinsonrsquos Disease Movement Disorders 2003 18 (10) 1157-62
19 Beach TG Sue L Scott S Layne K Newell A Walker D Baker M Sahara N Yen S-H Hutton M
Caselli R Adler C Connor D Sabbagh M Hippocampal Sclerosis Dementia with Tauopathy Brain Pathology 2003 13 263-278
20 Sparks DL Lopez J Sabbagh M Connor D Seward J Browne P A position paper based on
observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the AD Cholesterol-Lowering Treatment Trial J Molecular Neuroscience 2003 20 407-410
21 Caselli RJ Beach TG Sue LI Connor DJ Sabbagh MN Progressive aphasia with Lewy bodies
Dementia Review Series 2003 4 10-11
22 Sabbagh MN Thompson N Tweedy D Stipho-Majeed S Kawas C Connor DJ Successful and Unsuccessful Recruitment and Retention Strategies for Alzheimerrsquos Disease Clinical Trials Pharmaceutical Regulation and Development 2003 1(4) 269-276
11 23 Johnson SC Baxter LC Susskind-Wilder L Connor DJ Sabbagh MN Caselli RJ Hippocampal
Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment Neuropsychologia 2004 42(7) 980-989
24 Li R Lindholm K Yang LB Yue X Citron M Yan R Beach T Sue L Sabbagh M Cai H Wong P
Price D Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimers disease patients Proc Natl Acad Sci U S A 2004 Mar 9 101(10)3632-3637
25 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A Masliah E Alford M Thal
LJ Corey-Bloom J Alzheimerrsquos disease without neocortical neurofibrillary tangles ldquoa second lookrdquo Neurology 2004 621141-1147
26 Davie JE Azuma T Goldinger SD Connor DJ Sabbagh MN Silverberg N Sensitivity to Expectancy
Violations in Healthy Aging and Mild Cognitive Impairment Neuropsychology 2004 18(2) 269-275
27 Sabbagh MN Silverberg NB Descheny RL Baxter LC Connor DJ Crocker-Sabbagh IP Dementia with Lewy bodies in a Native American Alzheimerrsquos Disease and Associated Disorders 2004 18 (4)259-261
28 Sabbagh MN Zahiri HR Ceimo J Cooper K Gaul W Connor DJ Sparks DL Is there a characteristic
lipid profile in Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2004 6 (6) 585-589
29 Sabbagh MN Tyas SL Emery SC Hansen LA Alford MF Reid RT Tiraboschi P Thal LJ Smoking Affects the Phenotype of Alzheimerrsquos Disease Neurology 2005 Apr 1264(7)1301-3
30 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Petanceska S Browne P Wassar D Johnson-Traver S Lochhead J Ziolwolski C Benefit of Atorvastatin in the treatment of mild to moderate Alzheimerrsquos disease results from the Alzheimerrsquos disease cholesterol lowering treatment (ADCLT) trial Archives of Neurology 2005 62753-757
31 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Browne P Johnson-Traver S Lochhead J
Ziolwolski C Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD Current Alzheimerrsquos Research 2005 Jul2(3)343-53
32 Sabbagh MN Silverberg N Bircea S Majeed B Samant S Caviness JN Reisberg B Adler CH Is
the functional decline in PD similar to the functional decline of AD Parkinsonism and Related Disorders 2005 11 311-315
33 Sabbagh MN Hake AM Ahmed S Farlow MR The use of memantine in Dementia with Lewy Bodies
Journal of Alzheimerrsquos Disease 2005 7(4) 285-289
34 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C rols MCI AD and the AD Cholesterol
Lowering Treatment Trial Current Alzheimerrsquos Research 2005 2527-539
35 Rogers J Li R Mastroeni D Grover A Leonard B Ahern G Cao P Kolody H Vedders L Kolb WP Sabbagh M Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes Neurobiology of Aging 2006 271733-1739
36 Caviness JN Shill HA Sabbagh MN Evidente VGH Hernandez J Adler CH Cortico-Muscular
coherence is increased in the small postural tremor of Parkinsonrsquos disease Movement Disorders 2006 21 (4)492-499
37 Sabbagh MN Sandhu S Lahti T Kolody H Silverberg NB Sparks DL What is the effect of the
apolipoprotein E genotype on the lipid profile in Alzheimerrsquos disease Current Alzheimerrsquos Research 2006 3(2) 157-160
38 Sparks DL Connor DJ Sabbagh MN Petersen RB Lopez J Browne P Circulating cholesterol
levels apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
11 23 Johnson SC Baxter LC Susskind-Wilder L Connor DJ Sabbagh MN Caselli RJ Hippocampal
Adaptation to Face Repetition in Healthy Elderly and Mild Cognitive Impairment Neuropsychologia 2004 42(7) 980-989
24 Li R Lindholm K Yang LB Yue X Citron M Yan R Beach T Sue L Sabbagh M Cai H Wong P
Price D Shen Y Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimers disease patients Proc Natl Acad Sci U S A 2004 Mar 9 101(10)3632-3637
25 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A Masliah E Alford M Thal
LJ Corey-Bloom J Alzheimerrsquos disease without neocortical neurofibrillary tangles ldquoa second lookrdquo Neurology 2004 621141-1147
26 Davie JE Azuma T Goldinger SD Connor DJ Sabbagh MN Silverberg N Sensitivity to Expectancy
Violations in Healthy Aging and Mild Cognitive Impairment Neuropsychology 2004 18(2) 269-275
27 Sabbagh MN Silverberg NB Descheny RL Baxter LC Connor DJ Crocker-Sabbagh IP Dementia with Lewy bodies in a Native American Alzheimerrsquos Disease and Associated Disorders 2004 18 (4)259-261
28 Sabbagh MN Zahiri HR Ceimo J Cooper K Gaul W Connor DJ Sparks DL Is there a characteristic
lipid profile in Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2004 6 (6) 585-589
29 Sabbagh MN Tyas SL Emery SC Hansen LA Alford MF Reid RT Tiraboschi P Thal LJ Smoking Affects the Phenotype of Alzheimerrsquos Disease Neurology 2005 Apr 1264(7)1301-3
30 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Petanceska S Browne P Wassar D Johnson-Traver S Lochhead J Ziolwolski C Benefit of Atorvastatin in the treatment of mild to moderate Alzheimerrsquos disease results from the Alzheimerrsquos disease cholesterol lowering treatment (ADCLT) trial Archives of Neurology 2005 62753-757
31 Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ Browne P Johnson-Traver S Lochhead J
Ziolwolski C Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinically benefit in the treatment of mild-to-moderate AD Current Alzheimerrsquos Research 2005 Jul2(3)343-53
32 Sabbagh MN Silverberg N Bircea S Majeed B Samant S Caviness JN Reisberg B Adler CH Is
the functional decline in PD similar to the functional decline of AD Parkinsonism and Related Disorders 2005 11 311-315
33 Sabbagh MN Hake AM Ahmed S Farlow MR The use of memantine in Dementia with Lewy Bodies
Journal of Alzheimerrsquos Disease 2005 7(4) 285-289
34 Sparks DL Petanceska S Sabbagh M Connor D Soares H Adler C Lopez J Ziolowski C rols MCI AD and the AD Cholesterol
Lowering Treatment Trial Current Alzheimerrsquos Research 2005 2527-539
35 Rogers J Li R Mastroeni D Grover A Leonard B Ahern G Cao P Kolody H Vedders L Kolb WP Sabbagh M Peripheral clearance of amyloid b peptide by complement C3-dependent adherence to erythrocytes Neurobiology of Aging 2006 271733-1739
36 Caviness JN Shill HA Sabbagh MN Evidente VGH Hernandez J Adler CH Cortico-Muscular
coherence is increased in the small postural tremor of Parkinsonrsquos disease Movement Disorders 2006 21 (4)492-499
37 Sabbagh MN Sandhu S Lahti T Kolody H Silverberg NB Sparks DL What is the effect of the
apolipoprotein E genotype on the lipid profile in Alzheimerrsquos disease Current Alzheimerrsquos Research 2006 3(2) 157-160
38 Sparks DL Connor DJ Sabbagh MN Petersen RB Lopez J Browne P Circulating cholesterol
levels apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
12 treatment in AD Results from the Alzheimerrsquos disease Cholesterol Lowering Treatment Trial Acta Neurologica Scandinavica 2006 185 S3-7
39 Roher AE Garami Z Alexandrov AV Kokjohn TA Esh CL Kalback WM Vedders LJ Wilson JR
Beach TG Sabbagh MN Interaction of cardiovascular disease and neurodegeneration Transcranial Doppler ultrasonography and Alzheimerrsquos disease Neurological Research 2006 Sep28(6)672-8
40 Baxter LC Sparks DL Johnson SC Lenoski B LopezJE Connor DJ Sabbagh MN MRI
Relationship of cognitive measures and gray and white matter in Alzheimers Disease Journal of Alzheimers Disease 2006 Aug9(3) 253-260
41 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN
Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2006 Sep 20 epub ahead of print
42 Valla J Coon K Caselli R Sabbagh MN Ahern G Baxter L Alexander G Walker DG Reiman EM
Impaired Platelet Mitochondrial Activity in Alzheimerrsquos disease and Mild Cognitive Impairment Mitochondrion 2006 Dec 6(6) 323-330
43 Sabbagh MN Shah
F Reid RT Sue L Peterson LK Beach TG Pathological and Nicotinic Receptor
Binding Differences between Mild Cognitive Impairment Alzheimerrsquos disease and Normal Aging Archives of Neurology 2006 Dec 63 (12) 1771-76
44 Baxter LC Sabbagh MN Voxel-based morphometry in Alzheimerrsquos patients Journal of Alzheimerrsquos
Disease 2006 Dec 10 (4)449
45 Beach TG Wilson JR Sue LI Newell A Poston M Cisneros R Pandya Y Connor DJ Sabbagh MN Walker D Roher A Circle of Willis Atherosclerosis Association with Alzheimerrsquos Disease Neuritic Plaques and Neurofibrillary Tangles Acta Neuropathologica 2007 113(1)13-21
46 Caviness JN Driver-Dunckley E Connor DJ Sabbagh MN Noble B Evidente VGH Shill HS Adler
CH Defining mild cognitive impairment in Parkinsonrsquos disease (PD-MCI) Movement Disorders 2007 Apr 522(9)1272-1277
47 Caviness JN Hentz J Evidente VGH Driver-Dunckley E Samanta J Mahant P Connor DJ
Sabbagh MN Shill HA Adler CH Electroencephalography as a biomarker for cognitive state in Parkinsonrsquos disease Parkinsonism and Related Disorders 2007 Mar 7 [Epub ahead of print]
48 Lyketsos CG Breitner JCS Green RC Martin BK Meinert C Piantadosi S Sabbagh M for the
ADAPT Research Group No immediate reduction in AD incidence with naproxen and celecoxib results from a randomized prevention trial Neurology 2007 May 68 1800-1809
49 Beach TG Sue LI Walker DG Lue LF Caviness J Sabbagh MN Adler CH Marked microglial
reaction in normal aging human substantia nigra correlation with extraneuronal neuromelanin pigment deposits Acta Neuropathologica 2007 114419-424
50 Sabbagh MN Lahti T Connor DJ Caviness JN Shill H Mahant P Samanta J Burns RS Evidente
VGH Driver-Dunckley E Reisberg B Bircea S Adler CH Functional decline correlates with cognitive impairment in Parkinsonrsquos disease and Alzheimerrsquos disease Dementia and Geriatric Cognitive Disorders 200724327-334
51 Ray S Britschgi M Herbert C Takeda-Uchimura Y Boxer A Blennow K Friedman LF Galasko
DF Jutel M Karydas A Kaye JA Leszek J Miller BL Minthon L Quinn JF Rabinovici GD Robinson WH Sabbagh MN So YT Sparks DL Tabaton M Tinklenberg J Yesavage JA Tibshirani R Wyss-Coray T Classification and prediction of clinical Alzheimer diagnosis based on plasma signaling proteins Nature Medicine 2007 Oct 14 [Epub ahead of print]
52 Beach TG Adler CH Sue LI Peirce JB BachalakuriJ Dalsing-Hernandez JE Lue LF Caviness JN
Connor DJ Sabbagh MN Walker DG Reduced Striatal Tyrosine Hydroxylase in Incidental Lewy Body Disease Acta Neuropathol 2007 Nov 6 [Epub ahead of print]
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
13 53 Shill HA Adler CH Sabbagh MN Connor DJ Caviness JN Hentz JG Beach TG Pathological
findings in prospectively ascertained essential tremor subjects Neurology 2008 Apr 1570(16 Pt 2)1452-5
54 Sparks DL Lemieux SK Haut MW Baxter LC Johnson SC Sparks LM Sampath H Lopez JE
Sabbagh MN Connor DJ Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial Cleve Clin J Med 2008 Mar75 Suppl 2S87-93
55 Griffin-Pierce T Silverberg N Jim M Connor D Peters J Kaszniak A Sabbagh M Challenges to
developing neuropsychological instruments for assessing Alzheimerrsquos disease in American Indians and Alaska natives Alzheimerrsquos and Dementia 2008 4 291-299
56 Stamper C Siegel A Liang WS Pearson JV Stephan DA Shill H Connor D Caviness JN Sabbagh
M Beach T Adler C Dunckley T Neuronal gene expression correlates of Parkinsonrsquos disease with dementia Movement Disorders 2008 Jul 22 [epub ahead of print]
57 Sparks DL Kryscio R Sabbagh MN Connor DJ Sparks LM Liebsack C Reduced risk of incident AD
with selective statin use in a clinical trial cohort Current Alzheimerrsquos Research 2008 5(4) 416-421
58 Sparks DL Ziolkowski C Connor D Beach T Adler C Sabbagh M et al Copper and cognition in Alzheimerrsquos and Parkinsonrsquos disease Cell Biol Toxicol 2008 24 423-470
59 Reid RT Sabbagh MN Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and
in vitro Journal of Neural Transmission 2008 Aug 26 [epub ahead of print]
60 Sabbagh MN Lue LF Reid RT Walker DG Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (SwInd) Neuroscience Letters 2008 448 217-220
61 Connor DJ Sabbagh MN Administration and scoring variance on the ADAS-cog Journal of
Alzheimerrsquos Disease 2008 15 (3) 461-464
62 Connor DJ Sabbagh MN Cummings JL Comment on administration and scoring of the Neuropsychiatric Inventory in clinical trials Alzheimerrsquos and Dementia 2008 4(6)390-394
63 Beach TG White CL Hladik
CL Sabbagh MN Connor DJ Shill HA Sue L Sasse J Bachalakuri J
Henry-Watson Akiyama JH Adler CH Olfactory Bulb Synucleinopathy Has High Specificity and Sensitivity for Lewy Body Disorders Acta Neuropathologica 2009 Feb117(2)169-74
64 Roher
AE Esh CL Kokjohn TA Castantildeo EM Van Vickle GD Kalback WM Patton RL Luehrs DC
Daugs ID Kuo YM Emmerling MR Soares H Quinn JF Kaye J Connor DJ Silverberg NB Adler
CH Seward JD Beach TG Sabbagh MN A peptides in human plasma and tissues and their
significance for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2009 5(1) 18-29
65 Ignatov I Belden C Jacobson S Connor DJ Sabbagh MN Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Journal of Alzheimerrsquos Disease 2009 Jan 16(1)35-38
66 Beach TG Adler CH Lue LF Sue LI Sasse J Bachalakuri J Henry-Watson J Boyer S Shirohi S
Brooks R Eschbacher J White CL Akiyama H Caviness J Shill HA Connor DJ Sabbagh MN Walker DG Unified Staging System for Lewy Body Disorders Correlation with Nigrostriatal Degeneration Cognitive Impairment and Motor Dysfunction Acta Neuropathologica 2009 Jun117(6)613-34
67 Caselli RJ Hentz JG Osborne D Sabbagh MN Connor DJ Ahern G Baxter L Rapcsak S Hutton
MF Reiman EM Longitudinal Growth Modeling of cognitive aging and the ApoEe4 effect New England Journal of Medicine 2009255-263
68 Driver-Dunckley E Connor DJ Hentz J Sabbagh MN Silverberg N Hernandez JE Vedders L
Evidente V Shill H Caviness J Adler CH No evidence of cognitive dysfunction or depression in patients with mild RLS Movement Disorders 2009 Jul 16 [epub ahead of print]
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
14
69 Sabbagh MN Sandhu SS Farlow MR Beach TG Vedders L Shill HA Caviness JN Connor DJ Sue L Adler CH Correlation of Clinical Features to Argyrophilic Grains at Autopsy Alzheimerrsquos Disease and Associated Disorders 2009 23(3) 229-233
70 Sabbagh MN Adler CH Lahti TJ Connor DJ Peterson LK Caviness JN Shill HA Sue
LI Ziabreva
I Perry E Ballard CG Aarsland D Reid RT Walker DG Beach TG Parkinsonrsquos disease with dementia comparing patients with and without Alzheimer pathology Alzheimerrsquos disease and Associated Disorders 2009 23(3) 295-297
71 Sabbagh MN Cooper K Fleming SR Thind
K Stoehr JD Lahti T Reisberg B Sue L Vedders L
Beach TG Functional Global and Cognitive Decline Correlates to Accumulation of Alzheimerrsquos Pathology in MCI and AD Current Alzheimerrsquos Research 2009 Dec 1 [epub ahead of print]
72 Goldknopf IL Bryson JK Strelets I Quintero S Sheta EA Mosqueda M Park HR Appel SH Shill H
Sabbagh M Chase B Kalidjian E Markopoulou K Abnormal Serum concentrations of proteins in Parkinsonrsquos disease Biomedical Biophysical Research Communications 2009 Aug 31 [epub ahead of print]
73 Driver-Dunckley E Connor DJ Hentz J Sabbagh M Silverberg N Hernandez J Vedders L Evidente
V Shill HA Caviness JN Adler CH No evidence of cognitive dysfunction or depression in mild restless legs syndrome Movement Disorders 2009 1840-1842
74 Baholavek M Jiamsripong P Calleja A McMahon E Marouf C Kokjohn T Chaffin TL Vedder LJ
Garami Z Beach TG Sabbagh MN Roher AE Alzheimerrsquos disease patients have altered transmitral flow dysfunction as analyzed by echocardiocardiography vortex formation time Journal of Ultrasound in Medicine 2009 Nov28(11)1493-1500
75 Soares HD Chen Y Sabbagh M Roher A Schrivjers E Breteler M Identifying early markers of
Alzheimerrsquos disease using quantitative multiplex proteomic immunoassay panels Annals of the NY Academy of Sciences 2009 1180 56-67
76 Salloway S Sperling R Gilman S Fox NC Blennow K Raskind M Sabbagh M Honig LS Doody R
Van Dyck CH Mulnard R Barakos J Gregg KM Liu E Lieberburg I Schenk D Black R Grundman M for the Bapineuzumab 201 Clinical Trial Investigators Neurology 2009 epub ahead of print November 18
77 Choi SA Evidente VGH Caviness JN Shill HA Sabbagh MN Connor DJ Hentz JG Adler CH
Beach TG Are there differences in cerebral white matter lesion burdens between Parkinsonrsquos disease patients with or without dementia Acta Neuropathologica 2009 epub ahead of print December 7
78 Holland D Brewer JB Hagler DJ Fenema-Notestine C Dale AM the Alzheimers Disease
Neuroimaging Initiative Weiner M Thal L Petersen R Jack CR Jr Jagust W Trojanowki J Toga AW Beckett L Green RC Gamst A Potter WZ Montine T Anders D Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G Bandy D Koeppe RA Foster N Reiman EM Chen K Shaw L Lee VM Korecka M Crawford K Neu S Harvey D Kornak J Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Vorobik R Quinn J Schneider L Pawluczyk S Spann B Fleisher AS Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Mintun MA Schneider S Marson D Griffith R Badger B Grossman H Tang C Stern J Detoledo-Morrell L Shah RC Bach J Duara R Isaacson R Strauman S Albert MS Pedroso J Toroney J Rusinek H de Leon MJ De Santi SM Doraiswamy PM Petrella JR Aiello M Clark CM Pham C Nunez J Smith CD Given CA 2nd Hardy P Dekosky ST Oakley M Simpson DM Ismail MS Porsteinsson A McCallum C Cramer SC Mulnard RA McAdams-Ortiz C Diaz-Arrastia R Martin-Cook K Devous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Laubinger MM Bartzokis G Silverman DH Lu PH Fletcher R Parfitt F Johnson H Farlow M Herring S Hake AM van Dyck CH Macavoy MG Bifano LA Chertkow H Bergman H Hosein C Black S Graham S Caldwell C Feldman H Assaly M Hsiung GY Kertesz A Rogers J Trost D Bernick C Gitelman D Johnson N Mesulam M Sadowsky C Villena T Mesner S Aisen PS Johnson KB Behan KE Sperling RA Rentz DM Johnson KA Rosen A Tinklenberg J Ashford W Sabbagh M Connor D Obradov S Killiany R Norbash A Obisesan TO Jayam-Trouth A Wang P
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
15 Auchus AP Huang J Friedland RP Decarli C Fletcher E Carmichael O Kittur S Mirje S Johnson SC Borrie M Lee TY Asthana S Carlsson CM Potkin SG Highum D Preda A Nguyen D Tariot PN Hendin BA Scharre DW Kataki M Beversdorf DQ Zimmerman EA Celmins D Brown AD Gandy S Marenberg ME Rovner BW Pearlson G Blank K Anderson K Saykin AJ Santulli RB Pare N Williamson JD Sink KM Potter H Ashok Raj B Giordano A Ott BR Wu CK Cohen R Wilks KL Safirstein BE Subregional neuroanatomical change as a biomarker for Alzheimers disease Proc Natl Acad Sci U S A 2009 Dec 8106(49)20954-20959
79 McKinnon J Evidente V Driver-Dunckley E Premkumar A Hentz J Shill HA Sabbagh MN
Caviness J Connor DJ Adler CH Olfaction in the elderly a cross-sectional analysis comparing with controls and other disorders Int J Neurosci 2010 Jan120(1)36-9
80 Caselli RJ Beach T Sue L Sabbagh M Connor D Walker D Amyloid load in nondemented
autopsied brains correlates with APOEe4 Neuroscience Letters 2010 Feb 11 [epub ahead of print]
81 Adler CH Connor DJ Hentz JG Sabbagh MN Caviness JN Shill HA Noble B Beach TG Is incidental Lewy Body Disease really incidental Movement Disorders 2010 Feb 19 [Epub ahead of print]
82 Stieler J Grimes R Weber D Hardy C Gartner W Sabbagh MN Arendt T Multivariate Analysis of
Differential Lymphocyte Cell Cycle Activity in Alzheimers Disease Neurobiology of Aging 2010 Apr 13 [Epub ahead of print]
83 Beach TG Adler CH Sue LI Vedders L Lue LF White CL Akiyama H Caviness J Shill HA
Sabbagh MN Walker DG Multi-organ Distributions of phosphorylated alpha-synuclein histopathology in subjects with Lewy Body Disorders Acta Neuropathologica 2010 Jun119(6)689-702 Epub 2010 Mar 21
84 Sparks DL Kryscio RJ Connor DJ Sabbagh MN Sparks LM Lin Y Liebsack C Cholesterol and
cognitive performance in normal controls and the influence of elective statin use after conversion to MC results in a clinical trial cohort Neurodegenerative Diseases 20107(1-3)183-6 Epub 2010 Mar 12
85 Wolk DA Dickerson BC the Alzheimers Disease Neuroimaging Initiative Weiner M Aiello M Aisen
P Albert MS Alexander G Anderson HS Anderson K Apostolova L Arnold S Ashford W Assaly M Asthana S Bandy D Bartha R Bates V Beckett L Bell KL Benincasa AL Bergman H Bernick C Bernstein M Black S Blank K Borrie M Brand C Brewer J Brown AD Burns JM Cairns NJ Caldwell C Capote H Carlsson CM Carmichael O Cellar JS Celmins D Chen K Chertkow H Chowdhury M Clark D Connor D Correia S Crawford K Dale A de Leon MJ De Santi SM Decarli C Detoledo-Morrell L Devous M Diaz-Arrastia R Dolen S Donohue M Doody RS Doraiswamy PM Duara R Englert J Farlow M Feldman H Felmlee J Fleisher A Fletcher E Foroud TM Foster N Fox N Frank R Gamst A Given CA 2nd Graff-Radford NR Green RC Griffith R Grossman H Hake AM Hardy P Harvey D Heidebrink JL Hendin BA Herring S Honig LS Hosein C Robin Hsiung GY Hudson L Ismail MS Jack CR Jr Jacobson S Jagust W Jayam-Trouth A Johnson K Johnson H Johnson N Johnson K Johnson KA Johnson S Kachaturian Z Karlawish JH Kataki M Kaye J Kertesz A Killiany R Kittur S Koeppe RA Korecka M Kornak J Kozauer N Lah JJ Laubinger MM Lee VM Lee TY Lerner A Levey AI Longmire CF Lopez OL Lord JL Lu PH Macavoy MG Malloy P Marson D Martin-Cook K Martinez W Marzloff G Mathis C Mc-Adams-Ortiz C Mesulam M Miller BL Mintun MA Mintzer J Molchan S Montine T Morris J Mulnard RA Munic D Nair A Neu S Nguyen D Norbash A Oakley M Obisesan TO Ogrocki P Ott BR Parfitt F Pawluczyk S Pearlson G Petersen R Petrella JR Potkin S Potter WZ Preda A Quinn J Rainka M Reeder S Reiman EM Rentz DM Reynolds B Richard J Roberts P Rogers J Rosen A Rosen HJ Rusinek H Sabbagh M Sadowsky C Salloway S Santulli RB Saykin AJ Scharre DW Schneider L Schneider S Schuff N Shah RC Shaw L Shen L Silverman DH Simpson DM Sink KM Smith CD Snyder PJ Spann BM Sperling RA Spicer K Stefanovic B Stern Y Stopa E Tang C Tariot P Taylor-Reinwald L Thai G Thomas RG Thompson P Tinklenberg J Toga AW Tremont G Trojanowki JQ Trost D Turner RS van Dyck CH Vanderswag H Varon D Villanueva-Meyer J Villena T Walter S Wang P Watkins F Weiner M Williamson JD Wolk D Wu CK Zerrate M Zimmerman EA Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimers disease Proc Natl Acad Sci U S A 2010 May 17
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
16
86 Escabi Y San Miguel L Judd T Hertza J Nicholson J Schiff W Bell C Estes B Millikin C Shelton P Marotta P Wingler I Barth J Parmenter B Andrews G Riordan P Lipinski D Sawyer J Brewer V Kirk J Green C Kirkwood M Brooks B Fay T Barlow K Chelune G Duff K Wang A Franchow E Card S Zamrini E Foster N Duff K Chelune G Wang A Card S Franchow E Zamrini E Foster N Green D Polikar R Clark C Kounios J Malek-Ahmadi M Kataria R Belden C Connor D Pearson C Jacobson S Yaari R Singh U Sabbagh M et al Grand rounds Arch Clin Neuropsychol 2010 Sep25(6)475-583
87 Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD Holly A Shill
MD Donald J Connor PhD PhD Lucia Sue BS Virgilio GH Evidente MD Erika Driver-Dunckley MD Thomas G Beach MD PhD Heterogeneous neuropathological findings in Parkinsons disease with mild cognitive impairment Acta Neuropathologica 2010 Sept 14 [epub ahead of print]
88 Geula C Sabbagh M Efthymiopoulos S Friedland RP The 4th International Conference on
Alzheimerrsquos Disease and Related Disorders in the Middle East Amyloid 1786-90 2010
89 Sabbagh MN Malek Ahmadi M Kataria R Belden C Connor DJ Pearson C Yaari R Singh U The Alzheimerrsquos Questionnaire A Pilot Study for a New Informant-Based Dementia Assessment Journal of Alzheimerrsquos Disease 2010 Oct 7 [Epub ahead of print]
90 Cole L Belden C Jacobson S Myers K Reininger C Berk C Sabbagh M Probable early onset
Alzheimerrsquos disease in an Apolipoprotein E2 homozygote Dementia and Geriatric Cognitive Disorders 2010 Oct 2330(5)387-391 [Epub ahead of print]
91 Maarouf CL Daugs ID Kokjohn TA Kalback WM Patton LR Leuers DC Masliah E Nicoll JAR
Sabbagh MN Beach TG Castano EM Roher AE The Biochemical Aftermath of Anti-amyloid Immunotherapy Molecular Neurodegeneration 2010 Oct 7539
92 Sabbagh MN Agro A Bell J Aisen P Schweiser E Galasko D Safety and Tolerability of PF-
04494700 an oral inhibitor of RAGE in Alzheimerrsquos disease subjects Alzheimerrsquos Disease and Associated Disorders 2010 Dec 28 [Epub ahead of print]
93 Clark CM
12 Schneider JA
3 Bedell BJ
45 Beach TG
6 Mintun MA
17 Pontecorvo MJ
1 Hefti F
1
Carpenter A1 Flitter M
1 Krautkramer M
1 Kung HF
2 Coleman RE
8 Fleischer A
910 Sabbagh M
Sadowsky C Doraiswamy PM8 Reiman EM
9 Skovronsky DM
1 and the AV45-A07 study group
Validation of Florbetapir-PET for Imaging Alzheimerrsquos Disease Amyloid Pathology JAMA 2011 305(3)275-283
94 Roher AE Marouf CL Daugs ID Kokjohn TA Hunter JM Sabbagh MN Beach TG Neuropathology and amyloid b-spectrum in a bapineuzumab immunotherapy recipient Journal of Alzheimerrsquos Disease 2011 Jan 24 [Epub ahead of print]
95 Beach TG Maarouf CL Brooks RG Shirohi S Daugs ID Sue LI Sabbagh MN Vedders L Walker
DG Lue LF Roher AE Reduced clinical and postmortem measures of cardiac pathology in subjects with Alzheimerrsquos disease BMC Geriatrics 2011 Jan 2511(1)3 [Epub ahead of print]
96 Damian AM Jacobson SA Hentz JG Belden C Shill HA Sabbagh MN Caviness JN Adler CH
Deconstruction of the MoCA and the MMSE as screening instruments for cognitive impairment Dement Geriatr Cogn Disord 2011 Jan 2931(2)126-131 [Epub ahead of print]
97 Caselli RJ Dueck AC Locke DEC Sabbagh MN Ahern GL Rapscak SZ Baxter LC Yaari R Woodruff BK Hoffman-Snyder C Rademakers R Findley S Reiman EM Cerebrovascular risk factors influence age related memory decline in APOE e4 carriers Neurology 2011 Feb 16 [Epub
ahead of print]
98 Roher AE Garami Z Tyas SL Maarouf CL Daugs ID Kokjohn TA Belohlavek M Vedders L Connor D Sabbagh MN Beach TG Emmerling MR Transcranial Doppler ultrasound blood flow
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
17 velocity and pulsatility index as systemic indicators for Alzheimerrsquos disease Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
99 Roher AE Tyas SL Maarouf CL Daugs ID Kokjohn TA Emmerling MR Garami Z Belohlavek M
Sabbagh MN Sue LI Beach TG Intracranial atherosclerosis as a contributing factor to Alzheimerrsquos disease dementia Alzheimerrsquos and Dementia 2011 Mar 8 [Epub ahead of print]
100 Evidente VG Adler CH Sabbagh MN Connor DJ Hentz JG Caviness JN Sue LI Beach
TG Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism Relat Disord 2011 Mar 18 [Epub ahead of print]
101 1CH Adler MD PhD
2JG Hentz MS
3HA Shill MD
3MN Sabbagh MD
1E Driver-Dunckley
MD 1VGH Evidente MD
3SA Jacobson MD
3TG Beach MD PhD
4B Boeve
1JN Caviness MD
Increased prevalence of RBD in Parkinsonrsquos disease but not in Essential Tremor or RLS Parkinsonrsquos Disease and Related Disorders 2011 Apr 7 [Epub ahead of print]
102 Potter PE Rauschkolb PK Pandya Y Sue LI Sabbagh MN Walker DG Beach TG Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimers disease Acta Neuropathol 2011 May 1 [Epub ahead of print]
103 Caviness JN Lue LF Beach TG Hentz JG Adler CH Sue L Sadeghi R Driver-Dunckley E Evidente VG Sabbagh MN Shill HA Walker DG Parkinsons disease cortical dysfunction and alpha-synuclein Mov Disord 2011 May 3 doi 101002mds23697 [Epub ahead of print]
104 Caviness JN Adler CH Hentz JG Shill HA Evidente VG Driver-Dunckley ED Sabbagh MN Sue L Beach TG Incidental Lewy body disease Electrophysiological findings suggesting pre-clinical Lewy body disorders Clin Neurophysiol 2011 May 25 [Epub ahead of print]
105 Klassen BK Hentz JG Shill HA Driver-Dunckley ED Evidente VGH Sabbagh MN Adler
CH Caviness JN Quantitative EEG as a Predictive Biomarker for Parkinsons disease dementia Neurology 2011 Jun 1 [Epub ahead of print]
106 Virgilio Gerald H Evidente Charles H Adler Marwan N Sabbagh Donald J Connor Joseph G Hentz John N Caviness Lucia I Sue Thomas G Beach Neuropathological findings of PSP in the elderly without clinical PSP Possible incidental PSP Parkinsonism amp Related Disorders 2011 Volume 17 Issue 5 Pages 365-371
107 Cabral D Beach TG Vedders LJ Sue LI Jacobson SA Myers K Sabbagh MN Frequency of Alzheimerrsquos Disease Pathology at Autopsy in Patients with Clinical Normal Pressure Hydrocephalus Alzheimerrsquos and Dementia 2011 Jun 30 [Epub ahead of print]
108 Breitner JC Baker LD Montine TJ Lyketsos CG Ashe KH Brandt J Craft S Evans DE Green RC Ismail MS Martin BK Meinert CL Mullan MM Sabbagh M Tariot P for the ADAPT Research Group Effects of the NSAIDs naproxen and celecoxib vary with stage of Alzheimerrsquos disease pathogenesis Alzheimerrsquos and Dementia 2011 Jul7(4)402-11
109 Gonzales A DeCourt B Walker A Condjella R Nural H Sabbagh MN Development of a specific ELISA to measure BACE1 levels in human tissues Journal of Neuroscience Methods 2011 202 70ndash 76
110 Shill HA
1 Adler CH
2 Beach TG
1 Lue LF
1 Caviness JN Sabbagh MN
1 Sue LI
1 Campbell A
Sadeghi R1 Walker DG Brain biochemistry in autopsied patients with essential tremor Movement
Disorders 2011 Oct 28 doi 101002mds24004 [Epub ahead of print]
111 Sabbagh MN Fleisher A Chen K Rogers J Berk C Reiman E Pontecorvo M Mintun M Skovronsky D Jacobson SA Sue LI Liebsack C Charney AS Cole L Belden C Beach TG Positron
Emission Tomography and neuropathological estimates of fibrillar amyloid- in a Down syndrome patient with Alzheimerrsquos disease Archives of Neurology 2011 681461-1466
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
18 112 Chera L Maarouf
1 Ian D Daugs
1 Tyler A Kokjohn
12 Douglas G Walker
3 Jesse M
Hunter1 Jane C Kruchowsky
3 Randy Woltjer
4 Jeffrey Kaye
5 Eduardo M Castantildeo
6 Marwan N
Sabbagh7 Thomas G Beach
8 and Alex E Roher
1 Alzheimerrsquos disease and non-demented high
pathology control nonagenarians Comparing and contrasting the biochemistry of cognitively successful aging PLoS One 20116(11)e27291 Epub 2011 Nov 7
113 Thomas G Beach Lucia I Sue Douglas G Walker Marwan N Sabbagh Geidy Serrano Brittany Dugger Monica Mariner Kim Yantos Jonette Henry-Watson Glenn Chiarolanza Jose Hidalgo and Leslie Souders Striatal Amyloid Plaque density predicts Braak Neurofibrillary Stage And Clinicopathological Alzheimerrsquos Disease Implications For Amyloid Imaging Journal of Alzheimerrsquos Disease 2011 Nov 23 [Epub ahead of print] 28 1-8
114 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
115 Shill HA Adler CH Beach TG Lue L Caviness JN Sabbagh MN Sue LI Walker DG Brain
biochemistry in autopsied patients with essential tremor Mov Disord 201227113-117
116 Reisa Sperling Stephen Salloway David J Brooks Donatella Tampieri Jerome Barakos Nick C Fox Murray Raskind Marwan Sabbagh Lawrence S Honig Anton P Porsteinsson Ivan Lieberburg H Michael Arrighi Kristen A Morris Yuan Lu Enchi Liu Keith M Gregg Robert H Brashear Gene G Kinney Ronald Black Michael Grundman Amyloid related imaging abnormalities (ARIA) in Alzheimers disease patients treated with bapineuzumab risk factors and clinical characteristics Lancet Neurology 2012 DOI101016S1474-4422(12)70015-7
117 Malek-Ahmadi M Davis K Belden C Jacobson S Sabbagh MN Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment) BMC Geriatrics 2012 123 (3 February 2012)
118 Lue LF Walker DG Adler CH Shill H Tran H Akiyama H Sue LI Caviness J Sabbagh MN Beach TG Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies Brain Pathol 2012 Feb 27 doi 101111j1750-3639201200585x [Epub ahead of print]
119 Malek-Ahmadi M Davis K Belden C Laizure B Jacobson S Yaari R Singh U Sabbagh
MN Validation and diagnostic accuracy of the Alzheimers questionnaire Age Ageing 2012 May41(3) 396-9 Epub 2012 Feb 23
120 Bakken TE Roddey JC Djurovic S Akshoomoff N Amaral DG Bloss CS Casey BJ Chang
L Ernst TM Gruen JR Jernigan TL Kaufmann WE Kenet T Kennedy DN Kuperman JM Murray SS Sowell ER Rimol LM Mattingsdal M Melle I Agartz I Andreassen OA Schork NJ Dale AM Alzheimers Disease Neuroimaging Initiative Pediatric Imaging Neurocognition and Genetics Study Weiner M Aisen P Petersen R Jack CR Jr Jagust W Trojanowki JQ Toga AW Beckett L Green RC Saykin AJ Morris J Liu E Montine T Gamst A Thomas RG Donohue M Walter S Gessert D Sather T Harvey D Kornak J Dale A Bernstein M Felmlee J Fox N Thompson P Schuff N Alexander G DeCarli C Bandy D Koeppe RA Foster N Reiman EM Chen K Mathis C Cairns NJ Taylor-Reinwald L Trojanowki JQ Shaw L Lee VM Korecka M Crawford K Neu S Foroud TM Potkin S Shen L Kachaturian Z Frank R Snyder PJ Molchan S Kaye J Quinn J Lind B Dolen S Schneider LS Pawluczyk S Spann BM Brewer J Vanderswag H Heidebrink JL Lord JL Johnson K Doody RS Villanueva-Meyer J Chowdhury M Stern Y Honig LS Bell KL Morris JC Ances B Carroll M Leon S Mintun MA Schneider S Marson D Griffith R Clark D Grossman H Mitsis E Romirowsky A deToledo-Morrell L Shah RC Duara R Varon D Roberts P Albert M Onyike C Kielb S Rusinek H de Leon MJ Glodzik L De Santi S Doraiswamy PM Petrella JR Coleman RE Arnold SE Karlawish JH Wolk D Smith CD Jicha G Hardy P Lopez OL Oakley M Simpson DM Porsteinsson AP Goldstein BS Martin K Makino KM Ismail MS Brand C Mulnard RA Thai G Mc-Adams-Ortiz C Womack K Mathews D Quiceno M Diaz-Arrastia R King R Weiner M Martin-Cook K DeVous M Levey AI Lah JJ Cellar JS Burns JM Anderson HS Swerdlow RH Apostolova L Lu
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
19 PH Bartzokis G Silverman DH Graff-Radford NR Parfitt F Johnson H Farlow MR Hake AM Matthews BR Herring S van Dyck CH Carson RE MacAvoy MG Chertkow H Bergman H Hosein C Black S Stefanovic B Caldwell C Ging-Yuek Hsiung R Feldman H Mudge B Assaly M Kertesz A Rogers J Trost D Bernick C Munic D Kerwin D Mesulam MM Lipowski K Wu CK Johnson N Sadowsky C Martinez W Villena T Turner RS Johnson K Reynolds B Sperling RA Johnson KA Marshall G Frey M Yesavage J Taylor JL Lane B Rosen A Tinklenberg J Sabbagh M Belden C Jacobson S Kowall N Killiany R Budson AE Norbash A Johnson PL Obisesan TO Wolday S Bwayo SK Lerner A Hudson L Ogrocki P Fletcher E Carmichael O Olichney J Kittur S Borrie M Lee TY Bartha R Johnson S Asthana S Carlsson CM Potkin SG Preda A Nguyen D Tariot P Fleisher A Reeder S Bates V Capote H Rainka M Scharre DW Kataki M Zimmerman EA Celmins D Brown AD Pearlson GD Blank K Anderson K Santulli RB Schwartz ES Sink KM Williamson JD Garg P Watkins F Ott BR Querfurth H Tremont G Salloway S Malloy P Correia S Rosen HJ Miller BL Mintzer J Longmire CF Spicer K Finger E Rachinsky I Drost D Jernigan T McCabe C Grant E Ernst T Kuperman J Chung Y Murray S Bloss C Darst B Pritchett L Saito A Amaral D DiNino M Eyngorina B Sowell E Houston S Soderberg L Kaufmann W van Zijl P Rizzo-Busack H Javid M Mehta N Ruberry E Powers A Rosen B Gebhard N Manigan H Frazier J Kennedy D Yakutis L Hill M Gruen J Bosson-Heenan J Carlson H Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A 2012 Mar 6109(10)3985-90 Epub 2012 Feb 16 PMID 22343285 [PubMed - indexed for MEDLINE]
121 Hunter JM Kwan J Malek-Ahmadi M Maarouf CL Kokjohn TA Belden C Sabbagh MN Beach TG Roher AE Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimerrsquos disease PLoS One 20127(5)e36893
122 Haijun Tian PhD Safiya Abouzaid PharmD Marwan N Sabbagh MD FAAN Wei Chen
Susan Gabriel MSc Kristijan H Kahler PhD RPh Edward Kim MD MBA Health Care Utilization and Costs among Patients with AD with and without Dysphagia Alzheimerrsquos disease and Associated Disorders 2012 May 16 [Epub ahead of print] PMID 22596081
123 Fleisher AS Chen K Liu X Ayutyanont N Roontiva A Thiyyagura P Protas H Joshi AD
Sabbagh M Sadowsky CH Sperling RA Clark CM Mintun MA Pontecorvo MJ Coleman RE Doraiswamy PM Johnson KA Carpenter AP Skovronsky DM Reiman EM Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease Neurobiol Aging 2012 May 24 [Epub ahead of print]
124 Clark CM Pontecorvo MJ Beach TG Bedell BJ Coleman RE Doriswamy PM Fleisher AS Reiman EM Sabbagh MN Sadowsky CH Schneider JA Arora A Carpenter AP Flitter ML Joshi AD Krautkrammer MJ Lu M Mintun MA Skovronsky DM for the A16 study group Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid--plaques a prospective cohort study The Lancet Neurology 2012 Jun 27 [Epub ahead of print]
125 Murali Doraiswamy Reisa A Sperling MD Edward Coleman MD Keith Johnson MD Eric M Reiman MD Mat D Davis MS Michael Grundman MD Marwan N Sabbagh MD Carl H Sadowsky MD Adam Fleisher MD Alan Carpenter PhD Christopher M Clark MD Abhinay D Joshi MS Mark A Mintun MD Daniel M Skovronsky MD Michael J Pontecorvo PhD Florbetapir F 18 PET rating of cortical amyloid-β burden and 18-month cognitive decline A multi-center longitudinal study Neurology WNL0b013e3182661f74 published ahead of print July 11 2012
126 Decourt B Walker A Gonzales A Malek-Ahmadi M Liebsack C Davis K Belden C Jacobson S Sabbagh M Can platelet BACE1 levels be used as a biomarker for Alzheimerrsquos disease Proof-of-concept study Platelet 2012 (Jul 9 [Epub ahead of print]
127 Damian A Adler CH Hentz JG Shill HA Caviness JN Sabbagh MN Evidente VG Beach TG Driver-Dunckley E Autonomic function as self-reported on the SCOPA-autonomic questionnaire is normal in essential tremor but not in Parkinsons disease Parkinsonism Relat Disord 2012 Jul 6 [Epub ahead of print]
128 Schipke CG Peters O Heuser I Grimmer T Sabbagh MN Sabri O Hock C Kunz M Kuhlmann J Reininger C Blankenburg M Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimers Disease Dement Geriatr Cogn Disord 2012 Jul 2033(6)416-422 [Epub ahead of print]
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
20 129 Reisa Sperling Keith A Johnson P Murali Doraiswamy Eric M Reiman Adam S Fleisher
Marwan Sabbagh Carl Sadowsky Alan Carpenter Christopher M Clark Mat Davis Matthew Flitter Abhinay Joshi Mark Mintun Daniel Skovronsky Michael Pontecorvo for the AV45-A05 Study Group Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals Neurobiology of Aging 2012 Aug 7 [Epub ahead of print]
130 Maarouf CL Beach TG Adler CH Shill HA Sabbagh MN Wu T Walker DG Kokjohn TA Roher AE Arizona PD Consortium Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinsons disease subjects Neurol Res 2012 Sep34(7)669-76
131 Brittany N Dugger Geidy E Serrano Lucia I Sue Douglas G Walker Charles H Adler Holly A Shill Marwan N Sabbagh John N Caviness Jose Hidalgo Megan Saxon-LaBelle Glenn Chiarolanza Monica Mariner Jonette Henry-Watson Thomas G Beach and the Arizona Parkinsonrsquos Disease Consortium Presence of Striatal Amyloid Plaques in Parkinsonrsquos Disease Dementia Predicts Concomitant Alzheimerrsquos Disease Journal of Parkinsonrsquos disease 2012 Jan 12(1)57-65
132 Sabbagh MN Ahmadi MM Levenson I Sparks DL KIF6 719Arg Allele Predicts Statin Responsiveness in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients Journal of Alzheimerrsquos Disease2012 Aug 22 [Epub ahead of print]
133 Goldknopf I Park H Sabbagh MN Apolipoprotein E4 Serum Concentration for Increased Sensitivity and Specificity of Diagnosis of Drug Treated Alzheimerrsquos Disease Patients vs Parkinsonrsquos Disease Patients and Age-matched Normal Controls contribution Current Alzheimerrsquos Research 2012 Aug 29 [Epub ahead of print] 1149-1167
134 Kaur B Harvey DJ DeCarli C Zhang L Sabbagh MN Olichney JM Extrapyramidal signs by
dementia severity in Alzheimerrsquos disease and dementia with Lewy bodies Alzheimerrsquos Disease and Associated Disorders 2012 Sep 27 [Epub ahead of print]
135 Decourt B Gonzales A Beach TG Malek-Ahmadi M Walker A Sue L Walker DG Sabbagh MN BACE1 levels by ApoE genotype in non-demented and Alzheimerrsquos postmortem brains Current Alzheimerrsquos Research 2012 October 2 [epub ahead of print]
136 Roher AE Debbins JP Malek-Ahmadi M Chen K Pipe JG Maze S Belden C Maarouf CL
Thiyyagura P Mo H Hunter JM Kokjohn TA Walker DG Kruchowsky JC Belohlavek M Sabbagh MN Beach TG Cerebral blood flow in Alzheimers disease Vasc Health Risk Manag 20128599-611 Epub 2012 Oct 23
137 Michael Malek-Ahmadi Kathryn Davis Christine M Belden Marwan N Sabbagh Comparative Analysis of the Alzheimerrsquos Questionnaire (AQ) with the CDR Sum of Boxes MoCA and MMSE Alzheimerrsquos Disease and Associated Disorders 2012 Nov 7 [Epub ahead of print]
138 Walker DG Lue LF Adler CH Shill HA Caviness JN Sabbagh MN Akiyama H Serrano GE Sue LI Beach TG Arizona Parkinson Disease Consortium Changes in Properties of Serine 129 Phosphorylated α-Synuclein with Progression of Lewy Type Histopathology in Human Brains Exp Neurol 2012 Nov 28 doipii S0014-4886(12)00437-2 101016jexpneurol201211020 [Epub ahead of print] 240 (2013) 190ndash204
139 Castantildeo EM Maarouf CL Wu T Leal MC Whiteside CM Lue LF Kokjohn TA Sabbagh MN
Beach TG Roher AE Alzheimer Disease Periventricular White Matter Lesions Exhibit Specific Proteomic Profile Alterations Neurochem Int 2012 Dec 8 doipii S0197-0186(12)00391-9 101016jneuint201212001 [Epub ahead of print]
140 Kokjohn TA Maarouf CL Daugs ID Hunter JM Whiteside CM Malek-Ahmadi M Rodriguez
E Kalback W Jacobson SA Sabbagh MN Beach TG Roher AE Neurochemical profile of dementia pugilistica J Neurotrauma 2012 Dec 26 [Epub ahead of print]
141 Delvaux E Bentley K Stubbs V Sabbagh M Coleman PD Differential Processing of Amyloid Precursor Protein in Brain and Peripheral Blood Leukocytes Neurobiol Aging 2013 Jan 5 doipii S0197-4580(12)00619-7[Epub ahead of print]
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
21
142 Sparks DL Kryscio RJ Ziolkowski C Lin Y Sabbagh MN Sparks LM Liebsack C Johnson-Traver S Tau levels are reduced in AD plasma and validation of ELISA methods employed Am J Neurodegener Dis 20121(1)99-106
143 Beach TG Adler CH Dugger BN Serrano G Hidalgo J Henry-Watson J Shill HA Sue LI
Sabbagh MN Akiyama H the Arizona Parkinsonrsquos Disease Consortium Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease J Neuropathol Exp Neurol 2013 Feb72(2)130-136
144 Johnson KA Sperling RA Gidicsin CM Carmasin JS Maye JE Coleman RE Reiman EM
Sabbagh MN Sadowsky CH Fleisher AS Murali Doraiswamy P Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM AV45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimers disease dementia mild cognitive impairment and normal aging Alzheimers Dement 2013 Jan 30 S1552-5260(12)02517-4 [Epub ahead of print]
145 Ferris S Cummings J Christensen D Doody R Farlow M Sabbagh M Liu L Mackell J Fain
R Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimers disease evaluating the impact of baseline severity Alzheimers Res Ther 2013 Feb 215(1)12 [Epub ahead of print]
146 Boeve BF Silber MH Ferman TJ Lin SC Benarroch EE Schmeichel AM Ahlskog JE Caselli RJ Jacobson S Sabbagh M Adler C Woodruff B Beach TG Iranzo A Gelpi E Santamaria J Tolosa E Singer C Mash DC Luca C Arnulf I Duyckaerts C Schenck CH Mahowald MW Dauvilliers Y Graff-Radford NR Wszolek ZK Parisi JE Dugger B Murray ME Dickson DW Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder Sleep Med 2013 Mar 6 pii S1389-9457(12)00387-5 doi 101016jsleep201210015 [Epub ahead of print]
147 Michael Malek-Ahmadi MSPH1 Vickram Kahlon
1 Charles H Adler MD PhD
2 Aleksandra
Obradov1 Kabir Thind MD
1 Holly A Shill MD
14 Lucia I Sue BS
3 John N Caviness MD
2 Sandra
Jacobson MD14
Marwan N Sabbagh MD14
Prevalence of Hippocampal Sclerosis in a Clinicopathologically Characterized Cohort Clinical and Experimental Medical Sciences 2013 1 (7) 317-327
148 Maarouf CL Beach TG Adler CH Malek-Ahmadi M Kokjohn TA Dugger BN Walker DG Shill HA Jacobson SA Sabbagh MN Roher AE Arizona Parkinsonrsquos Disease Consortium Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinsons disease cases lacking Alzheimers disease pathology Biomark Insights 2013819-28 doi 104137BMIS11422 Epub 2013 Mar 12
149 Roher AE Cribbs DH Kim RC Maarouf CL Whiteside CM Kokjohn TA Daugs ID Head E Liebsack C Serrano G Belden C Sabbagh MN Beach TG Bapineuzumab alters aβ composition implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy PLoS One 20138(3)e59735 doi 101371journalpone0059735 Epub 2013 Mar 21
150 Michael Malek-Ahmadi1 MSPH Thomas Beach
1 MD PhD Aleksandra Obradov
1 BS Lucia
Sue1 BS Christine Belden
1 PsyD Kathryn Davis
1 BA Douglas G Walker
1 PhD LihFen Lue
1 PhD
Abdu Adem2 PhD Marwan N Sabbagh
1 MD Type 2 diabetes is associated with increased
Alzheimerrsquos disease neuropathology in ApoE ε4 Carriers Current Alzheimerrsquos Research 2013 Apr 29 [Epub ahead of print]
151 Myers K Capek D Shill H Sabbagh M Aquatic Therapy and Alzheimerrsquos disease Annals of Long Term Care Clinical Care and Aging 2013 21(5) 36-41
152 Sabbagh MN Malek-Ahmadi M Dugger B Lee K Sue L Serrano G Walker DG Davis KJ Jacobson SA Beach TG The influence of the apolipoprotein E genotype on regional pathology in Alzheimerrsquos Disease BMC Neurology 2013 1344DOI 1011861471-2377-13-44
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
22 153 Marwan Sabbagh Jeffrey Cummings Daniel Christensen Rachelle Doody Martin Farlow
Liang Liu Joan Mackell and et al Evaluating the cognitive effects of donepezil 23 mgd in moderate and severe Alzheimers disease analysis of effects of baseline features on treatment response BMC Geriatrics 2013 Jun 613(1)56
154 Roher AE Maarouf CL Malek-Ahmadi M Wilson J Kokjohn TA Daugs ID Whiteside CM Kalback WM Macias MP Jacobson SA Sabbagh MN Ghetti B Beach TG Subjects harboring presenilin familial Alzheimers disease mutations exhibit diverse white matter biochemistry alterations Am J Neurodegener Dis 2013 Sep 182(3)187-207
155 Shneyder N Adler CH Hentz JG Shill H Caviness JN Sabbagh MN Beach TG Driver-Dunckley E Autonomic complaints in patients with restless legs syndrome Sleep Med 2013 Sep 21 doipii S1389-9457(13)01100-3 101016jsleep201308781 [Epub ahead of print]
156 Johnson KA Sperling RA Gidiscin CM Carmasin JS Maye JE Coleman RE Reiman EM Sabbagh MNSadowsky CH Fleisher AS Doriswamy MP Carpenter AP Clark CM Joshi AD Lu M Grundman M Mintun MA Pontecorvo MJ Skovronsky DM for the AV 45-A11 study group Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimerrsquos disease dementia mild cognitive impairment and normal aging Alzheimerrsquos and Dementia 2013 9(5supplement) S72-83
157 Henderson-Smith A Chow D Meechoovet B Aziz M Jacobson SA Shill HA Sabbagh MN
Caviness JN Adler CH Driver-Dunckley ED Beach TG Yin H Dunckley T SMG1 Identified as a Regulator of Parkinsons Disease-Associated alpha-Synuclein through siRNA Screening PLoS One 2013 Oct 308(10)e77711 doi 101371journalpone0077711
158 MiMi P Macias Amanda M Gonzales Ashley L Siniard Aaron W Walker Jason J Corneveaux Matthew J Huentelman Boris Decourt Marwan N Sabbagh A Cellular Model of Amyloid Precursor Protein Processing and Amyloid-beta Peptide Production J Neurosci Methods 2013 Dec 12 pii S0165-0270(13)00413-5
159 Malek-Ahmadi M Patel A Sabbagh MN KIF6 719Arg Carrier Status Association with Homocysteine and C-Reactive Protein in Amnestic Mild Cognitive Impairment and Alzheimerrsquos Disease Patients International Journal of Alzheimerrsquos Disease 2013 doi1011552013242303
160 Maarouf CL Kokjohn TA Whiteside CM Macias MP Kalback WM Sabbagh MN Beach TG
Vassar R Roher AE Molecular differences and similarities between Alzheimerrsquos disease and the 5x FAD Transgenic Mouse Models of Amyloidosis Biochemistry Insights 201361-10
161 Aaron H Burstein Imogene Grimes Douglas R Galasko Paul S Aisen Marwan Sabbagh
Adnan MM Mjalli Effect of TTP488 in patients with mild to moderate Alzheimers disease BMC Neurology 2014 1412 (15 January 2014)
162 Stephen Salloway MD MS
1 Reisa Sperling MD MMSc
2 Nick C Fox MD FRCP
3
Kaj Blennow MD4 William Klunk MD
5 Murray Raskind MD
6 Marwan Sabbagh MD
7
Lawrence S Honig MD PhD8 Anton Porsteinsson MD
9 Steven Ferris PhD
10 Marcel Reichert
MD11
Nzeera Ketter MD11
Bijan Nejadnik MD11
Volkmar Guenzler MD11
Maja Miloslavsky PhD
11 Daniel Wang PhD
11 Cristina Tudor PhD
11 Julia Lull MA
12 Yuan Lu MS
11 Enchi Liu
PhD11
Michael Grundman MD MPH1314
Eric Yuen MD11
Ronald Black MD15
and H Robert Brashear MD
11 for the Bapineuzumab 301 and 302 Clinical Trial Investigators Intravenous
bapineuzumab in mild-to-moderate Alzheimer disease Phase 3 clinical trial results in apolipoprotein
E 4 carriers and non-carriers New England Journal of Medicine 2014370322-333
163 Brittany N Dugger PhDb Christopher M Clark MD
a Geidy Serrano PhD
b Monica Mariner BS
b
Barry J Bedell MD PhDc R Edward Coleman MD
d P Murali Doraiswamy MD
d Ming Lu
a Adam S
Fleisher MD MASe Eric M Reiman MD
e Marwan N Sabbagh MD
b Carl H Sadowsky MD
f Julie A
Schneider MDg Simone P Zehntner PhD
c Alan P Carpenter PhD
a Abhinay D Joshi PhD
a Mark A
Mintun MDa Michael J Pontecorvo PhD
a Daniel M Skovronsky MD PhD
a Lucia I Sue BS
b Thomas
G Beach MD PhDb Neuropathologic Heterogeneity Does Not Impair Florbetapir-PET Postmortem
Correlates J Neuropathol Exp Neurol 2014 Jan73(1)72-80
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
23 164 Brittany N Dugger PhD
1 Joseph G Hentz MS
2 Charles H Adler MD PhD
2 Marwan N
Sabbagh MD1 Holly A Shill MD
1 Sandra Jacobson MD
1 John N Caviness MD
2 Christine Belden
PhD1 Erika Driver-Dunckley MD
2 Kathryn J Davis BS
1 Lucia I Sue BS
1 and Thomas G Beach
MDPhD1 and the Arizona Parkinsonrsquos Disease Consortium Clinicopathological Outcomes of
Prospectively Followed Normal Elderly Brain Bank Volunteers J Neuropathol Exp Neurol 2014 Jan 30 [Epub ahead of print]
165 P Murali Doraiswamy Reisa Sperling Keith Johnson Eric Reiman Terence Wong Marwan Sabbagh Carl Sadowsky Adam Fleisher Alan Carpenter Abhinnay Joshi Ming Lu Michael Grundman Mark Mintun Daniel Skovronsky and Michael Pontecorvo Florbetapir F 18 amyloid PET and 36-month cognitive decline a prospective multicenter study Molecular Psychiatry 11 March 2014 doi101038mp20149
166 Douglas Galasko 1 Joanne Bell
2 Jessica Mancuso
2James Kupiec
2 Marwan Sabbagh
3
Christopher van Dyck4 Ronald G Thomas
1 Paul S Aisen
1 for the ADCS A clinical trial of an
inhibitor of RAGE-A interactions in Alzheimerrsquos disease Neurology 2014 Apr 2982(17)1536-42 doi 101212 Epub 2014 Apr 2
167 Andrew Siderowf1 Michael J Pontecorvo
1 Holly A Shill
2 Mark A Mintun
1 Anupa Arora
1
Abhinay D Joshi1 Ming Lu
1 Charles H Adler
3 Douglas Galasko
4 Carolyn Liebsack
2 Daniel M
Skovronsky1 Marwan N Sabbagh
2 PET Imaging of Amyloid with Florbetapir F 18 and PET Imaging
of Dopamine Degeneration With 18
F-AV-133 (Florbenazine) in Patients with Alzheimerrsquos Disease and Lewy Body Disorders BMC Neurology 2014 BMC Neurol 2014 Apr 91479 doi 1011861471-2377-14-79
168 Beach TG Carew J Serrano G Adler CH Shill HA Sue LI Sabbagh MN Akiyama H Cuenca N Arizona Parkinsons Disease Consortium Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinsons disease subjects Neurosci Lett 2014 Jun 1357134-8 doi 101016jneulet201404027 Epub 2014 Apr 28
169 Berchtold NC Sabbagh MN Beach TG Kim RC Cribbs DH Cotman CW Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimers disease Neurobiol Aging 2014 Sep35(9)1961-72 doi 101016jneurobiolaging201403031 Epub 2014 Apr 2
170 Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimers and Parkinsons diseases correlate with disease status and features of pathology PLoS One 2014 May 59(5)e94839 doi 101371journalpone0094839 eCollection 2014
171 Serrano GE Sabbagh MN Sue LI Hidalgo JA Schneider JA Bedell BJ Van Deerlin VM Suh E Akiyama H Joshi AD Pontecorvo MJ Mintun MA Beach TG Positive Florbetapir PET Amyloid Imaging in a Subject with Frequent Cortical Neuritic Plaques and Frontotemporal Lobar Degeneration with TDP43-Positive Inclusions J Alzheimers Dis 2014 Jun 13 [Epub ahead of print]
172 Charles H Adler Thomas G Beach Joseph G Hentz Holly A Shill John N Caviness Erika Driver-Dunckley Marwan N Sabbagh Lucia I Sue Sandra AJacobson Christine M Belden and Brittany N Dugger Low Clinical Diagnostic Accuracy of Early vs Advanced Parkinson Disease Clinicopathologic Study Neurology 2014 Jul 2983(5)406-12 doi 101212WNL0000000000000641 Epub 2014 Jun 27
173 Belden C Kahlon VSAhmadi MM Tsai A Sabbagh MN Clinical Characterization of Mild Cognitive Impairment as a Prodrome of Dementia with Lewy Bodies American Journal of Alzheimerrsquos Disease and Other Dementias 2014 Jul 9 pii 1533317514542642 [Epub ahead of print]
174 Jacobson SA Morshed T Dugger BN Beach TG Hentz JG Adler CH Shill HA Sabbagh MN Belden CM Sue LI Caviness JN Hu C the Arizona Parkinsons Disease Consortium Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations Parkinsonism Relat Disord 2014 Jun 28 pii S1353-8020(14)00238-7 doi 101016jparkreldis201406018 [Epub ahead of print]
175 Tsai A Ahmadi MM Kahlon V Sabbagh MN Differences in cerebrospinal fluid biomarkers
between clinically diagnosed normal pressure hydrocephalus and Alzheimerrsquos disease Journal of Alzheimerrsquos Dementia and Parkinsonism 2014 4 150 doi 1041722161-04601000150
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
24 176 Holly A Shill Joseph G Hentz Sandra Jacobson Christine Belden Marwan Sabbagh
Thomas G Beach Erika Driver-Dunckley and Charles H Adler Essential tremor in the elderly and risk for dementia Journal of Neurodegenerative Diseases 2014 Volume 2014 (2014) Article ID 328765
177 ADAPT-FS Research group (Sabbagh MN) Follow-up evaluation of cognitive function in the randomized Alzheimers Disease Anti-inflammatory Prevention Trial (ADAPT) and its Follow-up Study (ADAPT-FS) Alzheimerrsquos and Dementia 2014 Jul 8 pii S1552-5260(14)00115-0 doi 101016jjalz201403009 [Epub ahead of print]
178 Erika Driver-Dunckley Charles H Adler Joseph G Hentz Brittany N Dugger Holly A Shill John N Caviness Marwan N Sabbagh Thomas G Beach the Arizona Parkinson Disease Consortium Olfactory dysfunction In Incidental Lewy body disease and Parkinsonrsquos disease Parkinsonism and related disorders 2014 Aug 16 pii S1353-8020(14)00304-6 doi 101016jparkreldis201408006 [Epub ahead of print]
179 Chera L Maarouf Tyler A Kokjohn Douglas G Walker Charisse M Whiteside Walter M Kalback Alexis Whetzel Lucia I Sue Geidy Serrano Sandra A Jacobson Marwan N Sabbagh Eric M Reiman Thomas G Beach Alex E Roher MD PhD Biochemical Assessment of Precuneus and Posterior Cingulate in the Context of Brain Aging and Alzheimers Disease PLOS ONE 2014 Aug 289(8)e105784 doi 101371journalpone0105784 eCollection 2014
180 John N Caviness1 Joseph G Hentz
1 Christine M Belden
2 Holly A Shill
2 Erika D Driver-
Dunckley1 Marwan N Sabbagh
2 Jessica J Powell
2 Charles H Adler
1 Longitudinal EEG changes
correlate with cognitive measure deterioration in Parkinsonrsquos disease J Parkinsons Dis 2014 Nov 24 [Epub ahead of print]
181 Michael Malek-Ahmadi MSPH Kewei Chen PhD Kathryn Davis BA Christine Belden
PsyD Jessica Powell PsyD Sandra A Jacobson MD Marwan N SabbaghMD Sensitivity to Change and Prediction of Global Change for the Alzheimerrsquos Questionnaire (AQ) Alzheimers Research amp Therapy2015 71 DOI 101186s13195-014-0092-z
182 Danna Jennings John Seibyl Marwan Sabbagh Florence Lai William Hopkins Santi Bullich Corneila Reininger Barbara Putz Andrew Stephens Ana Catafau and Ken Marek Age dependence of brain β-amyloid deposition in Down syndrome a [18F]florbetaben PET study Neurology 2015 Jan 7 pii 101212WNL0000000000001212 [Epub ahead of print]
183 Craig Curtis Jose Gamez Upinder Singh Carl Sadowsky Teresa Villena Marwan Sabbagh Thomas Beach Ranjan Duara Adam Fleisher Kirk Frey Zuzana Walker Arvinder Hunjan Clive Holmes Yavir Escovar Carla Vera Marc Agronin Joel Ross Andrea Bozoki Mary Akinola Jiong Shi Rik Vandenberghe Milos Ikonomovic Paul Sherwin Igor Grachev Gillian Farrar Adrian Smith Christopher Buckley Richard McLain Stephen Salloway (corr_auth) Phase 3 Trial of [18F]Flutemetamol Imaging and Neuritic Plaque Density JAMA Neurology January 26 2015 doi101001jamaneurol20144144
184 Beach TG Adler CH Sue LI Serrano G Shill HA Walker DG Lue L Roher AE Dugger BN Maarouf C Birdsill AC Intorcia A Saxon-Labelle M Pullen J Scroggins A Filon J Scott S Hoffman B Garcia A Caviness JN Hentz JG Driver-Dunckley E Jacobson SA Davis KJ Belden CM Long KE Malek-Ahmadi M Powell JJ Gale LD Nicholson LR Caselli RJ Woodruff BK Rapscak SZ Ahern GL Shi J Burke AD Reiman EM Sabbagh MN Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program Neuropathology 2015 Jan 26 doi 101111neup12189 [Epub ahead of print]
185 Roher AE Maarouf CL Kokjohn TA Whiteside CM Kalback WM Serrano G Belden C Liebsack C Jacobson SA Sabbagh MN Beach TG Neuropathological and biochemical assessments of an Alzheimers disease patient treated with the γ-secretase inhibitor semagacestat Am J Neurodegener Dis 2014 Dec 53(3)115-33 eCollection 2014
186 Budolfson K Ahmadi MM Belden CM Powell J Davis K Jacobson SA Sabbagh MN Neuropsychological Correlates of the Alzheimerrsquos Questionnaire J Alzheimers Dis 2015 Mar 3 [Epub ahead of print]
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
25
187 Osama Sabri MD Marwan N Sabbagh MD John Seibyl MD Henryk Barthel MDHiroyasu Akatsu MD Yasuomi Ouchi MD Kohei Senda MD Shigeo Murayama MD Kenji Ishii MD Masaki Takao MD Thomas G Beach MD Christopher C Rowe MD James B Leverenz MD Bernardino Ghetti MD James W Ironside MD Anja Hoffmann MD Katrin Roth PhD Cornelia Reininger MD Walter J Schulz-Schaeffer MD (for the Florbetaben Phase 3 Study Group)A phase 3 trial of whole brain and regional szlig-amyloid pathology as compared to 18F-florbetaben positron emission tomography (PET) Alzheimers Dement 2015 Mar 27 pii S1552-5260(15)00060-6 doi 101016jjalz201502004 [Epub ahead of print]
188 Marwan N Sabbagh MD12
Kewei Chen PhD234
Joseph Rogers PhD5 Adam S Fleisher
MD236
Carolyn Liebsack RN12
Dan Bandy MS23
Christine Belden PsyD12
Pradeep
ThiyyaguraMS 23
Xiaofen Liu MS 23
Auttawut Roontiva MS 23
Sandra Jacobson MD12
Michael Malek-Ahmadi MSPH12
Stephanie Parks BS
23 Jessica Powell PsyD
12 Eric M Reiman
MD237
Florbetapir PET FDG PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Alzheimers Dement 2015 11(8) 994-1004 jalz201501006 [Epub ahead of print]
189 Mu L Chen J Sobotka S Nyirenda T Benson B Gupta F Sanders I Adler CH Caviness JN Shill HA Sabbagh M Samanta JE Sue LI Beach TG Arizona Parkinsonrsquos Disease Consortium Alpha-Synuclein Pathology in Sensory Nerve Terminals of the Upper Aerodigestive Tract of Parkinsons Disease PatientsDysphagia 2015 Jun 4 [Epub ahead of print]
190 Kathryn B Holroyd1 Lisa Fosdick
2 Gwenn Smith
3 Jeannie-Marie Leoutsakos
3 Cynthia
Munro3 Esther Oh
3 Kristen Drake
2 Paul B Rosenberg
13 William S Anderson
3 Stephen Salloway
9
Cara Pendergrass Anna Burke David A Wolk7 David F Tang-Wai
46 Francisco A Ponce
8 Wael F
Asaad10
Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steve Targum2
Andres M Lozano4 and Constantine G Lyketsos
3 Deep brain stimulation targeting the fornix for mild
Alzheimer Dementia design of the ADvance randomized controlled trial Open Access Journal of Clinical Trials 2015 July volume 7 63mdash76
191 Serrano GE Intorcia A Carew J Chiarolanza G Hidalgo JA Sue LI Dugger BN Saxon-
LaBelle M Filon J Scroggins A Pullen J Fornwalt BE Scott S Sabbagh MN Adler CH Akiyama H Beach TG Feasibility Study Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases J Neuropathol Exp Neurol 2015 Jul 30 [Epub ahead of print]
192 Marwan Sabbagh MD1 Sandra Jacobson MD
1 Christine Belden PsyD
1 Zoran Obradov MD
CCRC1 Michael Malek-Ahmadi MSPH Jessica Powell PsyD
1 Atul Syal MD
2 Maninder Kahlon MD
2
Jatin Shah MD2 Carolyn Liebsack RN CCRC Denise Drumm-Gurnee PhD
1 A pilot phase IV open-
label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD switched from Exelon patch 95mg daily Annals of Psychiatry and Mental Health 2015 3(5) 1041
193 Postuma RB Adler CH Dugger BN Hentz JG Shill HA Driver-Dunckley E Sabbagh MN Jacobson SA Belden CM Sue LI Serrano G Beach TG REM sleep behavior disorder and neuropathology in Parkinsons disease Mov Disord 2015 Aug 12 doi 101002mds26347 [Epub ahead of print]
194 Brittany N Dugger Kathryn Davis Michael Malek-Ahmadi Joseph G Hentz Shawn Sandhu Thomas G Beach Charles H Adler Richard Caselli Travis Johnson Geidy Serrano Holly Shill Christine Belden Erika Driver-Dunckley John Caviness Lucia Sue Sandra Jacobson Jessica Powell and Marwan N Sabbagh Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment BMC Neurol 2015 Aug 2015146 doi 101186s12883-015-0403-4
195 Heather B Rigby
1 Brittany N Dugger
2 Joseph G Hentz
3 Charles H Adler
1 Thomas G
Beach2 Holly A Shill
45 Erika Driver-Dunckley
1 Marwan N Sabbagh
45 Lucia I Sue
2 John N
Caviness1 Clinical features of patients with concomitant Parkinsonrsquos disease and progressive
supranuclear palsy pathology Movement Disorders Clinical Practice 2014 Article first published online 29 OCT 2014 | DOI 101002mdc312104
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
26
196 John N Caviness1 Rene L Utanski
1 Joseph G Hentz
1 Thomas G Beach
2 Brittany N
Dugger2 Holly A Shill
2 Erika D Driver-Dunckley
1 Marwan N Sabbagh
2 Shyamal Mehta
1 Charles
H Adler1 Differential Spectral Quantitative EEG Patterns between Control and Parkinsonrsquos disease
Cohorts European Journal of Neurology 5 Oct 31 doi 101111ene12878 [Epub ahead of print]
197 Beach TG Adler CH Serrano G Sue LI Walker DG Dugger BN Shill HA Driver-Dunckley E Caviness JN Intorcia A Filon J Scott S Garcia A Hoffman B Belden CM Davis KJ Sabbagh MN Prevalence of Submandibular Gland Synucleinopathy in Parkinsons Disease Dementia with Lewy Bodies and other Lewy Body Disorders J Parkinsons Dis 2016 Jan 9 [Epub ahead of print]
198 Lih-Fen Lue PhD1 Christopher T Schmitz BS1 Noelle Snyder MS2 Kewei Chen PhD2
Douglas G Walker PhD3 John Caviness MD4 Charles Adler MD PhD4 Marwan Sabbagh MD5 Holly Shill MD6 Converging mediators from immune and trophic pathways to identify Parkinsonrsquos disease dementia Neurology Neuroimmunology amp Neuroinflammation 20163e193
199 John Seibyl1 Ana M Catafau2 Henryk Barthel3 Kenji Ishii4 Christopher C Rowe5James B
Leverenz6 Bernardino Ghetti7 James W Ironside8 Masaki Takao 910Hiroyasu Akatsu11 Shigeo Murayama1213 Santiago Bullich2 Andre Mueller2 Norman Koglin2 Walter J Schulz-Schaeffer14 Anja Hoffmann 15 Marwan N Sabbagh16 Andrew WStephens2 Osama Sabri3 Impact of training method on the robustness of the visual assessment of 18Fflorbetaben PET scans - results from a phase 3 study J Nucl Med 2016 Jan 28 pii jnumed115161927 [Epub ahead of print]
200 Rene L Utianski John N Caviness Elisabeth CW van Straaten Thomas G Beach Brittany N Dugger Holly A Shill Erika D Driver-Dunckley Marwan N Sabbagh Shyamal Mehta Charles H Adler Joseph G Hentz Graph theory network function in Parkinsonrsquos disease assessed with
electroencephalography Clinical Neurophysiology May 2016 Volume 127 (5)2228ndash2236
201 Morgan Schwartz1 Geidy Serrano PhD
2 Thomas G Beach MD PhD
2 Andrew Tsai
1
Michael Malek-Ahmadi MSPH3 Sandra Jacobson MD
1 Lucia I Sue BS
2 Kathryn Davis BS
1
Marwan N Sabbagh MD1 Neurofibrillary Tangle Predominant Dementia Clinical and Pathological
Description in a Case Series J Alzheimerrsquos Disease and Parkinsonism 2016 61 httpdxdoiorg1041722161-04601000204
202 B Blair Braden PhD1 Kara B Dassel PhD2 Heather A Bimonte-Nelson PhD3 Holly P ORourke MA3 Donald J Connor PhD4 Sallie Moorhous1 Marwan N Sabbagh MD4 Richard J Caselli MD5 Leslie C Baxter PhD1Gender and post-menopause hormone therapy effects on hippocampal volume and verbal Memory Aging Neuropsychol Cogn 2016 Jun 41-20 [Epub ahead of print]
203 Jessica R Filon1 Anthony J Intorcia
1 Lucia I Sue
1 Elsa Vazquez Arreola
2 Jeffrey Wilson
2
Kathryn J Davis1 Marwan N Sabbagh
3 Christine M Belden
1 Richard J Caselli
4 Charles H Adler
4
Bryan K Woodruff 4 Steven Z Rapscak
5 Geoffrey L Ahern
5 Anna D Burke
6 Sandra Jacobson
1
Holly Shill3 and Erika Driver-Dunckley
4 Kewei Chen
6 Eric M Reiman
6 Thomas G Beach
1 and
Geidy E Serrano1 Gender Differences in Alzheimerrsquos Disease Brain Atrophy Histopathology Burden
and Cognition Journal of Neuropathology and Experimental Neurology 2016 Jun 12 pii nlw047 [Epub
ahead of print]
204 Constantine G Lyketsos
Gwenn Smith Lisa Fosdick Jeannie-Marie Leoutsakos Cynthia
Munro Esther Oh Kristen Drake Paul B Rosenberg William S Anderson Stephen Salloway Cara Pendergrass Anna Burke David A Wolk David F Tang-Wai Francisco A Ponce Wael F Asaad Marwan Sabbagh Michael S Okun Gordon Baltuch Kelly D Foote Steven D Targum and Andres M Lozano A phase 2 study of fornix deep brain stimulation in mild Alzheimer dementia J Alzheimerrsquos Dis 2016 Jul 18 [Epub ahead of print]
205 Alex E Roher Chera L Maarouf Tyler A Kokjohn Christine Belden Geidy Serrano Marwan
S Sabbagh Thomas G Beach Chemical and neuropathological analyses of an Alzheimerrsquos disease patient treated with solanezumab Am J Neurodegener Dis 20165(4)158-170
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
27 206 Eric Hamlett BS Edward Goetzl PHD Heather A Boger PhD Aurelie Ledreux PHD
Angela LaRosa MD David Clark MD Steven L Carroll MDPhD Elliott Mufson MDPhD Marwan Sabbagh MDPhD Abdul Mohammed PhD Dean Hartley PhD Juan Fortea MD Eric Doran PhD Ira Lotta MDPhD Ann-Charlotte (Lotta) Granholm Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome Alzheimers amp Dementia 2016 2016 Oct 15 pii S1552-5260(16)32892-8 doi 101016jjalz201608012
207 Powell J Lendrum J Huff R Belden C Sabbagh MN The Mild Cognitive Impairment of
Primary Progressive Aphasia A case series Current Aging Science 2016 Oct 24 [Epub ahead of print]
208 He Zhou1 PhD Marwan Sabbagh
23 MD Rachel Wyman
3 BS Carolyn Liebsack
3 Mark E
Kunik456
MD MPH Bijan Najafi1 PhD Instrumented Trail-Making Task (iTMT) to Differentiate
Persons with No Cognitive Impairment Mild Cognitive Impairment Alzheimerrsquos Disease - Proof of Concept Study Gerontology 2016 Nov 18 [Epub ahead of print]
209 Pal GD Ouyang B Serrano G Shill HA Goetz C Stebbins G Metman LV Driver-Dunckley E Mehta SH Caviness JN Sabbagh MN Adler CH Beach TG Arizona Study of Aging Neurodegenerative Disorders Comparison of neuropathology in Parkinsons disease subjects with and without deep brain stimulation Mov Disord 2016 Dec 2 doi 101002mds26882 [Epub ahead of print
210 MN Sabbagh MD1 B Schaumluble MDPhD
2 K Anand MD
1 D Richards DO
3 TG Beach MD
PhD3 S Murayama MD
45 H Akatsu MD
67 M Takao MD
58 CC Rowe MD
9 CL Masters MD
10 H
Barthel MDPhD11
H-J Gertz MDPhD11
O Peters MD12
N Rasgon MD PhD13
A Jovalekic PhD2 DR
Booth PhD14
O Sabri MDPhD11
WJ Schulz-Schaeffer MD15
J Seibyl MD16
Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimerrsquos disease Journal of Alzheimerrsquos Disease 2016 [Epub ahead of print]
211 Holly A Shill MD12 Joseph G Hentz MS3 John N Caviness MD3 Erika Driver-Dunckley MD3 Sandra Jacobson MD12Christine Belden PsyD1 Marwan N Sabbagh MD12 Thomas G Beach MD PhD1 Charles H Adler MD PhD3Unawareness of Hyposmia in Elderly People With and Without Parkinsonrsquos Disease Movement Disorders Clinical Practice 2016 doi101002mdc312220 43-47
212 John N Caviness
1 MD LihFen Lue
2 PhD Joseph G Hentz
3 MS Christopher T
Schmitz2
BA Charles H Adler1 MD PhD Holly A Shill
4 MD Marwan N Sabbagh
4 MD
Thomas G Beach5 MD PhD Douglas G Walker
2 PhD Cortical Phosphorylated α-Synuclein
Levels Correlate with Brain Wave Spectra in Parkinsonrsquos Disease Mov Disord 2016 Jul31(7)1012-9 doi 101002mds26621
213 Schwenk M Sabbagh MN Lin I Morgan P Grewal G Mohler J Coon DW Najafi B Exergaming improves balance in people with mild cognitive impairment a randomized controlled pilot study JRRD 2016 53 (6) 945-958
214 Boris Decourt PhD1 dagger
Denise Drumm-Gurnee PhD1 dagger
Jeffrey Wilson PhD2 Sandra Jacobson
MD1 Christine Belden PsyD
1 Sherye Sirrel CCRC
1 Michael Ahmadi MSPH
1 Holly Shill MD
1 Jessica
Powell PsyD1 Aaron Walker BS
1 Amanda Gonzales MS
1 Mimi Macias PhD
1 Marwan N Sabbagh
MD1
Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimerrsquos disease Results from a Double-Blind Placebo-Controlled Trial Current Alzheimerrsquos Research Curr Alzheimer Res 2017 Jan 17 17(3) 403-411 [Epub ahead of print] PMID28124585
215 David A Weidman MD1
Edward Zamrini MD2 Marwan N Sabbagh MD
2 Sandra Jacobson
MD2 Anna Burke MD
1 Christine Belden PsyD
2 Jessica Powell PsyD
2 Auttawut Roontiva MS
1
Pradeep Thiyyagura MS1 Xiaoying Kuang MS
1 Ji Luo
1 MS Kewei Chen PhD
1 Garrett Riggs MD
1
William Burke MD1 Added value and limitations of amyloid imaging in diagnostically uncertain cases
of mild cognitive impairment and dementia A case series review Neurocase 2017 Feb23(1)41-5
216 Kyle B Smith Paul Kang Marwan N Sabbagh MD The effect of statins on mild cognitive impairment Alzheimerrsquos and Dementia 2017 3(2)149-156
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
28
217 Douglas G Walker PhD Lih-Fen Lue PhD Tiffany M Tang BSc Charles H Adler MD PhD John N Caviness MD Marwan N Sabbagh MD PhD Geidy E Serrano PhD Lucia I Sue BSc Thomas G Beach MD PhD Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimers pathology not alpha-synuclein pathology Neurobiol Aging 2017 Mar 16 pii S0197-4580(17)30078-7 doi 101016jneurobiolaging201703007 [Epub ahead of print]
218 Brubaker WD Crane A Johansson JU Yen K Garfinkel K Mastroeni D Asok P Bradt
B Sabbagh M Wallace TL Glavis-Bloom C Tenner AJ Rogers J Peripheral complement interactions with amyloid β peptides in Alzheimers disease Erythrocyte clearance of amyloid β peptides Alzheimers Dement 2017 May 2 pii S1552-5260(17)30149-8 doi 101016jjalz201703010 [Epub ahead of print]
219 Lue LF Sabbagh MN Chiu MJ Leung N Snyder N Schmitz C Guerra A Belden C Chen
TF Yang CC Yang SY Walker DG Chen K Reiman EM Plassma leves of Ab40 Ab42 and tau measured by ultra-sensitive imminomagnetic reduction assays identified probable Alzheimerrsquos dementia Findings from two cohorts Frontiers in Aging Neuroscience 2017 (submitted)
220 Adler Charles Beach TG Shill Holly A Caviness JN Driver-Dunckley Erika Sabbagh Marwan N Patel Akta Sue Lucia I Serrano Geidy Jacobson Sandra A Davis Kathryn Belden Christine Dugger Brittany N Paciga Sara A Winslow Ashley R GBA mutations in Parkinson disease Earlier death but similar neuropathological features European Journal of Neurology 2017 (submitted)
Multi-Center Consortium Manuscripts
1 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial of Creatine and Minocycline in Early Parkinsonrsquos Disease Neurology 2006 66 664-671
2 Tilley BC Palesch YY Kieburtz K Ravina B Huang P Elm JJ Shannon K Wooten GF Tanner CM
Goetz CG on behalf of the NET-PD investigators (Sabbagh MN) Optimizing the Ongoing Search for New Treatments for Parkinsonrsquos Disease Using Futility Designs Neurology 2006 628-633
3 Martin BK Breitner JCS Evans D Lyketsos CG Meinert CL For the ADAPT Research Group
(Sabbagh MN) Cardiovascular and Cerebrovascular results from the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS 2006 e330001-0010
4 The NINDS NET-PD Investigators (Sabbagh MN) A Randomized Double Blind Futility Clinical Trial
of CoEnzyme Q10 and GPI1485 in Early Parkinsonrsquos Disease Neurology 2007 6820-28
5 ADAPT Research Group Cognitive Function Over Time in the Alzheimers Disease Anti-inflammatory
Prevention Trial (ADAPT) Results of a Randomized Controlled Trial of Naproxen and Celecoxib (Sabbagh MN) Arch Neurol 200865(7) 896-905
6 The NINDS NET-PD Investigators (Sabbagh MN) A pilot clinical trial of creatine and minocycline in
early Parkinson disease 18-month results Clin Neuropharmacol 2008 May-Jun31(3)141-50
7 Cuenco KT Green RC Zhang J Lunetta K Erlich PM Cupples LA Farrer LA DeCarli C MIRAGE Study Group (Sabbagh MN) Magnetic resonance imaging traits in siblings discordant for Alzheimer disease J Neuroimaging 2008 Jul18(3)268-75
8 Aisen PS Schneider LS Sano M Diaz-Arrastia R van Dyck CH Weiner MF Bottiglieri T Jin S
Stokes KT Thomas RG Thal LJ Alzheimer Disease Cooperative Study (Sabbagh MN) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease a randomized controlled trial JAMA 2008 Oct 15300(15)1774-8
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
29 9 T Cuenco K Lunetta KL Baldwin CT McKee AC Guo J Cupples LA Green RC St George-Hyslop
PH Chui H DeCarli C Farrer LA MIRAGE Study Group (Sabbagh MN) Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease Arch Neurol 2008 Dec65(12)1640-8
10 ADAPT Research Group (Sabbagh MN) Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial
design methods and baseline results Alzheimerrsquos and Dementia 2009 5 93-104
11 Jack CR Jr Lowe VJ Weigand SD Wiste HJ Senjem ML Knopman DS Shiung MM Gunter JL Boeve BF Kemp BJ Weiner M Petersen RC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Serial PIB and MRI in normal mild cognitive impairment and Alzheimers disease implications for sequence of pathological events in Alzheimers disease Brain 2009 May132(Pt 5)1355-65
12 Lu PH Edland SD Teng E Tingus K Petersen RC Cummings JL Alzheimers Disease Cooperative
Study Group (Sabbagh MN) Donepezil delays progression to AD in MCI subjects with depressive symptoms Neurology 2009 Jun 1672(24)2115-21
13 Green RC Schneider LS Amato DA Beelen AP Wilcock G Swabb EA Zavitz KH Tarenflurbil
Phase 3 Study Group (Sabbagh MN) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease a randomized controlled trial JAMA 2009 Dec 6302(23)2557-64
14 Xu C Wang Z Fan M Liu B Song M Zhen X Jiang T Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimers disease Neuroreport 2010 Aug 2321(12)802-7
15 Schott JM Bartlett JW Barnes J Leung KK Ourselin S Fox NC Alzheimers Disease Neuroimaging Initiative investigators (Sabbagh MN) Reduced sample sizes for atrophy outcomes in Alzheimers disease trials baseline adjustment Neurobiol Aging 2010 Aug31(8)1452-62 1462e1-2
16 Perneczky R Wagenpfeil S Lunetta KL Cupples LA Green RC Decarli C Farrer LA Kurz A MIRAGE Study Group (Sabbagh MN) Head circumference atrophy and cognition implications for brain reserve in Alzheimer disease Neurology 2010 Jul 1375(2)137-42
17 Carmichael O Schwarz C Drucker D Fletcher E Harvey D Beckett L Jack CR Jr Weiner M
DeCarli C Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 2010 Nov67(11)1370-8
18 Tariot PN Schneider LS Cummings J Thomas RG Raman R Jakimovich LJ Loy R Bartocci B Fleisher A Ismail MS Porsteinsson A Weiner M Jack CR Jr Thal L Aisen PS Alzheimers Disease Cooperative Study Group (Sabbagh MN) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry 2011 Aug68(8)853-61
19 McEvoy LK Holland D Hagler DJ Jr Fennema-Notestine C Brewer JB Dale AM Alzheimers Disease Neuroimaging Initiative(Sabbagh MN) Mild cognitive impairment baseline and longitudinal structural MR imaging measures improve predictive prognosis Radiology 2011 Jun259(3)834-43 Epub 2011 Apr 6
20 Chiang GC Insel PS Tosun D Schuff N Truran-Sacrey D Raptentsetsang S Jack CR Jr Weiner MW Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes Radiology 2011 Jun259(3)844-51 Epub 2011 Apr 5
21 Kauwe JS Cruchaga C Karch CM Sadler B Lee M Mayo K Latu W Sua M Fagan AM Holtzman DM Morris JC Alzheimers Disease Neuroimaging Initiative (Sabbagh MN) Goate AM Fine mapping of genetic variants in BIN1 CLU CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimers diseasePLoS One 2011 Feb 96(2)e1591
22 Logue MW Schu M Vardarajan BN Buros J Green RC Go RC Griffith P Obisesan TO Shatz R Borenstein A Cupples LA Lunetta KL Fallin MD Baldwin CT Farrer LA Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group (Sabbagh MN) A comprehensive genetic association study of Alzheimer disease in African Americans Arch Neurol 2011 Dec68(12)1569-79
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
30 23 Swaminathan S Huentelman MJ Corneveaux JJ Myers AJ Faber KM Foroud T Mayeux R Shen
L Kim S Turk M Hardy J Reiman EM Saykin AJ Alzheimers Disease Neuroimaging Initiative and NIA-LOADNCRAD Family Study Group Analysis of copy number variation in Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals PLoS One 20127(12)e50640 doi 101371journalpone0050640 Epub 2012 Dec 5
24 Jahanshad N Rajagopalan P Hua X Hibar DP Nir TM Toga AW Jack CR Jr Saykin AJ Green RC Weiner MW Medland SE Montgomery GW Hansell NK McMahon KL de Zubicaray GI Martin NG Wright MJ Thompson PM the Alzheimerrsquos Disease Neuroimaging Initiative Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity Proc Natl Acad Sci U S A 2013 Mar 5 [Epub ahead of print]
Abstracts (over 200 total)
INVITED PRESENTATIONS over 100 invited presentations Completed Research Support Short-Term Training Students in Health Professional Schools NIH HL07479 1990-1991 PI(funded) $2500
The Stein Institute for Research on Aging (SIRA) Start-up grant 1996-7 UCSD IRASABB PI(funded) $7500
PfizerEisai Investigation of the effects of donepezil on nicotinic acetylcholine receptors in vitro and in vivo
Co-PI (funded) Co-Investigator $22500 NIAJohns Hopkins University Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site
Principal Investigator Fixed CostsBudget Site PI $129855year x 10 years A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the
treatment of Alzheimerrsquos Disease (funded) Co- Investigator ISOA Pfizer Co-I $350000year x 3 years
Cross-Validation of the SCIP with the FAST and GDS (Co-Principal Investigator) NYU ADCC Pilot Project
(funded) $5000 x 1 year SHRI109803 In vivo effects of nicotine on AD in animal models (Principal Investigator) Arizona Alzheimerrsquos Research
Center $12000 (funded) Reaching out to the mind and spirit of the elderly Native American (Principal investigator) Pfizer unrestricted
educational grant $5000 (funded)
ADCCIndian Health Service Conference on Memory disorders in Native Americans (Principal Investigator) Pfizer $20000 (funded)
Detection of the Nicotinic Acetylcholine Receptor in the Cerebrospinal Fluid of Patients with Alzheimerrsquos
Disease (Principal Investigator) ADCC pilot $25000 (funded) Education of dementia and AD to Native Americans (Co-Principal investigator) Novartis unrestricted
educational grant $10000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Ortho-McNeil Neurological
unrestricted educational grant $20000 (funded) Education of dementia and AD to Native Americans (Principal investigator) Forest unrestricted educational
grant $20000 (funded) Investigation of the effects of cholinesterase inhibitors on nicotinic acetylcholine receptors in vitro and in vivo
(Funded) PI Institute of Mental Health Research $25000 (funded)
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
31 Development of educational video of dementia and AD for Native Americans (Principal investigator) NIA
ADCC supplemental educational grant $97000 (funded) Creation and Validation of an Alzheimerrsquos Questionnaire ADCC pilot $25000 PI (funded) The effects of Lewy Body Dementia and Extrapyramidal signs on Cognitive and Functional Decline (NIA-
NACC-ADCC Supplement) Co-PI $87500 (funded) (Site PI) Study of thalidomide as a BACE1 inhibitor in Alzheimerrsquos disease (Co-PI) NIA R01 $1700000 (funded)
R01AG034155 A pilot phase IV open-label study investigating the safety and tolerability of Aricept 23mg once daily in
patients with moderate to severe AD switched from Exelon patch 95mg daily (PI) Eisai (funded)
NIA U01 AG15477-01A2 (PIs BreitnerSabbagh) 1110 ndash73113 Sabbagh Role Multi Principal Investigator Prevention of Alzheimerrsquos Dementia and Cognitive Decline This is a continuation grant of the Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial (ADAPT) that conducted a primary AD prevention trial using conventional NSAIDs This project aims to follow the cohort for another five years to learn whether these cognitive effects grow stabilize or reverse Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7113 ndash 63014 Sabbagh Role Principal Investigator Comparison of Alzheimerrsquos disease and Down syndrome post-mortem brain markers Hypothesize that Aβ metabolism and endosomal pathology have striking similarities and important differences in DS compared to non-DS brains at each stage in the progression of clinical and neuropathological AD Arizona Alzheimerrsquos Research Consortium (AARC) AZ-DHS (PI Reiman) 7111-63012 Sabbagh Role Co-Investigator Fibrillar Amyloid-Beta and Magnetic Resonance Imaging in Down Syndrome Individuals with and without Symptomatic Alzheimerrsquos Disease Arizona Biomedical Research Commission 0011(PI Adler) 10109 to 93012 Sabbagh Role Co-Investigator Arizona Parkinsonrsquos Disease Center This project is for continuing funding for the operations of an Arizona Parkinsonrsquos Disease Center that includes a Clinical Core directed by Dr Sabbagh NIH (via Subcontract) R01 (PI AisenSiffert) 12510-13012 Sabbagh Role Principal Investigator on subcontract A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimerrsquos Disease This project is for the requisite skills facilities and resources to enroll patients and conduct the study NIRG-12-237512 (DeCourt) 10112 ndash 93014 012 calendar Co-Investigator Alzheimerrsquos Association $45455 Annual DC Pre-clinical testing of lenalidomide as anti-amyloid treatment for AD Preclinical assessment of neuropathologic and cognitive efficacy of lenalidomide in APP23 transgenic mice AARC (SabbaghReimanAdler) 7114 ndash 63015 36 calendar Principal Co-Investigator State of Arizona DHS $35000 Annual DC (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC (Sabbagh) 7114 ndash 63015 24 calendar Principal Investigator State of Arizona DHS $75000 Annual DC (DHS) and Sun Health Foundation (match)
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
32 Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia AARC FYE 2015 (SabbaghReimanAdler) 7114 ndash 63015 Principal Co-Investigator State of Arizona DHS (DHS) and Sun Health Foundation (match) Long-Term Consequences of Repetitive Brain Injury in Athletes A Longitudinal Study with Eventual Brain Donation AARC FYE 2015 (Sabbagh) 7114 ndash 63015 State of Arizona DHS (DHS) and Sun Health Foundation (match) Florbetapir PET and MRI in Down Syndrome Individuals with and without Alzheimerrsquos Dementia Role Principal Investigator 2R01AG007367 (Rogers) 8112 ndash 73115 012 Calendar PI on Subcontract NIHNIA subcontract (Sabbagh) $33198 Annual DC Alzheimers disease a blood diagnostic and biomarker of disease progression Develop an inexpensive safe blood test based on erythrocyte Aβ levels that can diagnose AD Current Research Support ADHS14- 082998 102314-102217 144 calendar Principal Investigator Arizona Biomedical Research Commission $223816 Annual DC Longitudinal Assessment of Florbetapir FET FDG PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase 5P30 AG019610 (Reiman) 7111-63016 036 calendar Clinical Site PI Co-Investigator NIH $101435 (BSHRI clinic Annual DC) Arizona Alzheimerrsquos Disease Core Center ndash Clinical Core Maintain populations of clinically characterized AD and control patients for clinical research studies U24NS072026 (Beach) 9111-63016 024 calendar Co-Investigator NINDS $1012965 Annual DC National Brain and Tissue Resource for Parkinsons Disease and Related Disorders Assist between 50 and 100 LBD-focused research projects by supplying them with critically-needed human tissue that is not available elsewhere NiAD NIH RFA-AG-15-011 (HandenChristian) 4116- 33021 30 calendar Co-Investigator Site PI $306000 Annual DC Longitudinal Assessment of PIB-PET tau PET and MRI in Down Syndrome Characterize and quantify various biomarkers for DS progression in its early or preclinical phase DSAD-15-364262 10115-93018 10 calendar Principal Investigator Alzheimerrsquos Association $75000 Annual DC Blood Droplet Biomarker RNA Biomarker Discovery in Down Syndrome
MULTI-INSTITUTIONAL STUDIES Alzheimerrsquos disease Neuroimaging Initiative (Site PI) 2005-5015 Multi-institutional Research in Alzheimerrsquos Genetic Epidemiology (Site PI) 2002-2007 Alzheimerrsquos disease Cooperative Study (Site PI) 2005-2015 DOD-ADNI (Site PI) 2010-2015 COMMITTEES Steering Committee ADAPT trial ADCC Grants Management Committee State of ArizonaNIA AARC Internal Scientific Advisory Committee State of Arizona
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately
33 ADCC Diversity Committee State of Arizona Behavioral Neurology Section American Academy of Neurology Geriatric Neurology Section American Academy of Neurology Alzheimerrsquos Study Group Geriatric Neurology Board Examination Committee United Council of Neurological
Subspecialties CLINICAL TRIALS Over 100 clinical trials that Dr Sabbagh has been site PI for Here is the list of his role as
national PI
A phase II trial investigating the effect of the HMG-CoA reductase inhibitor Atorvastatin Calcium (Lipitor) in the treatment of Alzheimerrsquos Disease (Co-Principal Investigator) ISOA Pfizer
Alzheimerrsquos Disease Anti-Inflammatory Prevention Trial ndashADAPT (funded) Site Principal
Investigator NIAJohns Hopkins University
A double-blind randomized placebo-controlled phase Iia multiple dose multicenter study in patients with mild to moderate dementia of the Alzheimerrsquos type to evaluate the safety and tolerability of two 10-week dose regimens of orally-administered TTP488 TransTech Pharma (National PI) Blood Serum Biomarkers for Neurodegenerative Diseases Differential Diagnosis of Neurodegenerative Diseases Alzheimerrsquos Parkinsonrsquos and Like Disorders Protocol Number NAA-0001-S 1182007 Power 3 Medical Products (National PI)
Diagnosis of Alzheimerrsquos Disease Using PBL Mitogenic Stimulation Phase 3 ProVista Life Sciences (National PI)
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimerrsquos Disease DIM13 Medivation (National Co-PI)
Bayer Piramal - An open-label non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectionexclusion of cerebral szlig-amyloid when compared to postmortem histopathology (National Co-PI)
vTv therapeutics- A phase III randomized double-blind placebo controlled multi-center registration trial to evaluate the efficacy and safety azeliragon in patients with mild Alzheimerrsquos disease receiving acetylcholinesterase inhibitors andor memantine (National PI)
A complete accounting of all clinical trials is available separately